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III. Abstract 
 
Psoriasis is a complex genetic, chronic inflammatory disease of the skin with a prevalence of 
2 % among the population. It is characterized by a multi-faceted interplay of keratinocytes, 
dendritic and T cells, as well as downstream transcription factors and proinflammatory 
cytokines. The IL-23/TH17 axis is thought to play an important role in the pathogenesis of 
psoriasis. However, the relative contributions of keratinocytes and immune cells to disease 
initiation and maintenance remain unclear. Recent studies implicate a role of the receptor for 
advanced glycation end-products (aptly known as RAGE) in the development of chronic 
disorders due to its expression on involved cell types and its constitutive signaling in 
inflammatory conditions.  
The here presented thesis revealed a role for RAGE in psoriasis by demonstrating its 
upregulation in human and murine psoriatic specimens. In addition, RAGE drives and 
maintains chronic inflammation as the initial phase and the chronic stage of the inflammation 
were found to be diminished in Rage-deficient mice upon topical Imiquimod treatment. 
Moreover, RAGE was expressed on psoriatic effector cells such as keratinocytes and dermal 
inflammatory cells including CD11c+ dendritic cells. While the inflammation-associated 
activation of keratinocytes resulting in a release of the alarmins S100B and HMGB1 was 
demonstrated to be independent of RAGE, the functionality of plasmacytoid dendritic cells, 
which are major activators of dermal dendritic cells, strongly relied on active RAGE signaling. 
Indeed, both HMGB1 and S100B in complex with self-DNA activated plasmacytoid dendritic 
cells via RAGE. The finding that RAGE additionally controls the transcription of inflammatory 
response genes involved in the differentiation of naïve T cells into the T helper cell lineage 
further supported the hypothesis that RAGE signaling is essential for the activation of the IL-
23/TH17 axis in psoriasis. This was underlined by the rescue of the defective inflammatory 
phenotype of Rage-deficient mice by intradermal injections of recombinant IL-23. 
Taken together, these findings illustrate an epidermal-innate immune crosstalk mediated by 
RAGE signaling that in turn affects adaptive immune responses and points towards a central 
role of RAGE in the IL-23/TH17 axis of psoriasis. Therefore, this thesis highlights RAGE 
signaling as a potential target for new therapeutic strategies intervening ‘upstream’ of IL-23. 
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IV. Zusammenfassung 
 
Psoriasis ist eine komplexe genetische, chronisch entzündliche Erkrankung der Haut mit 
einer Prävalenz von 2 % in der Bevölkerung. Sie wird durch ein komplexes Wechselspiel von 
Keratinozyten, dendritischen  und T-Zellen, sowie nachgeschalteten Transkriptionsfaktoren 
und Zytokinen charakterisiert. Eine wichtige Rolle in der Pathogenese der Psoriasis wird der 
IL-23/TH17-Achse zugesprochen. Die relative Beteiligung von Keratinozyten und 
Immunzellen an der Initiierung und Aufrechterhaltung dieser Erkrankung bleibt jedoch unklar. 
Jüngste Studien implizierten eine Rolle für den Mustererkennungsrezeptor RAGE (engl. 
'receptor for advanced glycation end-products’) bei der Entwicklung von chronischen 
Erkrankungen basierend auf seiner Expression durch beteiligten Zelltypen und seiner 
kontinuierlichen Signaltransduktion während Entzündungsreaktionen.  
Die hier präsentierte Arbeit enthüllte eine funktionelle Rolle von RAGE in der  Psoriasis durch 
eine nachweisliche Hochregulierung der Rezeptorexpression in humanen und murinen 
psoriatischen Gewebeproben. Die Verminderung der initialen wie auch der chronischen 
Entzündungsphase in Imiquimod behandelten Rage-defizienten Mäusen zeigte, dass RAGE 
nicht nur an der Enstehung einer chronischen Entzündung beteiligt ist, sondern auch deren 
Aufrechterhaltung ermöglicht. Als RAGE exprimierend wurden psoriatische Effektorzellen wie 
Keratinozyten und kutane Entzündungszellen, CD11c+ dendritischen Zellen inbegriffen, 
identifiziert. Während die entzündungsbedingte Aktivierung von Keratinozyten, die zur 
Freisetzung der Alarmine S100B und HMGB1 führt, unabhängig von RAGE vonstattengeht, 
stützt sich die Funktionalität von plasmazytoiden dendritischen Zellen, die als wichtigste 
Aktivatoren dermaler dendritischer Zellen gelten, stark auf einen aktiven RAGE Signalweg. 
Komplexe, bestehend aus körpereigener DNA und HMGB1 oder S100B, aktivieren 
plasmazytoide dendritische Zellen durch Bindung an RAGE. Die Erkenntnis, dass RAGE die 
Transkription von Genen der Entzündungsantwort, die unter anderem an der Differenzierung 
von naiven T-Zellen in die T-Helfer-Zelllinien beteiligt sind, kontrolliert, unterstützt die 
Hypothese, dass die RAGE Signalkaskade für die Aktivierung der IL-23/TH17 Achse 
essentiell ist. Vorangetrieben wurde diese Vermutung durch die korrigierende Wirkung 
intradermaler rIL-23-Injektionen, die vergleichbare Phänotypen in Wildtypen- und Rage-
defizienten Mäuse induzierten. 
Die Studie veranschaulicht somit nicht nur ein Wechselspiel von epidermalen und 
angeborenen Immunzellen, das wiederum die erworbenen Immunreaktionen beeinflusst, 
sondern weist auch auf eine zentrale Rolle des RAGE-Signalweges in der IL-23/TH17-Achse 
der Psoriasis hin; dies identifiziert RAGE als potentielles IL-23-vorangeschaltetes Angriffsziel 
neuer therapeutischer Strategien. 
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V. Introduction 
 
V.1. Inflammation 
V.1.1. Definition 
Inflammation (latin, inflammatio, engl. ‘to set on fire’) is part of a complex response that 
occurs in reaction to chemical or physical irritation, injury or infection in living tissue. It 
involves a well-organized cascade of vascular and cellular changes and has both beneficial 
and detrimental, as well as local and systemic effects [1]. Closer examinations of 
inflammation-associated processes uncovered a close relationship between inflammation 
and the immune system [2]. 
V.1.2. Innate immune system 
The innate immune system is a universal system and part of the host defense against 
invading pathogens. It consists of chemical and physical barriers, the complement system, 
as well as phagocytic granulocytes such as neutrophils, eosinophils, macrophages, and 
dendritic cells (DCs). These granulocytes are capable of sensing microorganisms as soon as 
they penetrate the epithelial surface, thereby contributing to the ‘first line of defense’ [3]. 
Pathogens are not only recognized by granulocytes but also by the complement system, 
which becomes activated and initiates proteolytic lysis of the infiltrating microorganisms [3]. 
Germline-encoded pattern recognition receptors (PRRs) expressed on granulocytes bind 
common structures of pathogens, thus inducing the secretion of proinflammatory cytokines 
and chemokines, which initiate the process of inflammation [3], [4]. During initiation, 
neutrophils and macrophages derived from monocytes engulf and destroy the infiltrating 
pathogen. Moreover, eosinophils contribute via the 12/15-lipoxygenase route to the 
resolution of the inflammation [5]. Simultaneously, antigen-presenting DCs migrate through 
afferent lymphatics to local lymph nodes and present the antigens via the major 
histocompatibility complex (MHC) to naïve T cells. This feature, as well as the ability of DCs 
to discriminate between host and non-self antigens highlights their importance as key players 
in the interface between the innate and adaptive immune system. Indeed, the activation of 
T lymphocytes is dependent on the interaction between receptors like the cluster of 
differentiation (CD) 28 and costimulatory molecules, such as CD80 and CD86, expressed by 
DCs [3].  
V.1.3. Adaptive immune system 
In contrast to the innate immune recognition the adaptive immune system consists of B and 
T lymphocytes that are activated through antigen presentation by antigen-presenting cells 
(APCs) like DCs, thereby representing the ‘second line of defense’. Naïve T cells 
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continuously circulate in the blood and the lymphoid organs. In the latter, naïve 
T lymphocytes differentiate into T effector cells and clonally expand upon antigen 
presentation of APCs. After differentiation and proliferation, effector T cells are recruited to 
inflamed tissue by the expression of selectins, adhesion molecules and chemokines [6]. 
Effector T cells can be grouped into two main subtypes: CD4+ helper T (TH) cells that 
recognized MHC class II molecules on APCs, and CD8+ cytotoxic (TC) cells, which bind to 
MHC class I molecules [3]. TC cells directly respond to infected cells with the release of 
cytotoxic proteins, such as granzyme and perforin [7]. This release is highly effective 
declaring the need of required costimulation by, for instance, binding of costimulatory 
molecules on APCs to CD28 or by the present of TH cells [3]. The T helper cell subset 
consists of different subtypes. TH1 cells are characterized by the clearance of infiltrating 
pathogens and the production of interferon (IFN)-γ, whereas TH2 lymphocytes are involved in 
the clearance of specific parasitic infections and the production of interleukin (IL) -4, IL-5 and 
IL-13 [8]. The third subtype of TH cells are the so-called TH17 cells, which are characterized 
by the production of IL-17 and known to have an impact on autoimmune diseases as well as 
on tumorigenesis. T helper cell responses can be modulated with the help of other immune 
cells; for instance, IL-12 expression by DCs differentiates naïve T lymphocytes into type 1 
T helper (TH1) cells, while the expression of IL-23 leads to the proliferation of TH17 cells [8]–
[10]. Autoimmune diseases also involve the TH1 subset, whereas TH2 cells are thought to be 
associated with asthma [11]. Another main function of T helper cell subsets is the promotion 
of a B lymphocyte response [12]. These are crucial components of the immune system 
enable the removal of pathogens and toxins due to their ability to produce antibodies. B cells 
have membrane-bound immunoglobulins on their surface, so-called B cell receptors (BCRs), 
that bind and internalize foreign antigens leading to the production and secretion of antigen-
specific antibodies [13], [14]. As essential mediators of adaptive host defense, the antibodies 
are able to directly neutralize pathogens or opsonize them for phagocytosis [3]. In addition, 
the appearance of a T cell-independent B cell activation has been described [12]. 
Furthermore, B cells differentiated into diverse effector B cells have additional functions such 
as antigen presentation and production of multiple cytokines [15]–[17]. 
V.1.4. Classification of inflammation 
Inflammation can be classified by means of time and action as peracute, acute and subacute 
inflammatory response, as well as chronic inflammation. Peracute inflammation shows a 
rapid onset within minutes to a few hours and is usually induced by a potent stimulus such as 
bacterial or viral infection. The acute form of inflammation emerges due to bacterial or viral 
infections, but also upon mechanical trauma, physical and chemical agents or 
hypersensitivity reactions (immune reactions). Acute inflammation is mainly characterized by 
increased blood flow, increased vascular permeability for plasma proteins, and the 
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emigration of leukocytes, predominantly neutrophils [18]. The accumulation of leukocytes 
requires a series of successive processes. First, leukocytes adhere on endothelial surfaces 
due to the interactions between complementary adhesion molecules on leukocytes (e.g. 
C5a) and endothelial cells [19], [20]. Integrins, including members of the CD11/CD18 
adhesion family modulate cell-matrix and cell-cell interactions [21]. Additionally, endothelial-
leukocyte adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), ICAM-2 
and vascular cell adhesion molecules (VCAMs) on endothelial cells contribute to the 
leukocyte adhesion to the endothelium [22], [23]. After adhesion, cells emigrate in a process 
controlled by chemotaxis. Leukocytes express specific chemotactic receptors on their cell 
surface allowing them to bind a variety of chemotactic agents, and in turn follow respective 
chemical gradients. Accumulated at the site of injury or infection, leukocytes, such as 
neutrophils and macrophages, recognize, engulf, degrade microorganisms and foreign 
materials, and secrete leukocyte-specific enzymes; a process, which is known as 
phagocytosis [18], [24]. Acute inflammation is limited by apoptosis and subsequent clearance 
of activated cells resulting in the inflammatory resolution [25]. 
Clinically, acute inflammation exhibits five cardinal signs first described by Aulus Celsus (30-
38 B.C.) and Virchow (1821-1902), namely redness (rubor), swelling (tumor), heat (calor), 
pain (dolor), and loss of function (function laesa) [26]. Redness and heat result from the 
vasodilation of blood vessels, whereas the swelling arises from edema. The local release of 
prostaglandin and kinins can lead to pain.  
The subacute inflammation differs to the aforementioned in its extended duration and 
displays the period between acute and chronic responses [27]. Under normal conditions the 
inflammatory response is self-limiting, and has beneficial aspects including elimination of 
injury causes, neutralization of offending agents, and restoration of tissue integrity. Under 
pathological conditions inflammation becomes continuous and leads to the development of 
chronic inflammatory diseases [1]. Clinically, chronic inflammation exhibits less redness and 
heat compared to acute inflammatory reactions, while showing a tendency for swelling and 
firmness. Chronic inflammation represents a prolonged deregulated immune response that, 
in contrast to acute inflammation, is not only exudative, but also productive or proliferative 
(angiogenesis, wound healing). Characteristics are proliferation of blood vessels and 
connective tissue, as well as the presence of macrophages, T and B lymphocytes [28]–[31]. 
Macrophages and lymphocytes employ comparable processes in order to migrate into 
injured or infected tissue as known for neutrophils. Upon activation, for example by IFN-γ, 
macrophages execute neutrophil-like tasks, however because of their durability this response 
can be sustained over a longer period [24]. T lymphocytes have been demonstrated to be an 
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important source of macrophage-inducing cytokines, thereby setting up an ongoing 
inflammation.  
Chronic inflammation is linked to several human diseases such as neurological, metabolic, 
cardiovascular, pulmonary and Alzheimer´s disease as well as different types of autoimmune 
diseases and cancer [32].  
V.1.5. Mouse models of inflammation 
The understanding of complex biological and pathogenic processes requires in vivo systems 
that avoid the risk of harming a human being. The development of animal models that 
recapitulate the human system is crucial for the research field. Rodent disease models have 
expanded the knowledge of the pathogenesis of many human disorders [33]. However, 
findings from immunological animal studies cannot be directly translated to clinical 
intervention for human diseases due to differences between murine and human immune 
system [34], [35]. 
In the last decades, the mouse (mus musculus) has developed into the premier mammalian 
model system for research because of its close genetic and physiological similarities to 
humans. Several different mouse models exist, which can be used for the study of chronic 
inflammation, regardless of whether it is experimental, spontaneous, negative or orphane 
[36], [37]. Because of the amount of mouse models available today, the following section will 
focus on mouse models for psoriasis, a well-described chronic inflammatory disease of the 
skin.  
Psoriasis is a disease solely observed in humans, with the notable exception of two monkey 
species [38], [39]. Given the many disparities between human and mouse skin, it cannot be 
expected that psoriasiform phenotypes in mice will mirror the human disease in every 
respect [40]–[42]. The lack of suitable animal models impeded the investigations regarding 
psoriatic pathogenesis; however, in the last twenty years several psoriatic mouse models 
have been identified or created that mirror at least some aspects of human psoriasis [43]. 
Notably, mouse models are usually based on single gene manipulations, which stands in 
contrast to psoriasis that arises from interaction of multiple susceptibility loci [44]. An ideal 
mouse model of psoriasis should reflect many histological features such as epidermal 
hyperproliferation, altered differentiation of the epidermis, and moreover it should reproduce 
immunological features of the disease such as inflammatory infiltration and altered 
vascularity [40], [45], [46]. A number of spontaneous mouse models have been described 
that display histological features of psoriasis but lack pathological symptoms [40], [47]–[49]. 
Another category are the genetically engineered mouse models comprising transgenic and 
knockout models [40]. Contrary to spontaneous models these include pathological features 
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of the human disease. In most of these models, either increased expression or knockout of 
specific genes in the basal or suprabasal layer of the epidermis has been achieved by using 
promoters for the keratin genes keratin 5 or keratin 14, or respectively keratin 1, keratin 10, 
or involucrin. Existing models comprise the overexpression of the endothelial-specific 
receptor tyrosine kinase in basal keratinocytes (K5-Tie2) [50], the overexpression of the 
latent form of transforming growth factor β (TGF-β) 1 in basal keratinocytes (K5-TGFb1) [51], 
and the basal keratinocyte-specific overexpression of a constitutively active mutant of signal 
transducer and activator of transcription 3 (STAT-3) (K5-Stat3C) [52]. Xenotransplantation, 
where skin biopsies of psoriatic patients are transplanted on immunocompromised mice from 
spontaneously mutated or genetically modified strains, can also be used to study the 
pathogenesis of psoriasis [48]. Furthermore, a psoriasiform phenotype can be induced upon 
external stimuli, such as the intradermal injections of recombinant IL-23 or the application of 
Imiquimod (IMQ) [53], [54]. IMQ-induced phenotype differs in a fundamental way to the 
aforementioned mouse models. This model´s phenotype arises from direct stimulation of the 
immune system resulting in skin inflammation, immune cell infiltration, followed by 
hyperproliferation of keratinocytes and enhanced dermal vascularity [54]. 
 
V.2. Psoriasis 
V.2.1. Definition 
Psoriasis (greek, ψωρίασις, engl. ‘itching condition’) is one of the most common chronic 
inflammatory skin diseases in humans, mediated by cells and molecules of both the innate 
and the adaptive immune system [55], [56]. All dermal and epidermal elements guaranteeing 
barrier integrity under physiological conditions are deregulated in psoriasis, thereby leading 
to the development of a chronic skin inflammation [57], [58]. Since its pathology fits the 
definition of “a clinical syndrome caused by activation of T cells and B cells, or both, in the 
absence of an ongoing infection or other discernable causes” psoriasis is ranked among 
autoimmune diseases [59]. A variety of studies suggested that intra-lesional activated T cells 
produce cytokines that trigger basal stem cell keratinocytes to proliferate and perpetuate the 
disease [60]–[62]. In contrast, several reports have emphasized the causative role of 
epidermal defects in the initiation and maintenance of the disease [55], [63]. It is still under 
investigation what exactly causes psoriasis, however, research suggests that it may be 
founded in a deregulation of T cell differentiation or epidermal defects. 
The severity of psoriasis varies markedly between individuals, ranking from minor irritations 
to intense symptoms with serious impact on the patients quality of life [64]. Psoriasis is 
frequently associated with a certain form of arthritis, as well as cardiovascular diseases and 
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diabetes [65]–[68]. Psoriasis vulgaris is the most common clinical variant of the disorder 
affecting approximately 80 to 90 % of the patients [55]. Therefore, statements made in this 
thesis relate to psoriasis vulgaris except when otherwise noted.   
V.2.2. Clinical, histological, and epidemiological characterization 
V.2.2.1. Clinical features 
Psoriasis is a cutaneous chronic inflammatory disease with variable morphology, severity, 
distribution, and course. It is characterized by raised, erythematous, scaling plaques with a 
well-defined boarder and silvery dry scales all over the body. Predicted sites of psoriatic 
lesions are the elbows, knees, the sacral region as well as the capillitium and nails. However, 
psoriatic plaques may also develop at sites of mechanical trauma known as Koebner´s 
phenomenon [55]. Since the amount of skin lesions covering the body as well as their 
severity can vary strongly, Fredriksson and Pattersson proposed the `Psoriasis Area and 
Severity Index’ (PASI) to assess the occurrence of psoriasis [69]. This tool combines 
erythema, induration, desquamation of psoriatic lesions and the area affected into one single 
score. Nevertheless, the PASI is not a universal definition for the severity of psoriasis, 
because not all features of psoriasis are revealed and considered. For example, it is still 
unclear if the severity correlates with the presence and intensity of pruritus; however, it is 
known that pruritus is frequent symptom of psoriasis [70]. 
V.2.2.2. Histological features 
Psoriatic plaques are histologically characterized by thickened epidermis, so-called 
acanthosis, in combination with parakeratosis, hyperkeratosis, and elongated rete ridges, so-
called papillomatosis [55].  
Acanthosis and papillomatosis are caused by accelerated proliferation of basal and 
precipitous differentiation of suprabasal keratinocytes with abnormal replacement of annular 
squames with nucleated cells in the stratum corneum (parakeratosis) and by a loss of normal 
granular layer with thickening of the stratum corneum (hyperkeratosis) [71]. Furthermore 
suprabasal psoriatic keratinocytes are senescent, which contributes to the resistance of 
plaques to apoptosis and transformation [72]. Instead, erythema can be explained as greater 
number of dilated dermal blood vessels within the dermal papillae [55]. During plaque 
development neutrophils infiltrate the inflamed tissue, build spongiform pustule, so-called 
Munro´s microabscesses by invading the epidermis or migrate into the stratum corneum. 
These microabscesses have been only observed in epidermal compartments with 
parakeratotic phenotype [73]. The number of infiltrating neutrophils correlates with the 
severity of psoriatic plaques and is only restricted to pustule and guttate psoriasis [74]. 
Besides neutrophils, also CD4+ and CD8+ T lymphocytes are found in psoriatic epidermis. 
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Not only the epidermis is infiltrated, also the dermal compartment exhibits changes in the 
immune cell composition. The dermal inflammatory infiltrate mainly consists of 
T lymphocytes, dendritic cells and macrophages, as well as a small proportion of neutrophils 
[55]. Accumulation of T cells consisting of approximately 75 % CD4+ and only 25 % CD8+ 
T lymphocytes are mainly found in the tips of dermal papillae [74]. In contrast, the destination 
of infiltrating CD11c+ dendritic cells during inflammatory psoriatic responses is most often the 
upper part of the dermis [55]. 
V.2.2.3. Epidemiological features 
Psoriasis is estimated to affect 2 % of the population in Germany; however, variance in its 
prevalence has been observed between different ethnicities and countries ranging from 
0.2 to 10 % [75]. Both genders are equally affected by psoriasis, except for psoriasis 
pustulosa palmoplantaris, where women are preferentially concerned [44], [76]. 
In 1985, it was reported that the onset of psoriasis has two predicted age groups. Based on 
this finding a bimodal onset model of psoriasis was established comprising an early-onset at 
ages between 16 and 22 years (psoriasis type I) and a late-onset from 57 to 60 years, 
wherein early-onset cases are more frequent [77]. However, both types do not only differ in 
age but also in other clinical settings, such as inheritance. Consequently, there are two 
different types of psoriasis, on the one hand the hereditary early-onset form and on the other 
hand the sporadic late-onset form [77]. 
V.2.3. Forms of psoriasis 
Psoriasis can be variable in morphology, severity, and distribution. The most common variant 
is psoriasis vulgaris, affecting around 80 to 90 % of psoriasis patients [76]. Psoriasis vulgaris 
is also referred to as ‘plaque psoriasis’ reasoned by its typical hallmark, which is the 
development of plaques all over the body (described in V.2.2.1.). Psoriasis guttate is another 
well-described form of psoriasis. It arises upon infection and is an acute and self-limiting form 
in contrast to psoriasis vulgaris [76]. The transitions between the individual forms of psoriasis 
can be smooth. For instance, a study in 1996 was able to demonstrate that 33 % of patients 
with psoriasis guttate are more prone to develop a chronic psoriasis vulgaris [78]. 
Additional forms of psoriasis are pustulosa palmoplantaris, psoriasis inversa, psoriatic 
erythroderma, psoriatic arthritis, and psoriatic nail disease that differ in morphology, 
occurrence, or distribution from psoriasis vulgaris, as described in Table 1. 
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Type of 
psoriasis 
Occurrence Distribution Morphology Special features 
Psoriasis 
vulgaris 
80 to 90 % Elbows, knees, 
scalp, trunk 
Red plaques 
covered by silvery 
scales 
High prevalence 
of pruritus  
Psoriasis 
guttate 
2 %; post 
infectious 
Trunk Small, scattered 
papules 
Self-limiting, 
potential co-
occurrence with 
psoriasis vulgaris 
Psoriasis 
pustulosa 
palmoplantaris 
Preferably 
effecting smoking 
women over 40 
years 
Palms and soles Sterile pustules of 
yellow-brown color 
with scales 
 
Acute form, co-
occurrence with 
psoriasis vulgaris 
Psoriasis 
inversa 
- Intertriginous sites 
(inframammary, 
perineal and 
axillary) 
Red, shiny well-
demarcated 
plaques; w/o 
scales 
- 
Psoriatic 
erythroderma 
- Entire body 
surface 
Erythema, sterile 
pustules and 
scaling 
Psoriasis is not 
the only cause; 
life-threatening 
Psoriatic 
arthritis 
25 %  
 
Distal 
interphalangeal 
joints, dactylitis, 
calcaneal 
enthesitis  
Seronegative 
inflammatory 
arthritis  
5 different kinds 
Psoriatic nail 
disease 
50 % Nails Small pits in nail 
plate with ´oil 
spots` beneath nail 
plate 
Nail plate can 
detach and may 
become thickened 
and discolored 
Table 1 Features of different forms of psoriasis. [76], [79] 
 
V.2.4. Etiology  
In psoriasis, the cause leading to the establishment of a chronic inflammation with 
contribution of both the innate and adaptive immune system remains unknown. When 
associated with an abnormal skin barrier, either as a primary or secondary event, the activity 
of the immune system manifests the disease [55]. 
In the 1960s, studies investigating the family history of psoriasis patients suggested that 
relatives have a higher incidence for the development of the disease [80], [81]. Evidence for 
such a genetic predisposition was provided by twin studies several years later; indeed, the 
concordance rate for monozygotic twins with approximately 72 % for northern European 
individuals and 35 % for Australian individuals was higher when compared to dizygotic twins 
(15 to 13 % for European individuals, 12 % for Australian individuals) [82]–[84]. Furthermore, 
in both studies the character of psoriasis regarding age of onset, distribution, severity, and 
course was similar for monozygotic twins; a fact not observed in dizygotic twins [85]. 
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Interestingly, the absence of 100 % concordance in twin studies and a clear inherence 
pattern suggested a multifactorial etiology [86], [87].  
V.2.4.1. Genetic factors 
The mode of inheritance of psoriasis is complex. During the past twenty years classical 
genome-wide association studies (GWAS) have identified at least nine chromosomal loci 
with statistically significant linkage to psoriasis. These loci are known as psoriasis 
susceptibility loci (PSORS) 1 to 9 [88], whereas several others are still under discussion, e.g. 
PSORS 10 to 13 [89].  
The MHC class I molecule HLA-C is identified as a major susceptibility factor associated with 
the development of psoriasis and thereby defined as PSORS1 [90]–[92]. PSORS1, located 
on chromosome 6p21, accounts for 35 to 50 % of the psoriasis heritability [55]. Fine linkage 
mapping sequence and haplotype analysis suggested HLA-C and its allele HLA-Cw*0602 as 
the most likely PSORS1 gene [93], [94]. In up to 60 % of psoriasis patients the allelic variant 
HLA-Cw*0602 has been identified which confers a 20-fold-increased susceptibility [95]. In 
line with this finding, individuals who are homozygous for this allele have a fivefold-increased 
risk compared to heterozygous individuals [96]. To date, the precise role of HLA-C in the 
pathogenesis of psoriasis remains unknown. The high homology between MHC class I genes 
and the polymorphic nature of HLA-C impede functional studies. However, HLA-C is involved 
in innate and adaptive immune responses: APCs, such as DCs expressing HLA-C, are well-
described triggers of adaptive immunity by presenting processed antigens to epidermal CD8+ 
T lymphocytes. In addition, HLA-C expressing keratinocytes contribute to the immune 
response by interacting with killer immunoglobulin-like receptors (KIRs) on natural killer 
T lymphocytes, a cell subset that is involved in psoriatic disease [97], [98]. The HLA-C gene 
is not the only gene associated with PSORS1. For instance, CCHCR1 that encodes the 
coiled-coil α-helical rod protein 1 is overexpressed in psoriatic epidermis [99]. Upregulation of 
corneodesmosin (CDSN), uniquely expressed in the granular and cornified layers of the 
epidermis, has also been reported in psoriasis [100].  
Notably, diverse psoriasis-related genes belong to the IL-23/TH17 axis, the NF-κB signaling 
pathway, and the epidermal differentiation complex (EDC) [97], [98]. IL-23 is a heterodimeric 
cytokine composed of a unique IL-23p19 subunit and a common IL-12p40 subunit, and 
signals upon binding via the heterodimeric IL-23 receptor (IL-23R). Perera and others have 
identified single nucleotide polymorphisms (SNPs) in the IL-12B gene as well as in the IL-
23R gene, both associated with psoriasis [101], [102]; the latter is located in PSORS7 on 
chromosome 1p. The presence of SNPs leading to an arginine to glutamine (381R/Q) 
substitution at position 381 within the cytoplasmic domain of the IL-23R lends protection 
against psoriasis by impairing TH17 effector function [101]–[104]. This raises the option that 
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the protective IL-23R gene variant is involved in the contribution of a different phenotype in 
psoriasis like seen in Crohn´s disease patients [105]. Associated gene variants of regulatory 
components of NF-κB signaling pathway in psoriasis have been identified in multitude GWAS 
[104], [106]–[108]. Observed variants comprise genes such as TNFAIP3, which encodes for 
TNF-inducible protein 3, and TNIP1 encoding for ABIN-1, both regulating NF-κB activation 
[104], [107]. Moreover, associations with TRAF3IP2 encoding the signaling adaptor molecule 
ACT1 as well as NFKBIA that codes for the inhibitory protein IκBα give further hints for an 
impaired negative regulation of the NF-κB signaling pathway [106]–[109].  
In addition to the psoriasis susceptibility genes aforementioned, various other gene sets were 
reported to be involved in psoriasis. Genes from the EDC, including genes encoding for the 
S100 calcium-binding proteins have been identified as PSORS4 [89], [110], [111]. PSORS4 
is a cluster of more than 80 genes on chromosome 1q21, of which at least 45 genes are 
involved in skin cornification [112], [113]. As psoriasis displays abnormal epidermal 
differentiation, the EDC genes are candidates for psoriasis susceptibility, as members of all 
three families belonging to the EDC are deregulated in psoriatic inflammation [114]–[117]. In 
addition, genes for STAT-3 associated with PSORS2 on chromosome 17q25.3, and genes 
for Jun-B identified as PSORS6 on chromosome 19p13 were listed among various others 
[89]. Beside these factors, epigenetic mechanisms might also largely influence the 
pathogenesis of psoriasis.  
V.2.4.2. Epigenetic and environmental factors 
Epigenetic network might be a causative element in psoriasis. The deregulation of 
keratinocyte differentiation is closely linked to the epigenetic state of basal keratinocytes 
[118], [119]. The discordance in occurrence among twin studies as well as plaque formation 
have indicated that in addition to genetic predisposition, environmental and epigenetic factors 
might play a central role in the progression of psoriasis [120]. One epigenetic process 
postulated to play a role in psoriasis pathogenesis is DNA methylation, a silencing factor 
responsible for genome stability, cellular differentiation, imprinting, and X-linked inactivation 
[121]. Global DNA methylation profiling showed an increased DNA methylation in PBMCs 
from psoriasis patients when compared to healthy controls [122]. A second epigenetic 
regulatory process claimed to be from importance for the pathogenesis of psoriasis is histone 
modification [89]. It was shown that abnormal expression of a nicotinamide adenine 
dinucleotide (NAD+) dependent deacetylase sirtuin-1 leads to hyperproliferation of 
keratinocytes or promotion of keratinocyte differentiation [123], [124]. Beside DNA 
methylation and histone modification, another important mechanism is the posttranscriptional 
regulation of expression via microRNAs (miRNAs). However, the influence of epigenetic 
processes in psoriasis needs further investigations in order to elucidate their importance in 
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the development of psoriasis. In addition to genetic predisposition and epigenetic regulation, 
environmental factors may contribute to the formation of psoriasis. Especially streptococcal 
infections, but also other kinds of infections are listed among important factors inducing the 
development of psoriasis [125]. Psoriatic lesions formed at site of minor injury in previously 
unaffected skin areas occur with an incidence of 5 to 50 %. Such plaque formations upon 
physical trauma, the so-called Koebner’s phenomenon, illustrate another environmental 
factor leading to psoriasis [126]. The list of environmental factors is supplemented by certain 
medication such as antidepressants, antihypertensives and anticytokine therapies [127], 
[128], as well as smoking and alcohol [129], [130]. In addition, emotional factors, such as 
stress can contribute to the development or (re)activation of the disease [130].   
V.2.5. Pathogenesis  
The complex pathogenesis of psoriasis is driven by various cells, regulatory modulators, and 
pathways of the immune system – both, innate and adaptive – as well as by the skin 
epithelium and connective tissue [131]. In a psoriatic plaque two cellular responses are 
excluded: the balance between activation of immune cell types and the production of factors 
secreted by keratinocytes directly affecting T lymphocytes as well as dendritic cells and vice 
versa [56].  
Non-lesional skin of psoriatic patients appears normal until progression into a psoriatic lesion 
is induced by skin injury, inflammation or infections [132]. The combination of environmental 
and potential genetic predisposition causes cell death and leads to the production and 
secretion of antimicrobial peptides. Among these peptides are molecules such as the 
cathelicidin LL-37, S100A7 (psoriasin), and β-defensins, which are produced and secreted by 
keratinocytes, and which are known to have also chemotactic impacts on DCs besides their 
antimicrobial function [133]. A small subpopulation of DCs, known as plasmacytoid dendritic 
cells (pDCs), is chemoattracted from the blood into injured tissue [134]. Indeed, keratinocytes 
are not only responsible for the recruitment of DCs, but also involved in their activation via 
the secretion of cytokines such as IL-1α/β, IL-6, IL-18, and tumor necrosis factor-α (TNF-α) 
[55]. These cytokines also function as activators of other keratinocytes and epidermal 
Langerhans cells. Sustained activation of keratinocytes resulting in the release of ribonucleic 
acid (RNA) and deoxyribonucleic acid (DNA) molecules to the extracellular matrix [135]. LL-
37, secreted by keratinocytes, has the ability to build complexes with DNA and RNA, thereby 
activating pDCs and myeloid dendritic cells in a toll-like receptor (TLR)-dependent manner. 
This illustrates how host DNA is turned into a proinflammatory stimulus in psoriasis [136]. 
Activated pDCs represent the main source of INF-α, a cytokine essential for the maturation 
and activation of dermal dendritic into inflammatory dendritic cells [137], [138].  
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Activation and maturation of myeloid dendritic cells is not only induced by keratinocytes and 
pDCs. For instance, macrophages secrete TNF-α, IFN-γ, and chemokines (e.g. CCL19), and 
also TNF-α derived from natural killer T cells has the capacity to activate DCs [55]. Activated 
myeloid dendritic cells recognize and capture antigens, migrate to local draining lymph nodes 
and present antigens to T cells [139]. Presentation of antigens induces the differentiation of 
naïve T cells into effector cells such as type 1 helper cells (TH1 cells), and type 17 helper 
cells (TH17 cells), as well as type 1 cytotoxic T cells (TC1 cells) and type 17 cytotoxic T cells 
(TC17 cells) [55]. Chemokine profiling performed in the dermal compartment of inflamed 
tissue uncovered the recruitment of TH1 cells via binding to its chemokine receptor CXCR3. 
Additionally, TH17 cells follow the same chemokine gradients due to the expression of the 
chemokine receptors CCR6 and CCR4. In fact, T helper cell migration into the psoriatic 
lesion is the beginning of disease maintenance [55] (Figure 1).  
Key processes during the maintenance phase are the presentation of putative auto-antigens 
to T cells and the release of IFN-γ, TNF-α, IL-17A, IL-17F, and IL-22 by T helper cell subsets 
(TH1, TH17, and TH22 cells). Furthermore, dermal dendritic cells produce IL-23 and a special 
subgroup of myeloid dermal DCs (TIP-DCs) releases high levels of TNF-α and iNOS [140]. 
IL-23, elevated in psoriatic plaques and produced by dendritic cells, neutrophils, 
macrophages, and keratinocytes, is one of the key cytokine in the survival and proliferation of 
TH17 lymphocytes and signals via binding to the IL-23R on their cell surface [141]–[144]. In 
turn, all these proinflammatory mediators act on keratinocytes, leading to the activation, 
proliferation and sustained secretion of antimicrobial peptides, chemokines (e.g. CXCL1, 
CXCL9 through CXCL11, and CCL20), and S100 proteins [145], [146]. CCL19, a chemokine 
secreted by macrophages, initiates the formation of perivascular clusters and lymphoid-like 
structures consisting of dendritic cells and T lymphocytes [55]. Migration of T cells from the 
dermis into the epidermal compartment is an important event in psoriasis, which is controlled 
by the interaction of α1β1 integrin on T cells with collagen IV in the basal membrane of 
psoriatic epidermis [147].  
Feedback loops involving keratinocytes, fibroblasts, and endothelial cells contribute to tissue 
reorganization with endothelial-cell activation, proliferation, and deposition of extracellular 
matrix [55] (Figure 1). 
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V.2.5.1. Role of keratinocytes in psoriasis 
The epidermis is mainly formed by slowly differentiating keratinocytes that build the 
mechanical barrier of the body. Keratinocytes have a variety of functions including important 
roles in the initiation, maintenance and regulation of cutaneous immune responses [148].  
Figure 1 Summary of psoriasis pathogenesis.  
Genetic deposition and/or environmental stress lead to immune responses from both the innate and 
adaptive immune system. Stressed keratinocytes activate dermal DCs and lead to differentiation of 
other keratinocytes. Differentiated keratinocytes release DNA and RNA molecules, which build 
complexes with LL-37 thereby leading to the activation of pDCs and the secretion of IFN-α. IFN-α 
activates and matures dermal DCs, which circulate to the lymph nodes, where antigens are 
presented to naïve T cells that differentiate into different T helper subsets (TH1, TH17, TH22). 
Differentiated TH cells migrate into the dermis, where an interaction between keratinocytes, innate 
immune cells, and TH cells as well as cytokines such as TNF-α, IFN-γ, IL-17, IL-22, and IL-23 takes 
place (adapted from [97]). 
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In general, the function of keratinocytes is based on their state of activation and 
differentiation. In psoriatic lesions the terminal differentiation potential of keratinocytes is 
incomplete leading to the activation and proliferation of early-differentiated keratinocytes 
displayed by an upregulation of early differentiation markers like involucrin and a 
downregulation of filaggrin and loricrin [97]. Activated keratinocytes display a 
hyperproliferative and migratory phenotype that differs from differentiated keratinocytes, e.g. 
regarding cytokine secretion. The vascular endothelial growth factor (VEGF) is secreted by 
activated keratinocytes and is important for the recruitment of circulating lymphocytes [149] 
as well as for the induction of migration, survival, and proliferation of epithelial cells [150]. 
The complex situation in psoriasis is based on an incomplete terminal differentiation and 
deactivation of keratinocytes as well as their deregulated cytokine expression [151]. For 
instance, keratinocyte-derived IL-1 is one of the most important deregulated cytokines in 
psoriasis with multiple roles in orchestrating immune responses [152], [153]. Both IL-1 forms, 
IL-1α and IL-1β, are stored in the cytosol as precursor proteins [154], [155]. Activated 
caspase-1 cleaves the precursor pro-IL-1α, pro-IL-1β and pro-IL-18, hereby inducing the 
release of the active forms of these proinflammatory cytokines [156]–[158]. The IL-1 family 
exhibits diverse function during an inflammatory response. While IL-1 act as direct 
chemoattractant for lymphocytes [159], and as activator for fibroblast proliferation [160], IL-18 
and IL-1β are involved in the differentiation of naïve T cells into TH1 and TH17 cells [161]–
[163]. Furthermore, keratinocytes are entangled in leukocyte recruitment by producing 
immune-related proteins such as the MHC class II cell surface receptor HLA-DR, CD40, 
ICAM-1 and S100 proteins [164]. Through the expression of ICAM as well as MHC II and 
programmed death-ligand 1 (PD-L1) keratinocytes are directly involved in T cell activation 
[165]. Moreover, Li and colleagues have shown that differentiated keratinocytes signal 
through TLR-7 leading to the activation of the NF-κB pathway. This results in the secretion of 
proinflammatory cytokines such as IL-8 and TNF-α, contributing to an inflammatory 
phenotype [166]. As mentioned previously, clusters formed by keratinocyte-derived 
antimicrobial peptides (LL-37, S100A7, and β-defensins) and DNA as well as RNA molecules 
are able to activate different DC subsets and to induce infiltration of inflamed tissue by 
neutrophils and macrophages, thereby sustaining inflammation [97]. Production of AMPs by 
keratinocytes can be increased by T cell-derived cytokines like IL-17A and IL-22 leading to 
the generation of a positive feed-forward loop [167]. 
V.2.5.2. Role of plasmacytoid dendritic cells 
Dendritic cells are innate immune sentinel cells linking the innate and adaptive immunity by 
acting as APCs and inducing T cell-mediated adaptive immune responses [167]. Normal skin 
is comprised of epidermal Langerhans cells and dermal dendritic cells, whereas in psoriatic 
skin both lesional and non-lesional skin, additional DC subsets are present: TNF-α and 
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iNOS-producing inflammatory DCs (Tip-DCs), slan-DCs and dermal pDCs [168]–[170]. This 
altered immune cell composition contributes to the specificity of the inflammatory response 
[171].   
Human CD123+ BDCA-2+ BDCA-4+ pDCs are a rare subset of dermal dendritic cells (0.2 to 
0.8 %) characterized by a plasma cell-like morphology and a unique surface phenotype 
[138], [172], [173]. These cells are key effector cells in the innate immune system in 
response to viruses due to their unique ability to produce large amounts of IFN-α [174], [175]. 
pDC-derived IFN-α promotes the maturation and activation of dermal myeloid DCs that force 
the activation and expansion of pathogenic T cells [170].  
Under homeostatic conditions, pDCs are exclusively found in secondary lymph nodes and 
the peripheral blood, but upon viral infection they are recruited from the blood to peripheral 
infected tissue [176]. Nestle and colleagues have shown increased number of pDCs in 
‘normal-appearing pre-psoriatic skin’ of patients in comparison to the healthy control group; 
thereby demonstrating that the elevated amounts of pDCs in the skin represents a 
conditioning factor for future plaques of psoriasis [170]. Since skin injury is a well-known 
initiator of psoriasis [177], pDC activation might be explained by the release of skin-derived 
products upon mechanical stress or infection [170]. For instance, fibroblast-derived chemerin 
has been reported to promote the recruitment of pDCs in dermal compartment [134]. TLR-7 
and TLR-9, selectively expressed on pDCs have the ability to bind nucleic acids at non-
methylated CpG-rich motifs or phosphodiester backbones [178], [179], which consequently 
activates pDCs and initiates inflammatory responses. Under homeostatic conditions pDCs 
are tolerant to nucleic acids releases from stressed or dying host cells. Tolerance to self-
nucleic acid molecules occurs when self-RNA or self-DNA form complexes with LL-37 [135], 
an AMP released from keratinocytes, as mentioned before. Normally, host nucleic acids are 
rapidly degraded in the extracellular environment and are not able to enter the endosomes 
spontaneously [180]. LL-37 protects host nucleic acid from cellular degradation, and 
transports it into endosomal compartments of pDCs, where the complex of DNA-LL-37 
activates TLR-9 [136], and respectively the aggregation of RNA and LL-37 leads to the 
activation of TLR-7 [135].   
More specifically, self-DNA-LL-37 binding to TLR-9 leads to the association with the adaptor 
molecule MyD88 (myeloid differentiation factor 88), which then recruits IL-receptor 
associated kinase (IRAK) 1 and 4. After association of IRAK-1 with MyD88, IRAK-1 is 
phosphorylated by activated IRAK-4, and directly associates with TNFR-associated factor 
(TRAF) 6 [181]. Recruitment of TRAF-6 to the cytoplasmic transductional-transcriptional 
processor (CTTP) complex leads to the activation of the interferon regulatory factor (IRF) 7, a 
transcription factor for early IFN genes [182]–[185]. Furthermore, the CTTP complex is also 
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activating IRF-5 that induces together with NF-κB the secretion of proinflammatory cytokines, 
including IL-6 and TNF-α in pDCs [186].  
pDCs are key effector cells in inflammatory conditions linking innate and adaptive immunity. 
The production of large amounts of IFN-α induces several inflammatory responses: survival 
and differentiation of T lymphocytes, activation of NK cells, maturation of monocytes to fully-
differentiated, and activated dendritic cells as well as involvement in the differentiation of 
B lymphocytes [187]–[192].  
V.2.6. Therapies  
Although a range of diverse therapies is available for the treatment of psoriasis, there is no 
definite cure.  
The selection of therapy and potential combination of therapies is dependent on various 
factors. First, patient-related factors such as age, gender and physical and mental health. 
Second, psoriasis-related factors including type, severity disease duration, as well as 
comorbidities and previous therapies [56]. Existing therapies aim to induce remission and to 
mitigate the severity of psoriasis (PASI 50, i.e. 50% reduction of PASI), thereby improving 
quality of life [193]. Four therapy modalities are available for the treatment of psoriasis, which 
can be used either alone or as a combination: topical monotherapy, phototherapy, systemic 
treatments and biological agents. 
V.2.6.1. Topical treatment 
Despite their disadvantages, topical monotherapies remain the first-line treatment for most 
patients with mild psoriasis. Among those, topical corticosteroids, vitamin D3 derivatives, 
dithranol as well as retinoids are listed. They exist in different bases such as creams, lotions, 
foams and many more [194]. Keystones in psoriasis therapy are glucocorticoids, a member 
of corticosteroids that exhibit antiinflammatory and immunosuppressive features. Local side 
effects such as skin atrophy, purpura, as well as systemic effects including the iatrogenic 
Cushing´s syndrome limit the application period [195], [196]. Hyperproliferation of 
keratinocytes is hampered by the usage of dithranol as well as tazarotene; the latter 
represents the only topical retinoid available for treatment and is often combined with 
corticosteroids or vitamin D3 analogues. Monotherapy of tazarotene is moderately effective 
leading to local skin irritations [197]. Also vitamin D3 derivatives exhibit a beneficial effect on 
psoriatic plaques by modulating proliferation and differentiation, as well as infiltration and 
activation of neutrophils and other immune cells in psoriatic skin lesions [198].  
V.2.6.2. Phototherapy 
One of the most common treatments for managing psoriasis is phototherapy [199]. Narrow 
ultraviolet-B (nbUVB), highlighted at 311 nm, and psoralen combined with ultraviolet-A 
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between 315 and 400 nm (PUVA) are second-line therapies applied in between topical and 
systemic therapy [200], [201]. The dose of both therapeutic approaches is based on the 
minimal erythermogenic dose (MED). Their benefits are mainly based on suppressed 
TH1/TH17 inflammatory axis through altered cytokine expression, immune suppression of 
Langerhans cells and other immune cells, as well as induction of apoptosis [202]. 
Nevertheless frequent phototherapeutic treatments increase the risk of non-melanoma skin 
cancer [203]; both phototherapies are further associated with squamous cell carcinoma 
(SCC), whereas the PUVA method indicates a significantly higher risk [204]. Based on its 
decreased association with carcinogenesis and due to a comparable efficiency, nbUVB 
therapy is therefore the preferred phototherapy in psoriasis [201].  
V.2.6.3. Systemic treatment 
In moderate to severe psoriasis, affecting approximately 20 % of psoriatic patients, a 
systemic therapeutic approach is the most common choice of therapy [205]. Approved drugs 
are methotrexate (MTX), fumaric acid esters, acitretin, and cyclosporine. MTX, a folic acid 
antagonist, is a specific chemotherapeutic inhibiting DNA synthesis and cell cycle, but also 
acting on T cell and keratinocyte proliferation [194]. Nevertheless, other side effects are liver 
fibrosis, hepatotoxicity and gastrointestinal diseases. The latter is also described for fumeric 
acid esters, which in turn positively impacts clinical outcome by inhibiting the NF-κB pathway 
and increasing apoptotic effects on T lymphocytes [194], [206], [207]. A systemic drug that 
has no immunosuppressive effects is the retinoid acitretin. Its treatment leads to a 
normalization of keratinocyte proliferation and differentiation and is considered excellent for 
use in combination with phototherapies [194], [208]. Cyclosporines possess 
immunosuppressive effects by inhibiting T lymphocyte activation and production of cytokines 
as well as by decreasing the amounts of dendritic cells, and additionally effecting epidermal 
keratinocytes [201], [209]. However, side effects such as nephrotoxicity and increased risk 
for malignant melanoma are associated with cyclosporine treatment [194]. 
V.2.6.4. Biologica 
Recent advances in psoriasis research led to the development of new therapeutical agents, 
the so-called biologica; a group of recombinant proteins, fusion proteins and/or monoclonal 
antibodies. Two of the best-known representatives of biologica are T cell agents and TNF-α 
inhibitors [194]. Alefacept is a human leukocyte function associated antigen-3/IgG1 fusion 
protein that interferes with T cell antigen presentation and is involved in apoptosis of memory 
effector T cells in the skin [210]. Another example is Efalizumab, also referred to as T cell 
agent, which targets a crucial step in the pathogenesis of psoriasis, and resembles the 
adhesion between T lymphocytes and endothelial cells. After a 12-week cycle of T cell agent 
injections 20 to 25 % of the patients achieve a PASI 75 (75 % reduction of PASI) [194]. TNF-
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α inhibitors that have been approved by the ‘Food and Drug Administration’ (FDA) are 
Etanercept, Infliximab, and Adalimumab. Blockade of TNF-α results in many cases in 
disease improvement, but a clinical resolution is not achieved [211]. Novel biologicals such 
as the recently approved Ustekinumab or Secukinumab target interleukin-17A or p40, a 
subunit of interleukin 12/23, respectively [212], [213]. 
 
The psoriatic cascade starts with the activation and/or maturation of keratinocytes and DCs 
leading to the differentiation of T lymphocytes. Lymphocytes, DCs, neutrophils and 
keratinocytes produce cytokines, growth factors, as well as chemokines and activate diverse 
signaling pathways, including the NF-κB and the STAT-3 pathway, thereby driving 
inflammation and the formation of psoriatic plaques. However, many questions regarding the 
observed imbalanced regulation mechanisms supporting progression of psoriasis remain. 
Among others, the identity of factors guaranteeing the sustained activation of these pathways 
remains unresolved. Recent data provided evidence for a potential contribution of pattern 
recognition receptors (PRR). Among those, a role for the receptor for advanced glycation 
end-products (RAGE) in various inflammatory setting has been implicated, pointing towards 
a potential function also in the pathogenesis of psoriasis.  
 
V.3. The receptor for advanced glycation end-products (RAGE)  
V.3.1.  Characterization 
The receptor for advanced glycation end-products, short RAGE, is a multiligand pattern 
recognition receptor and belongs to the super-immunoglobulin gene family [214], [215]. 
RAGE was first identified from bovine lung endothelium as a transmembrane receptor for 
advanced glycation end-products (AGEs) [215].  
The gene AGER, which is encoding for RAGE, is located within the MHC class III region on 
human chromosome 6p21.3 [216], [217] and murine chromosome 17 [218]. Human AGER 
consists of 11 exons and 10 introns [216], [217] and is further characterized by a multiple 
number of functional elements within the regulatory 5’-untranslated region (UTR). Common 
elements regulating AGER transcription comprise binding sites for transcription factors such 
as NF-κB, activator protein (AP) -1 and AP-2, or specificity protein 1 (SP-1) [219], [220], as 
well as methylation sites, thereby additionally allowing an epigenetic regulation of AGER 
[221].  
The expression of RAGE and thereby its function is also affected by several single nucleotide 
polymorphisms (SNPs) in the AGER promoter. GWAS described a threonine to alanine 
Introduction 
19 
substitution at position -374 (-374T/A) and a threonine to cysteine substitution (-429T/C) 
[222], [223]. At position +82 a glycine to serine substitution is enhancing expression of AGER 
gene and has been associated with chronic inflammation, which is predicted by increase 
expression of proinflammatory cytokines [224]–[227]. Additionally, alternative promoters for 
AGER are described [228]. RAGE mRNA is 1.4 kilo base pairs (kb) in size and undergoes 
further regulations via polyadenylation at the 3’UTR as well as binding of miRNAs to target 
sites, leading to its transcriptional degradation or translational inhibition [229], [230].   
The unspliced mRNA is translated into a protein of 404 amino acids (aa) with a molecular 
mass of 55 kDa, known as full-length RAGE (fl-RAGE) [214]. RAGE is a highly conserved 
protein, showing 78 % amino acid homology between human and mice [231], and composed 
of a single hydrophobic transmembrane domain, a highly charged C-terminal intracellular tail 
and an extracellular region. This N-terminal extracellular region comprises a signal sequence 
for secretion (1-22 aa), one viable (V-type) immunoglobulin domain (23-116 aa), and two 
constant (C-type) immunoglobulin regions (124-221 aa, 227-317 aa) [232], [233]. The V-type 
domain together with the C1 domain builds an integrated structural unit that is principally 
required for RAGE binding to extracellular ligands [234], [235]. Only two of the wide variety of 
RAGE ligands shows a low binding affinity to the C2 domain [236], [237]. The separation of 
the V-C1 complex to the C2 region is provided by a 5 aa flexible linker sequence, thereby 
allowing the latter to function in a fully independent manner to the V-C1 unit [234]. The 
cytoplasmic tail (364-404 aa) is of high importance for RAGE-mediated intracellular signaling, 
despite the absence of known signaling motifs [232], [233], [238].  
Alternative splicing of the AGER transcript creates 19 natural splice variants beside fl-RAGE, 
mainly characterized by different extends and localizations of truncations [239], resulting in 
distinct amino acid sequences. For instance, these alterations affect the ligand binding 
domain or lead to the removal of the transmembrane helix [240]–[243]. The metalloproteases 
ADAM 10 and matrix metallopeptidase (MMP) 9 have been shown to restrict the presence of 
RAGE on the cell surface by receptor shedding. More specifically, cleavage of RAGE close 
to the transmembrane region leads to a soluble RAGE (sRAGE) isoform that shares the 
same V-C1-C2 region with fl-RAGE but lacks the transmembrane and intracellular domains 
[244], [245]. Extracellular sRAGE molecules can function as “decoy” receptors by competing 
with fl-RAGE for ligand binding, and thereby attenuate the activation of the RAGE signaling 
pathway [228], [246]. Besides that, the cleaved ectodomains can also accumulate in 
intracellular vesicles, while the C-terminal region has been found to localize in the cytoplasm 
or the nucleus [244], [245], [247].  
Moreover, besides posttranscriptional modification by proteolysis RAGE function can be 
regulated by phosphorylation and glycosylation, both known to promote ligand binding and 
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signaling, as well as by disulfide bond formation between conserved cysteine residues within 
the immunoglobulin domains [214].  
Not only intrastructural alterations within the RAGE molecule can lead to different properties, 
but also the preassembly into dimers or oligomers affects its function. Fluorescence 
resonance energy transfer (FRET) analyses showed that RAGE molecules can assemble 
and form homodimer and homooligomers, as well as heterodimer with heparin sulfate 
proteoglycans (HSPGs) and TLRs. Ligand binding enhances the heterodimerization; for 
instance, S100B stimulus leads to the stabilization of RAGE-TLR-2 heterodimers [235]. 
However, dimerization or oligomerization is not only a consequence of ligand binding, Xie 
and colleagues could show that the formation of homodimers and homooligomers of RAGE 
on the cell surface appears in a ligand-independent manner [248].  
During embryonic development, RAGE is highly expressed in a constitutive manner 
especially in the brain [249]. In comparison to embryonic cells, RAGE expression is 
predominantly reduced to basal levels in many differentiated adult cells like neutrophils, 
macrophages, lymphocytes, DCs, and vascular endothelial cells [249], [250]. An exception is 
the adult lung where RAGE is constitutively expressed at high level in the alveolar epithelium 
[249], [251]. It is believed that basal levels of RAGE but also the high expression in the lung 
guarantee homeostasis of cells and tissue [252], [253]. Under pathological conditions RAGE 
expression is drastically induced on the basis of accumulated RAGE ligands and/or 
inflammatory mediators in most of the tissues. [232], [252], [253]. Human disorders with 
observed high expression of RAGE are inter alia diabetes, Alzheimer´s disease, and acute 
and chronic inflammatory conditions [254]. 
RAGE represents a key molecule in the interplay between the innate and adaptive immune 
system highlighted by its expression on lymphocytes [255]–[258] and DCs [259]–[261]. 
Additionally, its sustained signaling leads to the establishment of chronic inflammatory 
diseases [262], [263]. 
V.3.2. RAGE ligands 
RAGE is a pattern recognition receptor mediating physiological and pathological effects 
through interaction with a variety of ligands characterized by diverse molecular properties 
[264]. Most ligands bind to the positive charged V-C1 domain of RAGE, implying an 
electrostatic and not a pattern-dependent interaction between RAGE and its ligands [265]–
[267]. 
V.3.2.1. Advanced glycation end-products 
Non-enzymatic glycation and oxidation of proteins and lipids during maillard reaction 
generate negatively charged advanced glycation end-products (AGEs) with high affinity for 
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RAGE [214], [268]. AGE accumulation is associated with diverse biological setting such as 
diabetes, aging, Alzheimer´s disease, and inflammation [269]–[273].  
V.3.2.2. Damage-associated molecular pattern molecules 
Damage-associated molecular pattern (DAMP) molecules, also known as alarmins, are either 
released actively or passively by stressed cells. These endogenous danger signals promote 
systemic inflammatory responses in the absence of an infection, which distinguishes them 
from exogenous pathogen-associated molecular pattern (PAMPs). Increased serum levels of 
DAMPs are associated with many diseases including sepsis, arthritis, cancer, and 
inflammation [63], [274]–[276]. DAMPs are characterized by their ability to recruit and 
activate receptor-expressing immune cells and to promote reconstruction of destroyed 
tissues [277]. They include proteins such as the high-mobility group box 1 (HMGB1), S100 
family members, heat shock proteins, uric acid, adenosine triphosphate (ATP), fibrils of 
amyloid-β, serum amyloid A, and DNA [277]–[284]. 
The next sections will focus on HMGB1 and the S100 protein family, since they represent 
well-known ligands of RAGE with high importance for chronic inflammatory diseases 
including psoriasis [285]–[287]. 
V.3.2.2.1. S100 proteins 
The S100 family consists of more than 20 family members that are 9 to 13 kDA acidic 
proteins, characterized by the presence of two calcium binding EF-hand motifs [288]. Most of 
these proteins are encoded within the EDC on chromosome 1q21 (PSORS4). S100 proteins 
are able to form dimers or oligomers spontaneously [289]–[291]. Despite the fact that S100 
family members show a high similarity regarding their sequence and structure, they are not 
functionally redundant and involved in diverse biological processes such as proliferation, 
migration, differentiation, and inflammation [292]–[294]. In the intracellular compartment 
S100 proteins modulate many processes, including calcium homeostasis, cytoskeletal 
organization, cell cycle progression as well as cell growth and differentiation [290], [295]. 
However, S100 proteins can also be released into the extracellular space, through a 
mechanism that remains elusive. They are not secreted via the classical Golgi pathways due 
to their lack of a leader sequence. Furthermore, it is still under discussion if S100 proteins 
are actively secreted or passively released by necrotic cells. [294]. Nevertheless, their 
extracellular functions are manifold and not been fully clarified for all family members. Most 
extracellular functions with impact on cancer and inflammatory responses are mediated via 
binding to RAGE. In general, S100-RAGE interaction activates multiple signaling pathways, 
including NF-κB, AP-1, and STAT-3 pathways, thereby resulting in enhanced expression of 
proinflammatory cytokines and cellular adhesion [287]. 
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Many members of the S100 family are connected to chronic inflammatory disorders. For 
example antimicrobial peptides as S100A8, S100A9, and S100A12 were shown to be 
involved in the attraction of immune cells to inflamed tissue, in the communication between 
keratinocytes and immune cells, as well as in enhanced production of proinflammatory 
cytokines by keratinocytes [238], [296], [297]. S100A8/A9, common antiparallel heterodimers 
of the S100 family, signal via RAGE with subsequent activation of the NF-κB pathway and 
induction of proinflammatory mediators, including themselves. This leads to the generation of 
a self-sustained proinflammatory feed-forward signaling loop [263], [298]. Accordingly, 
S100A8/A9 as well as S100A12 serum levels are often used as inflammatory biomarkers 
[299]–[301]. Moreover, cytokines released by TH1, TH17, and TH22 cells induce S100A7 and 
S100A15; both act as chemoattractants for different leukocytes, thereby linking innate and 
adaptive immune reactions [302]–[304].   
In most inflammatory lesions and blood of patients with different inflammatory and 
autoimmune disorders increased S100 protein levels have been found [278], [305]. 
Moreover, for several S100 proteins antimicrobial functions are described [133]. 
Nevertheless, their exact contribution to inflammation-associated process remains to be 
examined in detail.  
V.3.2.2.2. High-mobility group box 1 
The high-mobility group box 1 (HMGB1) is a small protein consisting of two tandem HMG box 
domains and an acidic C-terminal tail. Depending on its location HMGB1 is involved in DNA 
replication and repair, or in inflammatory immune responses. Within the nucleus HMGB1 acts 
as a non-histone DNA binding protein, binding DNA in a conformation-dependent but 
sequence-independent manner, and as a transcriptional regulator [306], [307]. In order to 
function as proinflammatory cytokine, HMGB1 has to be released which requires protein 
shuttling from the nucleus to the cytoplasm or/and prevention of nuclear transport of newly 
synthesized proteins. Furthermore, posttranslational modification such as phosphorylation, 
methylation, and acetylation leads to the inhibition of the nuclear import and thereby to the 
accumulation of HMGB1 in the cytoplasm [308]–[310]. The non-classical secretion of 
HMGB1 can be triggered by several stimulatory cytokines such as lipopolysaccharide (LPS), 
IFN-γ, TNF-α, and IL-1β [311]–[313]. As the localization of HMGB1 is crucial for its function, 
inhibitory mechanisms for the HMGB1 secretion also exist. For instance, the presence of 
ethyl pyruvate and cholinergic agonist prevent the secretion of HMGB1 [314], [315]. 
Furthermore, the function of HMGB1 is not only controlled by its location, but also regulated 
by its ability to interact with different molecules. Amongst molecules with inhibitory effects on 
HMGB1 function proinflammatory cytokines such as CD24 and thrombospondin are listed 
[316], [317]. In terms of thrombospondin, the inhibitory molecule directly binds to HMGB1, 
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thereby blocking its interaction with RAGE [318]. However, there are binding partners of 
HMGB1 that show a positive influence on the accessibility and signaling of HMGB1 through 
different receptors. Positive modulators include nucleosomes, PAMPs (in particular LPS), 
cytokines, and chemokines such as IL-1β and CXCL12, as well as DNA molecules [319]–
[323].  
A role of HMGB1 has been associated with a diversity of human diseases such as sepsis 
and cancer, where HMGB1-RAGE interactions regulate the migration and invasion of tumor 
cells [276], [324], as well as with inflammation and autoimmune diseases [285], [325]. At 
specific inflammatory sites high amounts of HMGB1 as well as a multitude of HMGB1-
sensing cells were detected [326], [327]. HMGB1-RAGE interaction on dendritic cells 
promotes their maturation and activation, and simultaneously induces upregulation of 
HMGB1 [328], [329]. In other words, HMGB1 is activating DCs in an autocrine as well as in a 
paracrine loop [330]. Moreover, binding of HMGB1 to RAGE influences T cell differentiation, 
invasion of monocytes to inflammatory regions, and the transmigration of neutrophils [256], 
[260], [331]–[333]; major processes during inflammatory response. 
V.3.3. RAGE signaling pathway 
RAGE ligation is capable of inducing an array of cell signaling pathways, including the 
activation of mitogen-activated protein (MAP) kinases [334]–[336], PI3K/Akt 
(phosphoinositide 3-kinase) pathways [337], and the induction of Rho GTPases [338]. All 
these pathways are involved in different important cell regulatory mechanisms. Downstream 
transcription factors such as NF-κB, AP-1, or STAT-3 induce the expression of chemokines, 
cytokines, and other regulatory molecules. For example in DCs, binding of HMGB1 to RAGE 
results in the activation of MAP kinases ERK1/2 and p38, and consequently in the induction 
of NF-κB. In turn, NF-κB leads to the expression of cytokines like IL-6 and TNF-α, which 
promotes DC maturation [328], [339].  
The outcome of RAGE signaling depends on a variety of conditions inter alia the identity of 
the ligand, ligand concentration, presence of co-receptors, co-ligands or adaptor molecules, 
as well as the surface concentration of RAGE and its oligomerization status [339]. Moreover, 
RAGE signaling is also dependent on cell types involved. For instance, RAGE engagement 
in macrophages induces signaling cascades including ERK1/2 and p38 MAP kinases, 
whereas neutrophils respond with an activation of PI3K-dependent signaling pathways 
instead of ERK1/2 or p38 MAP kinases activation [337], [340], [341] (Figure 2).  
While the ectodomain of RAGE is important for converting an extracellular into an 
intracellular signal, the C-terminal tail of RAGE is essential for translating the signal into a 
cellular response [342]. Indeed, studies showed that the cytoplasmic deletion mutant of 
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RAGE impaired intracellular signaling upon ligand engagement in a dominant-negative 
manner [276], [343], [344]. Recent studies using immunoprecipitation assays and yeast two-
hybrid system described the MAP kinases ERK1/ERK2 and the diaphanous 1 (DIA-1) as 
direct interaction partners of the cytoplasmic tail of RAGE [338], [345]. Due to ligand binding, 
the C-terminal tail of RAGE gets phosphorylated allowing the binding of adaptor molecules 
like MyD88 (Figure 2). Noteworthy, also the TLR-9/MyD88 pathway plays a critical role in the 
initiation of adaptive immune responses and thereby in the establishment of inflammatory 
conditions [346], linking RAGE to TLR signaling in these contexts.  
A characteristic feature of the RAGE signaling is the ability to induce, despite a diverse set of 
signaling molecules, also its own expression via a NF-κB-dependent positive feed-forward 
loop [342], [347]. The existence of two NF-κB response elements at position -1518/-1510 and 
-671/-663 in the promoter region of AGER enables the binding of NF-κB, which results in 
enhanced RAGE expression and signaling [220]. This self-induced mechanism allows the 
cells to immediately respond to external stimuli.  
However, deregulated RAGE signaling can cause hyperactivation of important signaling 
pathways leading to pathological features. Nevertheless these pathways are highly complex 
and have not been fully elucidated. 
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V.3.3.1. RAGE signaling in homeostasis 
While most studies focus on RAGE and its function in pathological conditions such as 
inflammation and cancer, little is known about the physiological function of RAGE, yet.  
Genetically engineered Rage-deficient mice (Rage-/-) appear normal and show no obvious 
alteration under physiological conditions. Furthermore, these mice exhibit any obvious 
developmental defects and functional neural development [349]. However, potential 
compensatory mechanisms in Rage-/- mice have not been studied in detail; therefore RAGE 
effects in homeostasis cannot be ruled out.  
In 2008, Reynolds and colleagues have proposed that RAGE is crucial for the embryonic 
lung development and postnatal pulmonary morphogenesis [350]. However, expression of 
Figure 2 Signaling pathway downstream of RAGE. 
RAGE serves as a receptor for various groups of ligands. Engagement of RAGE with one of its 
ligands induces a cytosolic signaling cascade resulting in the activation of NF-κB, AP-1 or STAT-3. 
Activation of transcription factors increases inter alia the secretion of proinflammatory cytokines, 
RAGE, and its ligands (adapted from [285], [348]). 
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RAGE during lung development as well as in adult lung can lead to lung hyperplasia and 
alveolar destructions [351], [352]. 
The physiological role of RAGE in the lung as well as in other tissues remains exclusive and 
needs further investigation.  
V.3.3.2. RAGE signaling under pathological conditions 
Since RAGE signaling mediates the recruitment of inflammatory immune cells as well the 
secretion of proinflammatory cytokines and chemokines [238], [333], [353], a role in 
pathological conditions has been hypothesized. Indeed, RAGE has been implicated in many 
different diseases including Alzheimer’s disease [354], [355], atherosclerosis [356], arthritis 
[224], diabetes mellitus [357], cancer [263], [276], and inflammatory diseases [262], [358]. 
In terms of Alzheimer´s disease, RAGE has been described as a receptor for amyloid-β, a 
major component of amyloid plaques [359]. More specifically, RAGE engagement generates 
oxidative stress and activates NF-κB in neurons, while microglia respond with enhanced cell 
proliferation and migration. This identifies RAGE as a mediator of neurotoxicity [215], [354], 
[355], [360]. Moreover, Amyloid-β/RAGE interaction is suggested to be involved in impaired 
memory in Alzheimer´s disease by decreasing on long-term potentials [361]. Several studies 
have demonstrated that also the RAGE-S100 interaction is associated with 
neurodegenerative diseases. For example, high doses of S100B induce death of neurons 
[362], [363] as well as activation of microglia [364], [365] and astrocytes [366]. 
RAGE has been detected in macrophages, T lymphocytes, as well as in some 
B lymphocytes in synovial tissue. As these cells are implicated in the development of 
arthritis, a role of RAGE in the pathogenesis of this disease has been suggested [367]. 
Enhanced activation of RAGE due to the accumulation of AGEs, HMGB1, and S100 proteins 
alters the mechanical properties and metabolism of the flexible connective tissue, cartilage, 
contributing to its degradation, as seen in arthritis [368], [369].  
Furthermore, elevated RAGE expression has been detected in a variety of tumors, including 
liver [370], gastric [371], colon [372], breast tumors [370], as well as malignant melanoma 
[373]–[375]. The role of RAGE in carcinogenesis depends on the tissue the tumor is located 
in and the involved coherent signaling pathways. A study from 2013 suggested that a 
possible explanation for this observation could be the presence of distinct isoforms of RAGE 
that effect tumor migration, invasion, and adhesion differential [376]. In contrast to most 
types of cancers, lung carcinomas exhibit decreased expression of RAGE, while, as 
mentioned before, RAGE is highly expressed in healthy lung tissues [377]. However, in 
general it is known that RAGE-dependent chronic inflammatory conditions predispose to 
carcinogenesis and also promote tumor progression [378]. 
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V.3.3.2.1. RAGE signaling in cutaneous chronic inflammation 
RAGE expression is low in adult tissue, including innate and adaptive immune cells such as 
neutrophils, T and B lymphocytes, monocytes, macrophages, dendritic cells, and endothelial 
cells but increases upon activation [253], [258], [379]. However, despite the expression of 
RAGE, these cells also secrete its ligands. Therefore, they are most likely not only 
contributing to RAGE-dependent inflammatory responses but also crucial for their initiation 
and propagation [380]. For instance, the autocrine/paracrine RAGE signaling of DCs 
facilitates the maturation of these cells and is necessary for their migration into draining 
lymph nodes allowing their interaction with naïve T lymphocytes [261]. Moreover, Chen and 
colleagues demonstrated increased levels of TH2-related cytokines in RAGE-deficient T cells, 
and vice versa a decreased expression of IFN-γ, a TH1 proinflammatory cytokine, thereby 
illustrating the importance of RAGE on T lymphocytes not only for the induction of an 
immune response but also for its modulation [256].  
Furthermore, RAGE engagement and consequent activation of proinflammatory transcription 
factors such as NF-κB leads to the expression of target genes, encoding for some well-
described regulators of the innate and adaptive immune system [347]. Another contribution 
of RAGE to the inflammatory response is given by its expression on endothelial cells and its 
ability to interact with leukocyte β2 integrin Mac1, thereby acting as an adhesion receptor for 
leukocytes [278], [381], [382]. Herold and coworkers demonstrated that oligomeric ligands 
have a higher affinity to RAGE thereby inducing a persistent signaling which leads to a 
chronic inflammation; whereas monomeric ligands are only able to induce an acute 
inflammation [383]. Upon signal transduction, RAGE-dependent activation of intracellular 
pathways leads to the subsequent induction of NF-κB and downstream target genes. 
Through the utilization of the aforementioned positive feedback loop, RAGE guarantees 
sustained signaling, thereby contributing to the maintenance of a chronic inflammation such 
as psoriasis. 
Besides immune cells also other cell types within the skin, such as keratinocytes, contribute 
to an inflammatory phenotype of the skin. Using Rage-/- mice, it was shown that RAGE 
signaling in keratinocytes is influencing epidermal structure and is involved in the dermal 
immune response, at least under acute inflammatory conditions [384]. 
V.3.3.2.2. Impact of RAGE in the pathogenesis of psoriasis 
The expression of RAGE in immune and cutaneous cells, the high stability of RAGE-ligand 
complexes, as well as the existence of a positive feed-forward loop sustained RAGE 
signaling in inflammatory conditions strongly recommend a role of RAGE in the initiation and 
maintenance of a cutaneous chronic inflammation such as psoriasis.  
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A first strong connection between RAGE and psoriasis is given by a genetic link; indeed, 
AGER encoded within the psoriasis susceptibility locus 1 (PSORS1) on chromosome 6p21.3 
[216], [217]. Furthermore, genes for the members of the S100 family, S100A7 and S100A15, 
are positioned within the PSORS4 on chromosome 1q21 in the EDC [385]. That psoriasis is 
genetically linked both, receptor and ligands, is not the only evidence for a potential role of 
the RAGE axis in psoriasis. During skin inflammation keratinocytes are characterized by 
increased production and secretion of S100A7 and S100A15 [386]–[388]. In 2008, Wolf and 
colleagues further demonstrated that the S100A7-RAGE interaction chemoattracts 
leukocytes into inflamed skin, displaying an important step in the induction and maintenance 
of an inflammation [302]. Two years later the same group exhibited that the overexpression 
of S100A7/A15 increases a RAGE-dependent secretion of TH1- and TH17-related 
proinflammatory cytokines by applying a double-transgenic mouse model [303]. 
Another early event in the initial phase of psoriasis is the induction of S100A8/A9 and their 
consequent binding to RAGE [63]. This interaction is connected to hyperplasia, a hallmark of 
psoriasis, by the stimulatory effects of the S100/RAGE axis on the growth of normal human 
keratinocytes in vitro [389].  
Moreover, the elevation of other RAGE ligands such as AGEs has been described as a 
characteristic of an inflammatory psoriatic response [390]. AGE-RAGE interaction stabilizes 
the active state of the receptor, thereby leading to enhanced production of proinflammatory 
cytokines [245], [391]. An additional characteristic of the inflammatory response found in 
psoriasis is the induced migration of T lymphocytes to the sites of skin inflammation that is at 
least partially established by RAGE-mediated signaling [331], [338]. 
 
Considering RAGE as a potential regulator of several processes involved in the development 
of a psoriatic disease, a better understanding of its activation in psoriasis, comprising the 
contribution of distinct ligands, and its functional relevance in different cell types associated 
with psoriasis can be beneficial for the development of new therapeutic targets.    
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VI. Material and Methods 
VI.1. Materials 
Reagents and kits Company Catalog # 
2-(4-Aminophenyl)-1H-indole-6-carboxamidine 
(DAPI) 
Roche Diagnostics 10236276001 
β-Mercaptoethanol Gibco® Life Technologies 31350-010 
7-AAD Viability Staining Solution affymetrix 00-6993-50 
20 % Sodium dodecyl sulfate (SDS) G-Biosciences 786016 
100bp DNA ladder Thermo Scientific  SM1143 
Acetone Sigma-Aldrich 32201 
Acid alcohol Sigma-Aldrich 56694 
Agarose NEEO ultra-quality Carl Roth 2267.4 
Albumin Fraction V Carl Roth 8076 
Antibody Diluent Dako S0809 
Arcturus PicoPure RNA isolation Kit Applied Biosystems KIT0204 
autoMACS® Columns Miltenyi 130-021-101 
autoMACSTM Rinsing Solution Miltenyi 130-091-222 
autoMACSTM Running Buffer Miltenyi 130-091-221 
Braunol® Braun 3864154 
Calcium (Ca2+) Sigma-Aldrich 215147 
Citric acid Sigma-Aldrich C-6445 
Cloroform (CHCl3) Sigma-Aldrich 32211 
Color Reagent A + B R&D DY999 
Dako Fluorescent Mounting Medium Dako S302380-2 
Delimiting Pan Dako S2002 
Diamond pDC isolation Kit Miltenyi 130-092-402 
Diamond pDC isolation Kit II Miltenyi 130-097-240 
Eosin Sigma-Aldrich HT110132 
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Ethanol (EtOH) Sigma-Aldrich 459844 
Ethidiumbromide Carl Roth 7870 
Ethylene diamine tetraacetic acid (EDTA) Gerbu 1034 
Hematoxylin Sigma-Aldrich GHS132 
HIER citrate buffer Zytomed systems ZUC028 
HMGB1 ELISA Kit IBL ST51011 
IL1β/IL1F2 DuoSet ELISA Kit R&D DY201 
MACS BSA Stock Solution Miltenyi 130-091-376 
Methanol (MeOH) Sigma-Aldrich 32213 
Paraformaldehyde Sigma-Aldrich P6148 
Phosphate Buffered Saline (PBS) Biochrom L182-50 
Phusion Taq Thermo Scientific F-530 
peqGOLD RNAPure peqlab  30-1020 
Peroxidase block solution Dako S2023 
Potassium chloride (KCl) Carl Roth 6781 
ProcartaPlex mouse TH9/TH22/TH17/Treg 
cytokine panel (6plex) 
affymetrix EPX-060-
20822-901 
Proteinase K New England Biolab P8102S 
RevertAid First Strand cDNA Synthesis Kit Thermo Scientific K1622 
RT2 ProfilerTM Mouse Innate & Adaptive   
Immune Response PCR Assay 
QIAGEN PAMM-052Z 
RNase-Free DNase Set QIAGEN 79254 
RNeasy Mini Kit QIAGEN 74106 
S100B ELISA Kit Abnova KA0037 
Sodium azide AppliChem A1430 
Sodium chloride (NaCl) Sigma-Aldrich 31434 
Sucrose Sigma-Aldrich S79003 
Sulfuric acid (H2SO4) Carl Roth 4623 
SYBR Green PCR Master Mix Applied Biosystems 4309155 
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Tissue Tek® Paraffin Wax Sakura 4502 
Tissue Tek® Mold Release Sakura 4141 
Tween® 20 Applichem A1389 
Tris-hydrochloride Carl Roth 9090 
Tri-sodium citrate Merck  1110371000 
Verikine™ IFN-α ELISA Kit Pbl assay science 41100-1 
Xylene Sigma-Aldrich 247642 
Table 2 Reagents and Kits 
 
Cell culture reagents Company Catalog # 
Corning™ cell scraper Sigma-Aldrich CLS3010 
Dimethylsulfoxide (DMSO) Carl Roth A994 
Dulbecco’s Phosphate Buffered Saline (PBS) Sigma-Aldrich D8537 
EDTA pH 8.0 Ambion AM9260G 
EpiLife® Medium with 60µM Calcium Gibco® Life Technologies MEPI-
500CA 
Fetal Calf Serum (FCS) Biochrom S0415 
Ficoll/Pancoll, human Pan-Biotech P04-60500 
Human Keratinocyte Growth Supplement 
(HKGS) 100x 
Gibco® Life Technologies S0015 
Lab Tek chamber slide Thermo Scientific 177402 
Normocin Invivogen ant-nr 
Nylon cell strainer (40-µm) BD falcon 352340 
Nylon cell strainer (100-µm) BD falcon 352360 
Penicillin-Streptomycin Sigma-Aldrich P4333 
RPMI-1640+GlutaMAXTM-I Gibco® Life Technologies 61870-044 
Trypan blue solution Fluca 93595 
Trypsin-EDTA solution Sigma-Aldrich T3924 
Table 3 Cell culture reagents 
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Stimulatory molecules Company Catalog # 
Disulfide HMGB1, LPS-free HMGBiotech HM-120 
Mouse IL-23 recombinant protein, carrier-free affymetrix 34-823185 
S100-b bovine brain Merck 559290 
Class A CpG oligonucleotide (ODN-2216) Invivogen tlrl-2216 
Recombinant human IL-3 PeproTech 200.03 
Imiquimod Invivogen tlrl-imq 
Aldara cream (5 % Imiquimod) MEDA  
Table 4 Stimulatory reagents  
 
Antibodies Company Catalog # 
Primary Antibodies 
Goat-anti-Calgranulin A SantaCruz sc-8113 
Goat-anti-Calgranulin B SantaCruz sc-8114 
Hamster-anti-CD11c BD 550283 
Hamster-anti-CD11c-APC Biolegend 117309 
Rat-anti-CD45 BD 550539 
Mouse-anti-CD123-FITC Miltenyi 130-090-897 
Mouse-anti-CD303-APC Miltenyi 130-090-905 
Rabbit-anti-Filaggrin Abcam ab24584 
Rat-anti-F4/80 Abd Serotec MCA497GA 
Rabbit-anti-IL17 Abcam ab79056 
Rabbit-anti-IL-22 Abcam ab18499 
Rabbit-anti-IL-23 LSBio LS-B1366 
Mouse-anti-Involucrin Sigma I9018 
Mouse IgG2B isotype ctrl R&D MAB004 
Mouse-anti-Keratin-14 Covance PRB-155P 
Rabbit-anti-Ki67 Abcam ab16667 
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Rat-anti-Ly-6B.2 Abd Serotec MCA771GT 
Rabbit-anti-RAGE Abcam ab37647 
Mouse-anti-RAGE R&D MAB11451 
Secondary Antibodies 
Donkey-anti-goat Cy3 Dianova 705-485-147 
Donkey-anti-rabbit Cy2 Dianova 711-225-152 
Donkey-anti-rabbit Cy3 Dianova 711-166-152 
Goat-anti-hamster Cy3 Dianova 127-165-160 
Goat-anti-mouse Cy3 Dianova 115-165-062 
Goat-anti-rabbit Cy3 Dianova 111-165-045 
Goat-anti-rabbit HRP AEC+ Dako K400911-2 
Goat-anti-rat Cy 3 Dianova 112-165-062 
Table 5 Antibodies 
VI.2. Buffer solutions 
Lysis buffer  
100 mM Tris-HCl (pH 8.8) 
5 mM EDTA (pH 8.0) 
0.2 % SDS 
200 mM NaCl 
prior use: 100 µg/ml Proteinase K 
Salt buffer 
4.21 M NaCl 
0.62 M KCl 
10 mM Tris (pH 8.0) 
Citrate buffer pH 6.0 
10 mM Citric acid 
0.05 % Tween® 20 
Sodium citrate buffer pH 6.0 
10 mM Tri-sodium citrate 
0.05 % Tween® 20 
Demasking buffer 
1.8 % Citrate buffer pH 6.0 
8.2 % Sodium citrate buffer pH 6.0 
Washing buffer (IF) pH7.6 
PBS 
0.05 % Tween®20 
FACS buffer 
PBS 
10 % FCS 
1 % Sodium azide 
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Analysis software Source 
7500 Software v2.0.5 Applied Bioscience 
BD FACSDivaTM Biolegend 
FlowJo 7.2.2. FlowJo 
GraphPad Prism 5 GraphPad Prism 
iControl 1.10©2012 TECAN 
ImageJ National Institute of Health (NIH) 
NIS-Elements Viewer Nikon 
Table 6 Analysis software 
Table 7 Devices 
Devices Company 
AB 7500 Real Time PCR machine Applied Biosciences 
AutoMACS Pro separator  Miltenyi 
Biovision + 1000/26MX Peqlab 
Cryostat CM3050S Leica 
Digital Caliper ETS Product Service AG 
DM LS light microscope Leica 
FACS Canto 4.0 BD biosciences 
Micro Dismembrator S Satorius 
NanoDrop ND-1000 Spectrophotometer Peqlab Biotechnologie GmbH 
Nikon Eclipse Ti Fluorescence microscope Nikon 
TECAN infinite F200 pro microplate reader Tecan 
Tissue Tek® TEC 5 Embedding System Sakura 
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VI.3. Methods 
VI.3.1. In vivo mouse experiments 
Rage-deficient (Rage-/-) mice were described previously [349], [392] and wildtype (wt) 
controls were obtained from Charles River Laboratories, France. Both, wt and Rage-/- mice 
were on a C57BL/5 background [349] and were housed in groups of 3 animals per cage with 
food and water ad libitum under specific pathogen-free and 12- hour light/dark cycle 
conditions. All animal experiments were performed with 11 to 13 week old female Rage-/- and 
wt mice.  
The procedures for performing animal experiments were in accordance with the principles 
and guidelines of the ‘Arbeitsgemeinschaft der Tierschutzbeauftragten in Baden-
Württemberg’, Germany, and were approved by the ‘Regierungspräsidium Karlsruhe’, 
Germany (G-13/12). 
VI.3.1.1. In vivo Imiquimod mouse experiments  
Chronic skin inflammation of mice back skin was generated according to the protocol of 
Imiquimod-induced psoriasis [54]. Mice received a daily topical dose of 62.5 mg Aldara 
cream (5 % Imiquimod) on the shaved back skins for six consecutive days. Progression of 
inflammatory response was measured daily by the adapted PASI score. Animals were 
euthanized 24 h after the last Imiquimod administration by cervical dislocation. Skin samples 
for RNA isolation were immediately frozen in liquid nitrogen. For histological analysis, tissue 
was fixed with 4 % (w/v) paraformaldehyde in PBS (pH 7.4) (PBS/PFA), paraffin-embedded, 
and subsequently cut into 1- µm sections.  Blood samples were taken, prepared and frozen 
in liquid nitrogen (VI.3.8.).  
VI.3.1.2. In vivo rIL-23 mouse experiments  
Chronic skin inflammation of the ear was generated according to the protocol of rIL-23-
induced psoriasis [53]. 20 µl PBS containing 500 ng recombinant mouse IL-23 (ebioscience) 
was intradermally injected into the ears of anesthetized mice. Injections were repeated every 
other day for 16 days. Ear thickness and adapted PASI score were measured directly before 
injections. Ear measurements were made in the center of the ear using a digital slide gauge 
(Digital Caliper). 24 h after the last treatment mice were euthanized by cervical dislocation, 
and tissues were collected. Skin samples for RNA isolation, histological analysis, and blood 
samples were prepared as described above. Lymph nodes were processed for FACS 
analysis (VI.3.9.). 
VI.3.2. Cell culture 
All cells were grown in a humidified atmosphere at 37 °C and 5 % CO2 and have been 
routinely tested for mycoplasma. Individual culture conditions are listed below.  
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VI.3.2.1. Cell culture of primary human keratinocytes 
Human keratinocytes were cultivated in EpiLife® Medium with 60 µM calcium supplemented 
with 1 % (v/v) human keratinocyte growth supplement (HKGS), 100 units/ml penicillin and 
100 µg/ml streptomycin, from here on referred to as keratinocyte medium. Every 5 to 6 days 
when 90 % confluence was reached the cells were subcultured using a 0.25 % to 0.5 % 
trypsin solution. 
VI.3.2.2. Isolation of primary human keratinocytes 
Human keratinocytes were obtained from foreskins, kindly provided by Dr. Uysal, Mannheim. 
Donor age ranged from newborns to three years old patients. Excised foreskins were 
incubated for 15 min at room temperature (RT) in 10 % Braunol solution, were washed with 
PBS, freed from subcutaneous adipose and loose connective tissues, and cut into strips 
about 2-3 mm width. Samples were incubated with the dermal side down in 0.25 % trypsin 
with 100 units/ml penicillin and 100 µg/ml streptomycin for 16 to 24 h at 4 °C. The epidermis 
of overnight digested tissue was peeled off and incubated in a 0.05 % trypsin/EDTA solution 
for 15 min at 37 °C. Primary keratinocytes were washed and transferred to 35- mm dishes 
containing keratinocyte medium supplemented with 0.05 % normocin. Approximately six 
days after isolation cells were attached and fibroblasts were removed by aspiration with 
1x phosphate buffered saline (PBS) with 0.2 % EDTA. 
VI.3.2.3. Stimulation of primary human keratinocytes 
Keratinocytes from passage 1 to 3 were used for all stimulation experiments. 
VI.3.2.3.1. Stimulation of primary human keratinocytes with RAGE ligands 
Keratinocytes were plated in 48- well plates at a density of 5 x 104 cells per well. Cells were 
stimulated with indicated concentrations of ligands (HMGB1 and S100B) alone, or pre-
complexed with CpG-A (ODN 2216) (Table 8). 
Stimulatory factors Concentration 
Disulfide HMGB1 5 µg/ml 
S100-b bovine brain 5 µg/ml 
CpG-A (ODN 2216) 300 nM 
Table 8 Stimulatory factors of primary human keratinocytes 
IL-1β protein concentration in cell culture supernatant was measured by ELISA. IL-1β mRNA 
levels were determined via RT-qPCR.  
VI.3.2.3.2. Stimulation of primary human keratinocytes with Imiquimod 
Keratinocytes were plated in 6-well plates at a density of 5 x 105 cells per well. Cells were 
differentiated for 7 days in keratinocyte medium containing 1.2 mM calcium and control cells 
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were cultivated in normal keratinocyte medium. After differentiation period, keratinocytes 
were stimulated with 100 µM Imiquimod for one to six hours. HMGB1 and S100B protein 
concentrations in cell culture supernatant were measured by ELISA.   
VI.3.2.4. Cell culture of primary plasmacytoid dendritic cells 
Human plasmacytoid dendritic cells (pDCs) were cultivated in RPMI-1640 medium 
supplemented with 10 % (v/v) heat inactivated fetal bovine serum (FCS), 100 units/ml 
penicillin, 100 µg/ml streptomycin, 0.05 % (v/v) normocin and 10 ng/ml interleukin-3, from 
here on referred to as pDC medium. 
VI.3.2.5. Isolation of primary human plasmacytoid dendritic cells 
pDCs were isolated from primary human peripheral blood mononuclear cells (PBMCs). For 
the isolation of PBMCs buffy coats, concentrated leukocyte suspension, from IKTZ 
Heidelberg were used. The buffy coat sample was diluted with an equal volume of 2 mM 
EDTA in PBS (PBS/EDTA) and overlayed on 15 ml ficoll (human density 1.077 g/l). The 
following ficoll gradient centrifugation was performed at 970 rcf for 15 min without brake. The 
PBMC interphase was transferred to 30 to 35 ml PBS/EDTA and centrifuged for 7 min at 
580 rcf with brake. Cell pellet was resuspended in 50 ml PBS and filtered through a 40- µm 
nylon mesh to provide a single cell suspension. Cells were counted with trypan blue and 
centrifuged for 10 min at 300 rcf at 4 °C. 4 x 106 cells were stored at 4 °C for FACS analysis. 
The remaining cells were used to isolate pDCs using the ‘Plasmacytoid dendritic cell 
Isolation Kit’ (Miltenyi) according to manufacturer’s instructions. Briefly, PBMCs were 
magnetically labeled with a biotin-antibody cocktail and anti-biotin microbeads. Non-
plasmacytoid dendritic cells were depleted with an autoMACS separator. The unlabeled 
fraction was collected, magnetically labeled with CD304 diamond microbeads and positively 
separated. The positive fraction contains pDCs, of which 5 x 105 were used for purity 
analysis via FACS.  
VI.3.2.6. Stimulation of primary human plasmacytoid dendritic cells 
pDCs were plated in 48- well plates at a density of 7.5 x 104 cells per well and either 
incubated with RAGE blocking antibody (MAB11451) or the corresponding isotype control 
(MAB004) at a concentration of 10 µg/ml 3 h prior as well as during stimulation. Cells were 
stimulated with indicated concentrations of ligands (HMGB1 and S100B) alone, or pre-
complexed with CpG-A (ODN 2216) for 24 h at 37 °C (Table 9).   
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Stimulatory factors Concentration 
Disulfide HMGB1 5 µg/ml 
S100-b bovine brain 5 µg/ml 
CpG-A (ODN 2216) 37.5 nM 
Table 9 Stimulatory factors of primary plasmacytoid dendritic cells  
After 24 h of stimulation supernatants were collected and stored at -20 °C until IFN-α ELISA 
analysis was performed. Cell lysates were resuspended in 70 µl extraction buffer and RNA 
was isolated (Arcturus PicoPure RNA isolation Kit). IFN-α mRNA levels were determined by 
RT-qPCR. 
In addition, pDCs were plated in a 4- well Lab Tek chamber slide at a density of 2.5 x 104 
cells per well, stimulated with Rage ligands alone or in complex with CpG and were prepared 
for immunofluorescence staining. 
VI.3.3. RNA isolation from cultivated cells  
RNA extraction was performed using the RNeasy Mini Kit (QIAGEN) or PicoPure RNA 
isolation kit (Life Technologies) according to manufacturer’s instructions. Briefly, pelleted 
cells were dissolved using RLT lysis buffer containing 1 % β-Mercaptoethanol followed by 
RNA extraction using a column-based purification. Every sample was DNase I-treated for 
15 min at RT followed by two washing steps and the elution in RNase-free H2O. RNA 
concentration and quality was measured using a NanoDrop ND-1000 spectrophotometer. 
Samples fulfilling the quality recommendations were further processed.  
VI.3.4. RNA isolation from murine skin  
For RNA isolation of murine skin, a teflon capsule was cooled down in liquid nitrogen, filled 
with 500 µl peqGOLD RNAPure and put in liquid nitrogen for another 20 to 30 sec. A 
precooled metal ball and tissue sample were added into the capsule. Covered capsule was 
inserted in a dismembrator and tissue was fragmented at 2500 rcf for 30 sec. Dismembered 
tissue was transferred into a corex tube, filled with 2 ml peqGOLD RNAPure and was 
incubated at RT until tissue powder was solved. Afterwards, 400 µl chloroform was added to 
the samples, followed by 15 sec shaking period and incubation on ice for 10 min. The 
following chloroform gradient centrifugation was performed at 12700 rcf for 20 min at 4 °C. 
The upper aqueous phase, containing RNA, was transferred into RNase-free tube and 
incubated on ice until RNA extraction was performed using the RNeasy Mini Kit (QIAGEN). 
RNA concentration and quality was measured using a NanoDrop ND-1000 
spectrophotometer. Samples fulfilling the quality recommendations were further processed.  
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VI.3.5. cDNA transcription  
500 ng RNA of each sample were then used for cDNA generation. In brief, RNA and H2O, as 
non-template control, were incubated with oligo (dT)18 primers in a volume of 12 µl for 5 min 
at 65 °C. Reverse transcription was performed using the RevertAid First Strand cDNA 
Synthesis Kit according to manufacturer’s advice. As control for successful removal of 
genomic DNA also reactions without reverse transcriptase were performed. Before use cDNA 
was diluted at a 1 : 5 ratio in nuclease-free H2O. 
VI.3.6. Quantitative real-time polymerase chain reaction (qPCR) 
VI.3.6.1. Standard qPCR analysis   
QPCR was performed using 2x SYBR Green PCR Master Mix and an Applied Biosystems 
7500 Real-Time PCR System. In each qPCR experiment 12.5 ng cDNA per sample were 
applied and amended by a non-template control as well as minus-reverse-transcriptase 
controls to monitor the quality of the assay. All primers used in this study show an efficiency 
within the range of 85 to 110 % as analyzed by cDNA dilution curves. After testing all 
samples for low variances of housekeeping gene expression (< 2 cycles) the results of 
human targets were normalized to hs_18S and for murine targets to mm_βActin. All samples 
were analyzed in triplicates and gene quantification was calculated using the Pfaffl method 
[393], calculating the delta-delta Ct (∆∆Ct). Statistical analysis was carried out in Excel and 
visualization of graphs in GraphPad Prism 5. Primers used in the study are listed in Table 10. 
 
Forward primer reverse primer 
human primer   
Hs_18S GAGGATGAGGTGGAAACGTGT TCTTCAGTCGCTCCAGGTCT 
Hs_HMGB1 CTAAGAAGTGCTCAGAGAGGTG GGAAGAAGGCCGAAGGAG 
Hs_IL-1β TGTGAAATGCCACCTTTTGA GGTCAAAGGTTTGGAAGCAG 
Hs_IFN-α AGTCTCTTCCACCCCAACCT TGGGAACAGAGCCTCCTAGA 
Hs_Involucrin TGTGAGTCTGGTTGACAGTAGC ATTCTTGCTCAGGCAGTCCC 
Hs_S100B CCACCAATATTCTGGAAGGG TCCACAACCTCCTGCTCTTT 
murine primer   
Mm_βActin TCACCCACACTGTGCCGATCTACGA GGATGCCACAGGATTCCATACCCA 
Mm_Il-17 CAGCAGCGATCATCCCTCAAAG TGAGGTTGACCTTCACATTCTGGA 
Mm_Il-22 ATACATCGTCAACCGCACCTTT AGCCGGACATCTGTGTTGTTAT 
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Mm_Il-23 TATCCAGTGTGAAGATGGTGGTG CACTAAGGGCTCAGTCAGAGTTG 
Mm_Ager TGGGCAGAGATGGCACAGGT AGCTGGCACTTAGATGGGAAACTT 
Table 10 QPCR primer 
VI.3.6.2. RT2 ProfilerTM PCR Array Mouse Innate & Adaptive Immune Responses 
The applied RT² Profiler™ Mouse Innate & Adaptive Immune Responses PCR Array profiles 
the expression of 84 immune response related genes, 5 house-keeping genes, as well as 
reverse transcriptase- and positive controls. Relevant genes out of following signaling 
pathways were analyzed and normalized to two house-keeping genes (βActin and Gapdh): 
Innate immunity, adaptive immunity, humoral immunity, inflammatory response, defense 
response to bacteria and defense response to viruses (Table 11). The average correlation 
coefficients of these arrays is higher than 0.99, ensuring reliable detection of differences in 
the expression between biological samples. cDNA from Imiquimod treated wildtype and 
Rage-deficient mice were used as biological samples in this assay. The arrays were 
performed using 2x SYBR Green PCR Master Mix and an Applied Biosystems 7500 Real-
Time PCR System according manufacturer’s protocol. 
RT² Profiler™ PCR Array Mouse Innate & Adaptive Immune Responses 
Pathway Genes 
 Innate Immunity  
PRRs Ddx58 (RIG-I), Nlrp3, Nod1 (Card4), Nod2, Tlr1, Tlr2, Tlr3, Tlr4, Tlr5, 
Tlr6, Tlr7, Tlr8, Tlr9. 
Innate cytokines Ccl12 (MCP-5, Scya12), Ccl5 (RANTES), Csf2 (GMCSF), Cxcl10 
(INP10), Ifna2, Ifnb1, Il18, Il1a, Il1b, Il2, Tnf. 
Other innate 
immunity genes 
Apcs, C3, C5ar1 (Gpr77), Casp1 (ICE), Cd14, Cd4, Cd40 (Tnfrsf5), 
Cd40lg (Tnfsf5), Cd8a, Crp, H2-Q10, H2-T23, Il1r1, Irak1, Irf3, Irf7, 
Itgam, Ly96 (MD2), Lyz2, Mapk1 (Erk2), Mapk8 (JNK1), Mbl2, Mpo, 
Mx1, Myd88, Nfkb1, Nfkbia (Iκbα, Mad3), Stat1, Ticam1 (TRIF), Traf6. 
 Adaptive Immunity  
Th1 marker Ccr5, Cd80, Cxcr3, Ifng, Il18, Il23a, Slc11a1, Stat4, Tbx21, Tlr4, Tlr6. 
Th2 marker Ccr4, Ccr8, Cd86, Gata3, Ifnb1, Il10, Il13, Il18, Il4, Il5, Il6, Nod2, Stat6. 
Th17 marker Ccr6, Il17a, Rorc, Stat3. 
Treg marker Ccr4, Ccr8, Foxp3, Il10. 
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T cell activation Cd80, Cd86, Icam1, Ifng, Il23a, Il6, Slc11a1. 
Adaptive 
cytokines 
Ccl12 (MCP-5, Scya12), Ccl5 (RANTES), Csf2 (GMCSF), Cxcl10 
(INP10), Ifna2, Ifng, Il10, Il13, Il17a, Il18, Il2, Il23a, Il4, Il5, Il6, Tnf. 
Other adaptive 
immunity genes 
Cd4, Cd40 (Tnfrsf5), Cd40lg (Tnfsf5), Cd8a, Crp, Fasl (Tnfsf6), H2-Q10, 
Ifnar1, Ifngr1, Il1b, Il1r1, Irf3, Irf7, Itgam, Jak2, Mapk8 (JNK1), Mbl2, 
Mx1, Nfkb1, Rag1, Stat1. 
  
Humoral 
immunity 
C3, C5ar1 (Gpr77), Ccl12 (MCP-5, Scya12), Ccr6, Crp, Ifnb1, Ifng, Il6, 
Mbl2, Nod2, Tnf. 
Inflammatory 
response 
Apcs, C3, Ccl5 (RANTES), Crp, Foxp3, Il1a, Il1b, Il4, Il6, Mbl2, Stat3, 
Tnf. 
Defense 
response to 
bacteria 
C5ar1 (Gpr77), Ifnb1, Ifng, Il23a, Il6, Lyz2, Mbl2, Myd88, Nod1 (Card4), 
Nod2, Slc11a1, Tlr1, Tlr3, Tlr4, Tlr6, Tlr9, Tnf. 
Defense 
response to 
viruses 
Cd4, Cd40 (Tnfrsf5), Cd86, Cd8a, Cxcl10 (INP10), Ddx58 (RIG-I), H2-
Q10, Ifnar1, Ifnb1, Il23a, Il6, Irf3, Nlrp3, Ticam1 (TRIF), Tlr3, Tlr7, Tlr8, 
Tyk2. 
Table 11 Genes involved in immune response pathways covered by RT² Profiler™ 
VI.3.7. PASI score  
The Psoriasis Area Severity Index (PASI) is a quantitative rating score for measuring severity 
of psoriasis. It combines plaque characteristics like erythema, induration and desquamation 
and the percentage of affected area [69]. Shaved back skin area was set up as 100 % body 
area for calculating the adapted PASI score.  
VI.3.8. Blood withdrawal and serum extraction  
Blood was withdrawal by cardiac puncture from the right ventricle or by puncture of vena 
saphena. Blood was transferred into a 1.5 ml tube, incubated 1 h at RT, and centrifuged for 
15 min at 400 rcf and 4 °C to separate the serum. The serum was transferred to fresh tubes, 
frozen in liquid nitrogen and kept at -80 °C. 
VI.3.9. Preparation of murine lymphoid organs 
Cervical lymph nodes were isolated from recently sacrificed mice. Lymph nodes were 
removed and transferred to a 100- µm cell strainer. Back of a syringe plunger was used to 
macerate the cells through the filter, and the filter was washed with PBS/EDTA. Isolated cells 
were centrifuged for 5 min at 300 rcf at 4 °C, before supernatant was discarded. Red cell 
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lysis was performed by incubating the cells 20 to 30 sec in 2.3 ml 1/6x PBS on ice and by 
adding 310 µl 10x PBS to the cells. Afterwards cell were centrifuged and counted with trypan 
blue.  
VI.3.10. Genotyping of mice  
Tail biopsies were lysed overnight at 55 °C in 500 µl lysis buffer. Lysates were vortexed for 
15 sec and afterwards centrifuged for 5 min at 3000 rcf at RT. Supernatant was then mixed 
with 139 µl salt buffer and centrifuged again. Addition of 640 µl 95 % EtOH led to the 
precipitation of DNA, which was pelleted by a centrifugation step (5 min; 3000 rcf; RT). DNA 
pellet was washed with 500 µl 70 % EtOH, centrifuged, air-dried for 15 min at 37 °C and 
resuspended in 100 µl ddH2O.  
PCR reactions were set up in 20 µl including 50 ng DNA, 5 µl 5x buffer, 10 mM primer mix 
(Table 12), 10 mM dNTPs and 0.2 µl Phusion Taq. 
 
Forward primer reverse primer 
Mm_Rage AGCTGGCACTTAGATGGGAAACTT TGGGCAGAGATGGCACAGGT 
Mm_eGFP CCTACGGCGTGCAGTGCTTCAGC CGGCGAGCTGCACGCTGCGTCCTC 
Table 12 PCR primer 
 
Program was designed as followed (Table 13).  
PCR step Temperature Time 
1. step: initial denaturation 94 °C 60 sec 
2. step: annealing 60.5 °C 30 sec 
3. step: elongation 72 °C 20 sec 
4. step: denaturation 94 °C 30 sec 
Repeat step 2 to 4 for a total of 35 cycles 
5. step: final elongation 72 °C 5 min 
6. step: storage 4 °C ∞ 
Table 13 Cycling condition 
VI.3.11. Agarose gel electrophoresis 
PCR reactions were run on 1.5 to 2 % agarose gels. 4 µl of 6x DNA loading dye were added 
to the samples and 10 µl of each samples were loaded. A 100 bp DNA ladder was used as 
marker. Gels were run at 110 V until the bands were separated and afterwards incubated in 
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an Ethidiumbromide bath for 20 min before bands were visualized by using the gel 
documentation system ‘Biovision’. 
VI.3.12. Embedding of murine skin 
VI.3.12.1. Paraffin-embedding of murine skin 
For histological analysis, tissue was fixed with PBS/PFA for 20 to 28 h at 4 °C. Once fixed, 
tissue was processed as follows using a gentle agitation (Table14). 
Solution Time Temperature 
1x PBS 1 h 4 °C 
0.85 % NaCl 30 min 4 °C 
1:1 0.85 % NaCl: EtOH 15 min RT 
1:1 0.85 % NaCl: EtOH 15 min RT 
70 % EtOH 15 min 4 °C 
70 % EtOH 30 min RT 
85 % EtOH 30-60 min RT 
95 % EtOH 1 h RT 
100 % EtOH 3 x 1 h RT 
100 % Xylene 2 x 1 h RT 
100 % Xylene 10-16 h RT 
1:1 Paraffin:Xylene 50 min 56 °C 
Paraffin 3 x 1 h 56°C 
Table 14 Paraffin-embedding condition 
Afterwards a small amount of molten paraffin was put in a mold and tissue was transferred 
into mold in upended position. Mold was then completely filled with molten paraffin. When the 
wax was cooled and hardened, the tissue within the paraffin block was sectioned in 1- µm 
sections using a microtome. The generation of tissue sections was kindly performed by 
Sayran Arif-Said, Clinical Cooperation Unit Dermato-Oncology, Mannheim.  
VI.3.12.2. Cryo-embedding of murine skin 
Tissue was fixed with PBS/PFA for 20 to 28 h at 4 °C, wash with 1x PBS at 4 °C for 1 h and 
subsequently incubated in 25 % sucrose for 20 to 24 h. Tissue samples were placed in a 
cryomold and were overlayed with Tissue Tek. Embedded samples were stored at -80 °C 
and cut in 2 to 3- µm slides by using the cryostat from Leica.    
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VI.3.13. Hematoxylin and eosin (H&E) staining  
Paraffin-embedded tissue was deparaffinized three times in 100 % xylene and rehydrated      
in descending alcohol series (twice for 10 min in 100 % EtOH, for 4 min in 95 % EtOH, 80 % 
EtOH and 70 % EtOH). Followed by a washing step with ddH2O for 5 min and stained with 
filtered hematoxylin for 6 min. Tissue was then washed with running tap water for 20 min 
before it was decolorized in acid alcohol, washed and counterstained in eosin for 15 sec. 
After counterstaining tissue slides were dehydrated in ascending alcohol series (twice for 
3 min in 95 % EtOH and twice for 3 min in 100 % EtOH), cleaned in 100 % Xylene two times 
for 5 min and subsequently mounted in Dako Fluorescent Mounting Medium (Dako).  
All HE stained tissue samples were analyzed under a Leica DM LS light microscope.   
VI.3.14. Immunofluorescence 
For immunofluorescence staining following antibodies were used (Table 15). 
Primary antibodies Concentrations Secondary antibodies Concentrations 
Rabbit-anti-Ki67 1 : 50 Goat-anti-rabbit Cy3 1 : 500 
Hamster-anti-CD11c 1 : 50 Goat-anti-hamster Cy3 1 : 500 
Rat-anti-F4/80 1 : 200 Goat-anti-rat Cy3 1 : 500 
Rat-anti-Ly-6B.2 1 : 100 Donkey-anti-goat Cy3 1 : 500 
Rat-anti-CD45 1 : 50 Goat-anti-mouse Cy3 1 : 500 
Goat-anti-Calgranulin A 1 : 150 Donkey-anti-rabbit Cy3 1 : 500 
Goat-anti-Calgranulin B 1 : 150 Donkey-anti-rabbit Cy2 1 : 500 
Rabbit-anti-IL-17 1 : 100 Goat-anti-rabbit Cy3 1 : 500 
Rabbit-anti-IL-22 1 : 500   
Rabbit-anti-IL-23 1 : 250   
Rabbit-anti-RAGE 1 : 100   
Rabbit-anti-Keratin-14 1 : 250   
Mouse-anti-Involucrin 1 : 500   
Rabbit-anti-Filaggrin 1 : 100   
DAPI 1 : 5000/ 10000   
Table 15 Primary and secondary antibodies used in immunofluorescence 
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VI.3.14.1. Immunofluorescence on paraffin-embedding tissues 
Paraffin-embedded murine tissue samples were deparaffinized and rehydrated in descending 
alcohol series (as described in H&E staining VI.3.13.). Rehydration was followed by an 
antigen unmasking step by incubating the slides for 40 min in demasking buffer pH 6.0 in a 
streamer and a washing step for 5 min in 1x PBS. To block unspecific bindings of the 
antibodies slides were incubated in 1 % (w/v) BSA in 1x PBS (PBS/BSA) for 1 h at RT in 
humid chamber. Afterwards tissue slides were incubated in primary antibody, diluted in 
PBS/BSA over night at 4 °C. On the next day slides were washed three times in 1x PBS for 
6 min and then incubated with secondary antibody and 4’,6-diamidin-2-phenylindol (DAPI) 
diluted in 1 % BSA/PBS for 2 h in the dark at RT. Staining procedure was finished by three 
washing steps with 1x PBS for 6 min and mounting of the samples with Dako Fluorescent 
Mounting Medium (Dako). Stainings were analyzed by fluorescence microscopy using a 
Nikon ECLIPSE Ti fluorescent microscope. Exposure time was set with isotype control or 
secondary antibody control stained samples to achieve minimal background and further 
applied for the analysis of all stainings. Images were analyzed using Nikon NIS-Elements AR 
4.00 image analysis software.  
VI.3.14.2. Immunofluorescence on cryo-embedding tissues 
Cryo-embedded tissue slides were fixed with 100 % acetone for 10 min at RT, washed for 
5 min with 1x PBS and blocked with PBS/BSA for 1 h at RT to limit unspecific binding of the 
antibodies. Slides were then stained following the protocol for paraffin-embedded tissue 
samples (IV.3.14.1.).  
VI.3.14.3. Immunofluorescence on seeded cells 
In Lab Tek chamber slides seeded cells were rinsed briefly in 1x PBS, and fixed with 4 % 
PFA/PBS for 5 min on ice and for 10 min at RT, followed by a 1 min-wash step in 1x PBS. 
Cell were permeabilized with methanol for 1 min at -20 °C and washed with 1x PBS for 
1 min. To avoid unspecific bindings of the antibodies cells were incubated in PBS/BSA with 
0.05 % Tween-20 for 30 min at RT in a humid chamber. Removal of the blocking buffer was 
followed by addition of primary antibody diluted in PBS/BSA over night at 4 °C. Cells were 
washed three times with 1x PBS for 1 min and incubated with secondary antibody and DAPI 
diluted in PBS/BSA for 60 min in a light-protecting humid chamber. After the second staining, 
cells were washed three times for with 1x PBS for 1 min each and were mounted with Dako 
Fluorescent Mounting Medium (Dako). The next day samples were analyzed with a Nikon 
ECLIPSE Ti fluorescent microscope. Exposure time was set with isotype control or 
secondary antibody control stained samples to achieve minimal background and further 
applied for the analysis of all stainings. Images were analyzed using Nikon NIS-Elements AR 
4.00 image analysis software.  
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VI.3.15. Immunohistochemistry  
Paraffin-embedded human tissue samples were deparaffinized and rehydrated in three 
washes of 5 min with xylene and a descending alcohol series (100, 90, 80 and 70 % EtOH) 
for 3 min each, and rinsed distilled water (dH2O) and Tris-buffered saline (TBS). Antigen 
retrieval was performed by heating the sample for 60 min at 100 °C in zytomed HIER citrate 
buffer (pH 6.0). After additional washing steps with TBS/TBST (TBST containing 1 % Tween-
20), blocking of the endogenous peroxide containing sodium azide for 10 min, as well as 
washing steps with dH2O and TBS/TBST followed. Then, tissue slides were stained with a 
specific anti-RAGE antibody (ab37647) in Dako antibody diluents overnight at 4 °C. Next, 
slides were washed twice for 2 min with PBS and stained with Dako EnVisionTM anti-rabbit 
secondary antibody conjugated with horse-radish peroxidase (HRP) for 60 min. After two 
washing steps with TBS/TBST for 5 min each samples were developed with AEC (Dako 
EnVisionTM) for 15 min, followed by an additional washing step and counterstaining with 
hematoxylin. Afterwards, the samples were mounted with Dako Fluorescent Mounting 
Medium (Dako). All tissue samples were analyzed under a Leica DM LS light microscope. 
VI.3.16. FACS analysis 
1 x 105 to 1 x 106 cells per well were transferred in 10 % FCS in PBS (PBS/FCS) into a round 
bottomed 96-well plate and centrifuged for 5 min at 300 rcf at 4 °C. Removal of the 
supernatant was followed by incubation of primary antibodies (Table 16) diluted in PBS/FCS 
for 15 min on ice. Next, cells were resuspended in 200 µl PBS/FCS and centrifuged for 5 min 
at 300 rcf at 4 °C. Plate was turned down to remove the supernatant and cells were 
incubated in secondary antibodies (Table 16) including DAPI diluted in PBS/FCS for 15 min 
on ice. If instead of DAPI 7-aminoactinomycin D (7-AAD) was used, it was added for 3 min. If 
direct-labeled primary antibodies were used, DAPI staining was performed during primary 
antibody incubation. Cells were washed, centrifuged, resuspended in 200 µl PBS/FCS.  
Antibodies Concentrations 
Rabbit-anti-RAGE 1 : 100 
Hamster-anti-CD11c-APC 1 : 50 
Mouse-anti-CD123-FITC 1 : 2 
Mouse-anti-CD303-APC 1 : 2 
DAPI 1 : 10000 
7-AAD 1 : 150 
Donkey-anti-rabbit Cy3 1 : 1000 
Table 16 Primary and secondary antibodies used in FACS analyses 
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FACS analyses were performed using FACS Canto 4.0 and FACSDiva provided by the 
DKFZ Flow Cytometry Core Facility and the FlowJo Single Cell Analysis software 7.2.2 
VI.3.17. Enzyme-linked immunosorbent assay (ELISA) 
For the quantification of different factor concentrations in the supernatant of cultivated cells 
we performed different sandwich ELISA kits. All ELISA protocols contain the same procedure 
consisting of coating, blocking, addition of standard probes and samples in duplicates, 
detection, enzyme reaction and development. However, the ELISA kits vary according to the 
desired factor particularly in the antibodies and buffers used as well as in the incubation 
times. Variances of the different ELISA kits were adapted to the specific protocols of the 
manufacturer. Between the individual working steps, unbound molecules were removed by 
multiple washing steps using a multichannel pipette. ELISAs were analyzed by absorbance 
measurement using the TECAN infinite F200 pro microplate reader and the TECAN iControl 
1.10.©2012 software.  
VI.3.17.1. Interferon-α ELISA   
To quantify the concentration of the cytokine interferon (IFN)-α in the supernatant of 
stimulated pDCs the VeriKineTM human IFN-α ELISA kit was used. Supernatant samples 
were used undiluted or up to a dilution of 1:20. The ELISA procedure was performed to 
manufacturer’s instructions. 
VI.3.17.2. Interleukin-1β ELISA   
To quantify the concentration of the cytokine interleukin (IL)-1β in the supernatant of 
stimulated keratinocytes the human IL-1β/IL-1F2 DuoSet ELISA kit was used. Supernatant 
samples were used undiluted or 1:2-diluted. The ELISA procedure was performed to 
manufacturer’s instructions. 
VI.3.17.3. HMGB1 ELISA   
To quantify the concentration of the Rage ligand HMGB1 in the supernatant of stimulated 
keratinocytes the human HMGB1 ELISA kit from IBL was used. Supernatant samples were 
used undiluted or up to a dilution of 1:10. The ELISA procedure was performed to 
manufacturer’s instructions. 
VI.3.17.4. S100B ELISA   
To quantify the concentration of the Rage ligand S100B in the supernatant of stimulated 
keratinocytes the human S100B ELISA kit from Abnova was used. Supernatant samples 
were used undiluted or up to a dilution of 1:10. The ELISA procedure was performed to 
manufacturer’s instructions.  
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VI.3.18. Multiplex immunoassay (Luminex) 
ProcartaPlex™ Immunoassays use the xMAP® technology (multi-analyte profiling beads) to 
enable the detection and quantitation of multiple protein targets (IL-9, IL-10, IL-17A, IL-22, IL-
23, IL-27) simultaneously in diverse matrices. The xMAP system combines a flow cytometer, 
fluorescent-dyed microspheres (beads), dual laser design and digital signal processing to 
effectively allow multiplexing within a single sample. ProcartaPlex™ Immunoassay was 
kindly performed by Ludmila Umansky, T cell tumor immunity, DKFZ, Heidelberg, according 
to manufacturer’s instructions. 
VI.3.19. Image analysis 
Quantification of immunofluorescence and H&E images was performed with skin of wt and 
Rage-/- mice. Acanthosis was measured by counting epidermal layers and cellular infiltration 
by counting the dermal infiltrates on H&E stained tissue sections from six to nine different 
mice of each genotype. Image analysis of immunofluorescence stainings was performed by 
counting positive cells in the dermal or the epidermal compartment and by setting these cells 
in relation to the DAPI positive cells (selected unit [%]). Immunofluorescence stained cells 
were counted on tissue sections from six to nine different mice per genotype. 
VI.3.20. Statistical analysis 
Tests for all data were performed using GraphPad Prism version 5.00 (2007) with the 
appropriate tests. Significance in two-tailed t-tests was assumed for p-values < 0.05 (*), 
< 0.01 (**) or < 0.005 (***). 
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VII. Aims of the thesis 
 
The identification of a complex interplay of epidermal and immune cells, inflammatory 
cytokines, and downstream transcription factors contributing to psoriasis resulted in 
advances that elucidate the pathomechanism of the disease. However, the exact qualitative 
and quantitative influence of keratinocytes, dendritic cells, T lymphocytes, and signaling 
pathways orchestrating the pathogenesis of psoriasis remains largely elusive and limits our 
understanding of the disease. 
Recent studies exhibit an evidence for the involvement of RAGE during initiation and 
maintenance of psoriasis. The expression of RAGE on immune and epidermal cells, a high 
stability of RAGE-ligand complexes, as well as the existence of a positive feed-forward loop 
sustaining RAGE signaling in inflammatory conditions, strongly recommend for a role of 
RAGE in the initiation and maintenance of a cutaneous chronic inflammation such as 
psoriasis. Although these findings suggested a central role of RAGE in psoriasis, cellular 
sources of aberrant RAGE signaling as well as the exact mechanisms of action remain.  
 
Taken together, this thesis aims to address the following questions:  
 
a) Is RAGE involved in chronic inflammatory skin diseases such as psoriasis?  
If yes, which consequences result from a lack of Rage during the 
establishment of a chronic inflammation in vivo? 
 
b) Is RAGE contributing to the activation of epidermal and/or immune cells in the 
inflammatory environment of a psoriatic disease? 
If yes, what are the soluble factors/ligands that activate RAGE signaling in 
these cells? 
 
By applying two different mouse models of psoriasis as well as suitable in vitro assays 
investigating functional impacts of RAGE on disease-associated effector cells, such as 
keratinocytes and dendritic cells, this thesis examines the importance of RAGE as a control 
element in the pathogenesis of psoriasis linking innate and adaptive immunity. 
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VIII. Results 
 
VIII.1. RAGE is overexpressed in psoriatic skin 
RAGE expression was evaluated between non-lesional skin and psoriatic plaques using 
human biopsy specimens. Immunohistochemical staining using an anti-RAGE antibody 
showed that RAGE is expressed in both, psoriatic plaques and non-lesional skin. 
Furthermore, RAGE expression in lesional skin sections of psoriatic patients was higher 
compared to corresponding non-lesional skin. Representative images for psoriatic plaque 
(right panel) and non-lesional skin samples (left panel) are illustrated in Figure 3A. Reasoned 
by the multitude of cells involved in the pathogenesis of a chronic inflammation, such as 
psoriasis, it is nearly impossible to create an appropriate controlled environment in vitro. 
Mouse models have often demonstrated remarkable similarity to human diseases since 
many of the genes responsible for complex diseases are shared between mice and men. 
Therefore, two previously established mouse models, comprising IMQ treatment and rIL-23 
injections, that display many features of human psoriasis were applied to C57/BL6 wildtype 
(wt) and Rage-deficient (Rage-/-) mice. Detailed information about both mouse models will be 
provided in section VIII.2. and VIII.7., respectively. Ager transcript level expression was 
analyzed in untreated murine skin samples of wt mice and samples exhibiting a IMQ-induced 
psoriasiform phenotype via qPCR analysis with βActin as endogenous control. Mice with 
psoriasiform phenotype showed an approximately 5-fold increased Rage expression, when 
normalized to the corresponding untreated mouse sample (Figure 3B). 
In addition, immunofluorescence analysis of Rage expression revealed a remarkable 
difference in control mice (Figure 3C, upper panel) compared to the skin of rIL23-treated 
mice (Figure 3C, bottom panel). Indeed, Rage expression was upregulated in the epidermis 
as well as in dermal compartment of mice exhibiting a psoriasiform phenotype. This 
observation might be due to an enhanced expression of Rage by resident stroma cells, or 
due to infiltration of Rage-expressing immune cells. Evidence for the latter will be provided in 
chapter VIII.2.2. 
The demonstration of an upregulation of Rage upon induction of a psoriasiform phenotype in 
mice as well as the finding of elevated RAGE protein in human psoriatic plaques strongly 
supports a role of RAGE in the development and/or progression of psoriasis in both mice and 
men. 
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Figure 3 RAGE is overexpressed in human and murine psoriatic skin. 
Representative microscopic pictures of the immunohistochemical expression of RAGE using an anti-
RAGE antibody on human lesional (psoriatic plaque) and non-lesional skin specimens of psoriasis 
patients (A). Ager transcript levels in psoriasiform wt mice topically treated with repetitive IMQ doses 
(n=3) were verified using qPCR analysis with βActin as endogenous control and untreated (control) 
wt as reference sample. Error bars indicate 95 % confidence intervals (B). Rage expressing cells in 
the epidermis and the dermis were detected by immunofluorescence staining using anti-Rage 
antibody (red staining; nuclei were stained with DAPI, blue signal) on skin sections derived from 
repeatedly PBS-treated (control) (n=3) or rIL-23 treated (psoriasiform) (n=3) ears of wt mice; the 
dotted lines represent the dermal-epidermal junction (C). P values were calculated by two-tailed, 
unpaired sample t-test. Two asterisks indicate t-test p value of ≤ 0.01 in comparison to the respective 
reference. 
Results 
52 
VIII.2. Imiquimod-induced inflammation in vivo is dependent on Rage  
In order to investigate the functional role of Rage in psoriasis in vivo, two previously 
established mouse models that share many features of human psoriasis were applied on wt 
and Rage-/- mice. Genotypic analysis was performed with primer targeting fl-Rage and eGFP 
confirming Rage deletion by eGFP detection (Figure 4A).  
The first mouse model used in this thesis, referred to as Imiquimod (IMQ) model, induces a 
psoriasiform chronic inflammatory phenotype of the skin represented by epidermal 
proliferation and dermal immune cell infiltration [54].  
VIII.2.1. Histological hallmarks of psoriasis are reduced in Rage-/- skin 
The shaved back skin of wt and Rage-/- mice was topically treated with Aldara cream (5 % 
IMQ). According to the protocol of van der Fits and colleagues, induction of a psoriasiform 
phenotype requires a six-time IMQ treatment every 24 h. In order to describe the severity of 
inflammatory reactions occurring during the experiment the ‘Psoriasis Area and Severity 
Index’ (PASI), originally designed for classifying human psoriatic severity, was adapted to 
mice and measured immediately before the application of IMQ. The timeline and structure of 
the applied mouse model are illustrated in Figure 4B. To examine the IMQ-inducibility of both 
mice strains, gene expression of involved receptors was measured. Normalizing gene 
expression of Tlrs to two housekeeping genes (βActin and Gapdh) and comparison of Rage-/- 
to wt data sets revealed that all investigated toll-like receptors were deregulated. However, 
the deregulation of both receptors (Tlr7 and Tlr8) engaged by IMQ was of an opposite 
character, so that no difference in the entirety of IMQ-induced receptors was investigated 
(Figure 4C).  
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Murine skin of wt and Rage-/- mice did not show any morphological differences after shaving 
the back skins and before the first IMQ administration (Figure 4D, left panel). The skin was 
hairless and without any shaving injuries. Two days after the start of the IMQ application the 
wt back skin started to display signs of erythema, scaling and thickening, whereas the Rage-/- 
mice displayed a delayed onset of these symptoms on day three to four. Scoring the severity 
and scope of these lesions by applying the adapted PASI score verified a delayed clinical 
response of Rage-/- mice. In the period from day 0 to day 4 for wt mice and up to day 5 for 
Rage-/- mice the psoriasiform inflammation continuously increased. From these dates on the 
inflammatory response exhibited a plateau phase (Figure 4E). Phenotypical presentation of 
both back skins at the end of the experiment revealed that the inflammatory response to IMQ 
is dampened in mice lacking Rage (Figure 4D, right panel). The PASI score confirms the 
reduction of the inflammatory reaction to IMQ, showing that PASI levels were significantly 
decreased at day 6 in Rage-/- mice in comparison to control wt mice (Figure 4E). These data 
Figure 4 Delayed inflammatory response to IMQ treatment in Rage-/- mice. 
Confirmation of receptor for advanced glycation end-products (Rage) deletion; genomic DNA was 
prepared from the tail of Rage-/- and wt mice. Equal amounts of DNA (50 ng) were used for PCR 
analysis with Rage- and eGFP- specific primers (A). Shaved back skins of wt (n=9) and Rage-/- mice 
(n=9) were topically treated with Aldara cream (5 % IMQ) daily for six days (B). IMQ-treated Rage-/- 
and wt skin was analyzed for differentially regulated Tlr genes applying the ‘RT2 ProfilerTM PCR 
Array’. Transcript levels of Rage-/- skin were illustrated by their fold change to wt skin samples. As 
endogenous controls βActin and Gapdh were used and mRNA expression changes of Tlr-2, -4, -7, -8 
and Tlr-9 were displayed (C). Representative macroscopic pictures of inflamed murine back skins 
before start of the treatment and after induction of the chronic inflammation at day 6 (D). Prior the 
daily IMQ administrations, cutaneous inflammatory response was measured using an adapted PASI 
score (E). P values were calculated by two-tailed, unpaired sample t-test. Asterisk indicates t-test p 
value of ≤ 0.05 in comparison to the respective reference (** p value ≤ 0.01; *** p value ≤ 0.005). 
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revealed that the development of psoriasiform skin inflammation upon IMQ treatment is 
diminished in Rage-deficient mice in comparison to wt controls. 
The typical skin lesion associated with psoriasis vulgaris is the psoriatic plaque. These 
plaques are histologically characterized by epidermal hyperplasia (acanthosis) with a 
downward extension of the epidermal rete ridges (papillomatosis), parakeratosis, as well as 
an inflammatory infiltrate of leukocytes, predominantly in the dermis [55], [97]. Hematoxylin-
eosin staining (H&E staining) of IMQ-treated murine back skins exhibited a multiplicity of 
these histological hallmarks of psoriasis (Figure 5A).  Rudimentary formation of rete ridges 
could be seen in brightfield microscopic pictures of wt back skins, but were absent in Rage-
deficient skin. Furthermore, differences in the severity of acanthosis were noted. More 
specifically, the epidermis of IMQ-treated wt mice showed severe acanthosis, while Rage-/- 
mice displayed a mild form of this psoriatic feature. Additionally, hyperplasia of the epidermis 
was found to be significantly reduced in Rage-/- mice in comparison to the levels in wt mice 
(*** p ≤ 0.005) (Figure 5B). The statistical analysis of the H&E staining showed significantly 
decreased dermal infiltration of immune cells in Rage-/- compared to wt mice (*** p ≤ 0. 005) 
(Figure 5C).  
 
Figure 5 Impairment of typical hallmarks of psoriasis in IMQ-treated Rage-/- mice. 
Brightfield microscopic pictures of hematoxylin-eosin stained (H&E staining) sections of Rage-/- (n=9) 
and wt (n=9) back skins 24 h after the last IMQ administration (A). Acanthosis was measured by 
counting epidermal layers (B) and cellular infiltration by counting dermal infiltrating cells (C). 
Proliferative cells in the epidermis of IMQ-treated skins were detected by immunofluorescence 
staining using anti-Ki67 (red staining; nuclei were stained with DAPI, blue signal) (D) and were 
statistically analyzed by counting Ki-67+cells within the epidermal compartment (E). The dotted lines 
represent the dermal-epidermal junction. P values were calculated by two-tailed, unpaired samples t-
test. Asterisk indicates t-test p value of ≤ 0.05 in comparison to the respective reference (** p value ≤ 
0.01; *** p value ≤ 0.005). 
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The number of proliferative keratinocytes is highly upregulated in psoriatic plaques and is 
known to correlate with the clinical severity of psoriasis [394]. In more detail, acanthosis as 
well as papillomatosis are caused by accelerated proliferation of basal and suprabasal 
keratinocytes [71]. Here, Ki67 was used as a marker of proliferation in the epidermis. 
Representative immunofluorescence images of Ki67 staining for wt and Rage-/- skin sections 
are displayed in Figure 5D, showing a positive nuclear staining of proliferative cells. Figure 
5E shows that approximately 4 % of all epidermal cells in wt mice were positive for Ki67, 
while only 2 % of Rage-/- epidermal cells were characterized as proliferative. This diminished 
proliferation marked by lower expression of the nuclear Ki67 protein in the epidermal 
compartment of Rage-/- back skin in contrast to the wt epidermis was found to be statistically 
significant (* p ≤ 0.05). 
VIII.2.2. Dermal infiltration is diminished in Rage-/- mice 
Since the infiltration of leukocytes into the dermal compartment plays an important role in the 
initiation and maintenance of a chronic disease such as psoriasis, and furthermore the Rage-
deficient dermis exhibited less infiltrating cells (Figure 5A, C), these cells were next examined 
in more detail.  
Therefore, immunofluorescence stainings using antibodies specific against Cd11c for 
dendritic cells (DCs), F4/80 for macrophages, and Ly-6B.2 for neutrophils were performed. 
The enumeration of infiltrating cells, for instance, of dendritic cells was realized by 
expressing the number of Cd11c-positive (Cd11c+) as percentage of DAPI+ cells. All 
immunofluorescence analyses were performed according to this method.  
Dermal dendritic cells function as antigen-presenting cells during inflammation and are 
upregulated in psoriatic skin [97], [395]. Immunofluorescence staining and accompanied 
statistical analysis of dermal DCs revealed significantly reduced amounts of Cd11c+ DCs in 
IMQ-treated Rage-/- (** p ≤ 0.01) (Figure 6A upper row, B). Not only DC amounts were 
impaired in Rage-/- skins, also diminished numbers of macrophages, known to secrete pro-
psoriatic cytokines and to activate DCs [55], were found in Rage-/- mice in comparison to the 
wt situation (*** p ≤ 0.005) (Figure 6A middle row, C). In line with the finding that numbers of 
infiltrating neutrophils correlate with the severity of psoriatic plaques [74], these cells were 
less abundant in the skin of Rage-/- mice compared to control mice (* p ≤ 0.05) (Figure 6A 
bottom row, D).  
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Figure 6 Impaired infiltration of immune cells in the dermis and decreased dermal expression 
of Rage ligands upon IMQ treatment in Rage-/- mice. 
Infiltrating immune cells in the dermis of IMQ-treated wt and Rage-/- skin (n=9) were analyzed by 
immunofluorescence stainings using anti-Cd11c for dendritic cells, anti-F4/80 for macrophages, and 
anti-Ly-6B.2 for neutrophils (red stainings; nuclei are stained with DAPI, blue staining). The dotted 
lines represent the dermal-epidermal junction (A). S100a8+ and S100a9+ cells of IMQ-treated back 
skins (n=9) were detected using immunofluorescence with anti-S100a8 and anti-S100a9 antibodies 
(red staining; nuclei were stained with DAPI, blue staining) (E). Statistical analysis of 
immunofluorescence pictures was done by expressing the number of staining-positive as percentage 
of DAPI+ cells (B-D, F). P values were calculated by two-tailed, unpaired sample t-test. Asterisk 
indicates t-test p value of ≤ 0.05 in comparison to the respective reference (** p value ≤ 0.01; *** p 
value ≤ 0.005). 
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Moreover, IMQ treatment led to an upregulation of Rage ligands, here S100a8 and S100a9 
expression in the dermal compartment of wt mice. The statistical analyses of the respective 
immunofluorescence stainings revealed approximately 12 % S100a8+ and S100a9+ dermal 
cells in wt mice but only 4 to 5 % in Rage-deficient mice. Indeed, the decreased amount of 
S100a8+ and S100a9+ cells of Rage-/- mice compared to wt mice was provided to be 
statistically significant (*** p ≤ 0.005) (Figure 6E, F). As described before, these proteins are 
important for the maintenance of a chronic cutaneous inflammation due to their ability to 
sustain activation of Rage signaling via the aforementioned positive signaling feed-forward 
loop [263], [298].  
Taken together, the results presented in this section demonstrated a dependence of Rage 
signaling in a chronic cutaneous inflammation induced by topical IMQ treatment. Lack of 
Rage led to diminished hallmarks of psoriasis and, furthermore, to decreased abundance of 
infiltrating cells of the innate immune system in the dermis.  
In the next chapters, the impaired inflammation will be investigated in more detail. More 
specifically, cells involved in the so-called ‘psoriatic cascade’, as well as signal transduction 
mediated by RAGE/ligand interaction and the effects of Rage signaling onto these cells 
during psoriasis as chronic inflammation model will be described.  
 
VIII.3. Rage controls the transcription of inflammatory response genes in 
vivo 
As described in V.2. psoriasis is a chronic inflammatory disease mediated by cells and 
molecules of both the innate and the adaptive immune system [55], [56]. In order to 
investigate a potential impact of RAGE onto the activation state or differentiation of immune 
cells involved in the pathogenesis of a chronic inflammation, effects of the loss of RAGE onto 
genes encoding for transcription factors of innate and adaptive immune cells or for effector 
molecules were investigated. More specifically, the applied ‘Mouse Innate and Adaptive 
Immune Responses RT2 ProfilerTM Array’ enabled the simultaneous monitoring of 79 immune 
responses-related genes as well as a potential differential expression upon IMQ treatment of 
wt or Rage-/- mice. The monitored genes were further allocated to distinct subgroups, namely 
‘TH1/TH2/TH17 differentiation’, ‘Treg markers’, ‘T cell activation’, ‘inflammatory response’, 
‘innate immunity’, ‘adaptive immunity’, as well as ‘humoral immunity’, and ‘viral/bacterial 
defense’.  
Normalizing gene expression of molecules involved in inflammatory innate and adaptive 
immune responses to two housekeeping genes (βActin and Gapdh) and comparison of the 
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Rage-/- to wt data sets revealed a tremendous downregulation of Cd4, a marker of T helper 
cells. While some genes associated with the differentiation of CD4+ T cells into TH1, TH2 or 
TH17 cell were found to be deregulated, no clear pattern emerged (Figure 7A). TH22 cells that 
are also known to be important for the pathogenesis of psoriasis, could not be investigated 
using this assay. Nevertheless, 71.43 % of the genes affecting T cell activation were found to 
be downregulated in Rage-/- psoriatic skin in comparison to matched wt samples (Figure 7B). 
However, as most affected subgroup the ‘inflammatory response’ was identified. In terms of 
numbers, 90 % of genes involved in inflammatory response were downregulated upon Rage 
loss under chronic inflammatory conditions. More specifically, Apcs, C3, Crp, Foxp3, Il-1a, Il-
1b, Il-4, Il-6, Stat-3 and Tnf-α were found to be downregulated, solely an upregulation for 
Ccl5 transcript level was detectable (data not shown). 
Next, the data sets were clustered in the context of psoriasis. Transcript levels of already 
described molecule with an involvement in psoriasis were investigated for differences 
between wt and Rage-/- mice. More than 70 % of the investigated psoriasis-associated 
transcript levels were downregulated in inflamed Rage-deficient mice compared to their 
inflamed controls, including proinflammatory cytokines like Il-1β, Il-6, Il-17a, Il-23a Ifn-α, and 
Tnf-α, co-stimulatory factors like Cd40 and Cd80, the adaptor protein Myd88, or transcription 
factors such as Nf-κb and Stat-3. In contrast, Nfkbia, Il-1r, and Cd86 transcript levels were 
found to be upregulated upon the loss of Rage (Figure 7A).  
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Figure 7 Psoriasis-related inflammatory genes are downregulated upon IMQ treatment in 
Rage-/- mice.  
IMQ-treated Rage-/- and wt skin was analyzed for differentially regulated innate and adaptive immune 
system-associated genes applying the ‘RT2 ProfilerTM PCR Array’. Transcript levels of Rage-/- skin 
were illustrated by their fold change to wt skin samples. As endogenous controls βActin and Gapdh 
were used. Representative graphs for mRNA expression of psoriasis-related genes (A) and 
percentage of downregulated genes per cluster (B) were indicated. Il-17a, Il-22, and Il-23a transcript 
levels in IMQ-treated wt (n=9) and Rage-/- (n=9) mice were verified in more detail using qPCR 
analysis. Untreated (ctrl) wt served as reference sample and βActin as endogenous control. Error 
bars indicate 95 % confidence intervals (C). Cytokine-secreting cells within the dermis of inflamed 
back skins were detected by immunofluorescence staining with anti-IL-17, anti-IL-22, and anti-IL-23 
antibodies (red staining; nuclei were stained with DAPI, blue staining) (D). Statistical analysis of 
immunofluorescence pictures was done by expressing the number of staining-positive as percentage 
of DAPI+ cells. The dotted lines represent the dermal-epidermal junction (E). P values were 
calculated by two-tailed, unpaired sample t-test. Asterisk indicates t-test p value of ≤ 0.05 in 
comparison to the respective reference (** p value ≤ 0.01; *** p value ≤ 0.005). 
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Analysis of the cellular infiltrate during IMQ-induced inflammation showed reduced 
accumulation of DCs in the dermal compartment of Rage-/- mice (Figure 6A, B). Under 
pathological conditions, these cells secrete high amounts of IL-23, a cytokine that is 
described to propagate a TH1/TH17/TH22 polarized immune response [9], [10]. The 
differentiation into these T helper subsets leads to the secretion of proinflammatory cytokines 
like IL-17 and IL-22 [55]. In order to confirm the observed downregulation of Il-17a and Il-23a 
by RT-PCR profiling, interleukin transcript levels comprising Il-17a, ll-22, and Il-23a were 
measured in IMQ-treated wt and Rage-/- mice; with untreated (ctrl) wt skin samples as 
reference and βActin as endogenous control. The analysis revealed a significant 
upregulation of all three interleukins in IMQ-treated wt mice compared to the healthy 
counterpart. IMQ-treated Rage-/- skin samples also displayed an upregulation of Il-17 and ll-
23, while Il-22 transcripts remained at their basal level (Figure 7C). Nevertheless, transcript 
levels of all three interleukins were significantly decreased in IMQ-treated Rage-/- skin 
samples in comparison to the inflamed wt counterpart (Figure 7C). This was confirmed via 
immunofluorescence staining and subsequent statistical analysis, exhibiting a significant 
reduction of interleukin-positive cells in Rage-/- mice in comparison to the wt mice (* p ≤ 0.05) 
(Figure 7D, E).  
  
The in vivo data obtained from the IMQ model indicates that IMQ-induced inflammation is 
dependent on Rage and that Rage has an impact on CD4+ T cell differentiation, T cell 
activation, as well as on psoriasis-related molecules. Furthermore, the investigation of IL-17 
and IL-23 revealed a consistent downregulation of these cytokines upon Rage-deficiency in 
chronic inflammation, and therefore a possible mechanism of action. In order to further verify 
if RAGE signaling contributes to the development of chronic inflammation by upregulating 
proinflammatory cytokines, cells involved in the pathogenesis of psoriasis were investigated 
in more detail.  
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VIII.4. Activation of keratinocytes is independent of RAGE  
Keratinocytes are known to be involved in the pathogenesis of psoriasis. Most of the clinical 
hallmarks of psoriasis feature keratinocyte deregulation; for instance, acanthosis and 
papillomatosis are caused by accelerated proliferation of keratinocytes [71]. Keratinocytes 
modulate immune reactions in the skin, but their role as initiators or amplifiers of the 
inflammatory reaction in psoriasis is still elusive [396].  
For this reason, the next chapter deals with the activation potential of keratinocytes by 
investigating potential stimulators as well as associated effects on their functional properties 
including the release of proinflammatory mediators, which contribute to the activation of 
RAGE signaling.  
VIII.4.1. Keratinocytes are not activated by alarmins 
Normal human epidermal keratinocytes (NHEK) were isolated from epidermis of juvenile 
foreskin as described in VI.3.2.2. and validated via immunofluorescence using the early 
keratinocyte marker K14. Representative images of the immunofluorescence staining are 
displayed in Figure 8A and verified the keratinocytic character of the cells. Moreover, 
immunofluorescence staining revealed expression of RAGE by keratinocytes (Figure 8B). 
Further experiments investigating the functional impact of RAGE axis were performed with 
these cells.  
Recent studies provide evidence that cell-free DNA levels can be directly linked to psoriasis 
severity [397]. Indeed, extracellular DNA as well as unmethylated cytosine-phosphate-
guanine (CpG) dinucleotides are known to stimulate immune effects either alone or in 
complex with proteins, such as HMGB1, a RAGE ligand described to be upregulated in 
psoriasis [398]–[400]. Therefore, primary human keratinocytes were stimulated with CpG, 
HMGB1 or another RAGE ligand S100B alone, or with a complex of CpG-HMGB1 or CpG-
S100B. The activation state of keratinocytes was monitored by levels of the proinflammatory 
cytokine IL-1β. The administration of RAGE ligands alone or in complex with CpG as well as 
the dinucleotide alone failed to upregulate IL-1β transcripts, when compared to untreated 
control keratinocytes serving as reference sample (Figure 8C). Furthermore, released IL-1β 
by keratinocytes upon stimulation was measured using enzyme-linked immunosorbent 
assays (ELISA). In line with the qPCR data, stimulation of keratinocytes with CpG, HMGB1, 
and HMGB1-CpG complexes could not lead to increased release of IL-1β. Moreover, 
increasing concentrations of HMGB1 could not change IL-1β release (Figure 8D). Similar 
results were obtained for keratinocytes stimulated with S100B instead of HMGB1 (Figure 
8E). However, increasing concentration of S100B alone seemed to enhance the release of 
IL-1β to a small extent, but the differences were not significant and the complex showed no 
ability to activate keratinocytes.   
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Taken together, these results demonstrate that RAGE ligands alone or in complex with CpG 
fail to stimulate keratinocytes towards IL-1β secretion. However, there has to be an activator 
for keratinocytes, since these cell were found to be hyperactivated in psoriasis. Li and 
colleagues could show that upon differentiation keratinocytes upregulate TLR-7 transcripts. 
Treatment with the TLR-7 agonist IMQ and keratinocyte differentiation cooperatively led to 
the secretion of proinflammatory cytokines such as IL-8 and TNF-α [166].  
That raised the question if differentiated keratinocytes could be encouraged to additionally 
secrete proinflammatory RAGE ligands such as HMGB1 and S100B.  
 
Figure 8 Alarmin-CpG-complexes fail to activate keratinocytes. 
NHEKs were isolated from epidermis of juvenile foreskin. Verification of keratinocytes was performed 
by immunofluorescence staining using anti-K14 (red staining; nuclei are stained with DAPI, blue 
staining) (A), and RAGE expression was measured using anti-RAGE antibody (ab37647) (B).  
Sections stained with secondary antibody alone served as a control for antibody specificity (A, B). 
Keratinocytes were stimulated with 5 µg/ml HMGB1, 5 µg/ml S100B, 300 nM CpG, HMGB1-CpG, or 
S100B-CpG (5 µg/ml, 300 nM CpG). Total RNA from stimulated keratinocytes was isolated, reverse 
transcribed and analyzed by qPCR for relative transcript levels of IL-1β. Expression levels were 
normalized to unstimulated (ctrl) with 18S as endogenous control. Error bars indicate 95 % 
confidence intervals (C). 24 h after stimulation, cell culture supernatants were harvested to determine 
IL-1β protein levels by ELISA (D, E). Data are shown as mean ± SD of two (qPCR) and three 
(ELISA) independent experiments.  
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VIII.4.2. IMQ-induced activation of keratinocytes  
Primary human keratinocytes were differentiated for 10 days with medium containing high 
Calcium (Ca2+) concentrations (Figure 9A). Differentiation was validated by morphological 
changes and mRNA expression of keratinocyte markers. Keratinocytes cultured in 60 µM 
Ca2+ conditions, defined as non-differentiated keratinocytes, were small polygonal cells 
growing in relatively homogenous monolayers (Figure 9B, left panel). Upon Ca2+ 
administration keratinocytes became more heterogeneous, displaying irregular sizes and 
shapes (Figure 9B, right panel). Additionally, these cells, from here on referred to as 
differentiated keratinocytes, were validated for their involucrin transcript levels using qPCR. 
When normalized to the corresponding non-differentiated cells, high Ca2+ concentration 
resulted in a marked upregulation of involucrin, thereby verifying the differentiated phenotype 
of the cells (** p ≤ 0.01) (Figure 9C).  
Differentiated and non-differentiated keratinocytes were then stimulated with 100 µM IMQ 
and the resulting upregulation of RAGE ligands S100B and HMGB1 was measured. Protein 
levels of HMGB1 and S100B measured by ELISAs revealed equal secretion of these 
proteins in untreated keratinocytes independent of their differentiation status. Moreover, also 
IMQ stimulated non-differentiated keratinocytes were unable to increase the secretion of 
proinflammatory RAGE ligands. In contrast, differentiated keratinocytes stimulated with IMQ 
showed a significantly increased amount of secreted HMGB1 and S100B in comparison to 
unstimulated differentiated as well as IMQ-stimulated non-differentiated cells (*** p ≤ 0.005) 
(Figure 9D, E). Along with that, qPCR analyses using untreated non-differentiated 
keratinocytes as reference sample and 18S as endogenous control showed that mRNA 
expression of HMGB1 as well as S100B was independent of the differentiation state of 
untreated keratinocytes (** p ≤ 0.01) (Figure 9F). In contrast, stimulation of differentiated 
keratinocytes with IMQ led to a significant upregulation of HMGB1 and S100B transcripts in 
comparison to untreated cells (** p ≤ 0.01).   
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Figure 9 Differentiated keratinocytes secrete RAGE ligands upon IMQ stimulus. 
NHEKs were cultured under low calcium conditions (60 µM; non-differentiated) or in the present of 
1.2 mM calcium (differentiated) for 10 days (A). Representative macroscopic pictures of non-
differentiated and differentiated keratinocytes before IMQ treatment (B). Total RNA from cells was 
isolated, reverse transcribed and analyzed by qPCR for relative transcript levels of involucrin. 
Expression levels were verified with 18S as endogenous control (C). Keratinocytes were treated with 
IMQ in a concentration of 100 µM. At 1 to 6 h after stimulation, cell culture supernatants were 
harvested to determine HMGB1 (D) and S100B (E) protein levels by ELISA and total RNA was 
collected for measurement of HMGB1 and S100B transcript levels via qPCR (F). Expression levels 
were normalized to untreated non-differentiated keratinocytes and 18S was used as endogenous 
control. Error bars indicate 95 % confidence intervals. In IMQ-stimulated keratinocytes RAGE 
activation was blocked by the administration of an anti-RAGE antibody (MAB11451) while IgG2B 
(MAB004) served as isotype control. HMGB1 (G) and S100B (H) protein levels were determined by 
ELISA. Data are shown as mean ± SD of two (qPCR) and three (ELISA) independent experiments. P 
values were calculated by two-tailed, unpaired sample t-test. Asterisk indicates t-test p value of ≤ 
0.05 in comparison to the respective reference (** p value ≤ 0.01; *** p value ≤ 0.005). 
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Next, a possible involvement of RAGE in the activation of keratinocytes was investigated. 
Therefore, RAGE signaling was blocked using an anti-RAGE antibody and the corresponding 
IgG isotype control to exclude artefact distortions by the blocking antibody. RAGE blockade 
was initiated 3 h before IMQ was added to the differentiated keratinocytes. No alteration in 
HMGB1 protein levels were detected in IMQ-stimulated cells treated with the anti-RAGE 
antibody compared to either corresponding IgG control cells or unblocked stimulated 
keratinocytes (Figure 9G); similar results were obtained for S100B protein levels (Figure 9H). 
Enzyme-linked immunosorbent assays revealed that RAGE neither plays a role for the 
secretion of HMGB1 nor for S100B under the here described conditions.  
In summary, in vitro experiments with keratinocytes clearly showed that RAGE ligands, at 
least HMGB1 and S100B, are no potential stimulators of keratinocytes, but were 
consequently secreted by those cells upon IMQ-induced activation. Moreover, these findings 
implicate that RAGE is not involved in the keratinocyte contribution to the development of a 
chronic inflammation.   
While results from the IMQ model suggest an involvement of Rage in psoriasis, 
consequently, an investigation of the potential role of RAGE on DCs was performed in the 
following two chapters.  
 
VIII.5. Expression of RAGE on DCs during inflammation 
As shown in VIII.1. RAGE expression is upregulated under inflammatory conditions in human 
and mouse (Figure 3). Moreover, with the in vivo model the involvement of Rage in the 
psoriatic context was locally limited to keratinocytes or/and DCs. Although keratinocytes do 
express RAGE (Figure 8 B), the activation of keratinocytes under inflammatory conditions 
was independent of RAGE as described before (Figure 9).  
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For all of these reasons, RAGE expression on DCs was investigated under pathological 
conditions seen in psoriasis. Immunofluorescence co-staining analysis was performed with 
murine skin sections from IMQ-induced inflamed wt mice using an anti-Rage and an anti-
Cd11c antibody. Representative images revealed that upon psoriasiform conditions Rage 
was predominantly expressed on DCs (Figure 10A). However, not only Cd11c+ DCs in 
murine psoriasis-like skin displayed Rage expression but a similar expression pattern was 
observed for human samples from patients exhibiting a high PASI score (Figure 10B, upper 
panel). Here, almost all DCs in the dermal compartment were expressing RAGE. 
Nevertheless, RAGE was also expressed on CD11c- cells within the dermis, showing that 
DCs are not the only cell type expressing RAGE in the context of chronic inflammation. In 
contrast, the investigation of human non-lesional skin of psoriatic patients barely showed 
RAGE+ DCs (Figure 14, bottom panel), indicating that RAGE is upregulated on DCs during 
psoriasis progression. As plasmacytoid dendritic cells are known to be involved in psoriasis, 
the next chapter will focus on the role of RAGE on this DC subtype.  
Figure 10 RAGE is expressed on dendritic cells within psoriasiform inflammation. 
Representative images of immunofluorescence stainings using an anti-Cd11c (red stainings) and 
anti-Rage antibody (green staining; nuclei are stained with DAPI, blue staining) performed on IMQ-
treated murine back skin (A). Immunofluorescence stainings of human lesional (psoriatic plaque) and 
non-lesional skin specimens of psoriasis patients were conducted using an anti-CD11c (green 
staining) and an anti-RAGE antibody (red staining; nuclei are stained with DAPI, blue staining). The 
dotted lines represent the dermal-epidermal junction (B).  
Results 
67 
VIII.6. Alarmin-CpG-complex-induced activation of plasmacytoid 
dendritic cells is mediated by RAGE 
The DC population can be divided into diverse subsets, one of these subpopulation are the 
so-called plasmacytoid dendritic cells (pDCs). Under pathological conditions, these cells are 
key effector cells due to their unique ability to produce large amounts of IFN-α, a cytokine of 
high importance in the pathogenesis of psoriasis [170], [174], [175]. Understanding all 
mechanisms of pDC activation is of high importance elucidating the pathogenesis of 
psoriasis. Recently, it was shown that self-DNA triggers TLR-9 signaling in pDCs by forming 
a complex with LL-37 [136]. Moreover, Tian and colleagues revealed that pDCs in systemic 
lupus erythematosus (SLE) are activated by a self-DNA-HMGB1-complex [257]. And another 
study linking cell-free DNA and psoriasis severity further highlighted the importance of self-
DNA in the pathogenesis of psoriasis [397]. 
Therefore, this chapter concentrates on the ability of RAGE ligand-self-DNA-complexes to 
activate pDCs in the context of psoriasis.   
pDCs were obtained from peripheral blood mononuclear cells (PBMCs), purified by magnetic 
beads, and flow cytometric-analyzed to determine purity of the population using the CD123 
and CD303 antibody as pDCs-specific marker combination. Figure 11A illustrates the 
enrichment of the pDCs population upon magnetic isolation. pDCs represent less than 1 % of 
all cells in the blood (Figure 11A, left panel). Representative image of the flow cytometry 
analysis shows the efficiency of the magnetic pDC isolation, demonstrating a pDC population 
with a purity of more than 80 % (Figure 11A, right panel). Populations used for the 
experiments contained at least 75 % pDCs.  
IFN-α is secreted by activated pDCs and is used in the here-displayed experiments as a 
read-out system for the activation status of these cells. By stimulating pDCs with 300 nM 
CpG a strong stimulatory effect on pDCs was observed (Figure 11B). However, under 
physiological conditions such effects are minimized by consequent degradation of DNA 
molecules by specific enzyme. Therefore, the minimal concentration of CpG sufficient to 
stimulate pDCs at low extent was detected by dilution series. Figure 11B demonstrates that 
CpG in concentration of 300 nM to 75 nM is able to activate the cells solely by its presence. 
In contrast, concentration below 75 nM of CpG showed only a slight induction of IFN-α 
secretion (Figure 11B).  
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For the following experiments a CpG concentration of 37.5 nM was used. Cultivated primary 
human pDCs were stimulated with CpG, 5 µg/ml S100B alone or with a complex of CpG and 
S100B (CpG-S100B). In brief, after a stimulus period of 24 h, total RNA was isolated, reverse 
transcribed and analyzed via qPCR using 18S as an endogenous control. When normalized 
to the corresponding unstimulated cells (ctrl) S100B as well as CpG stimulated cells 
displayed a consistent upregulation of IFN-α transcript levels. A detailed examination of the 
qPCR analysis revealed that the stimulatory effects of CpG-S100B were highly significant in 
Figure 11 Plasmacytoid dendritic cells are activated by S100B-CpG- and HMGB1-CpG-
complexes. 
Isolated PBMCs and primary human pDCs were stained with anti-CD123-FITC, anti-CD303-APC, 
and 7-AAD to identify the purity of pDC population. An illustration of a flow cytometric analysis of 
CD123+CD303+ subpopulation is shown (A). pDCs were stimulated with different concentrations of 
CpG for 24 h. Stimulatory effects of indicated CpG concentrations in pDCs were determined by 
measuring the IFN-α protein levels in the supernatant of cultivated pDCs via ELISA (B). pDCs were 
stimulated with 5 µg/ml S100B, 37.5 nM CpG or CpG-S100B (37.5nM, 5 µg/ml) (C, D), or with 
5 µg/ml HMGB1, 37.5 nM CpG or CpG-HMGB1 (37.5nM, 5 µg/ml) (E, F). Total RNA from stimulated 
and untreated pDC was isolated, reverse transcribed and analyzed by qPCR for relative transcript 
levels of IFN-α. Expression levels were normalized to untreated (ctrl) pDCs with 18S as endogenous 
control. Error bars indicate 95 % confidence intervals (C, E). At 24 h after the stimulation, cell culture 
supernatants were harvested to determine IFN-α protein levels by ELISA (D, F). Data are shown as 
mean ± SD of two (qPCR) and three (ELISA) independent experiments. P values were calculated by 
two-tailed, unpaired sample t-test. Asterisk indicates t-test p value of ≤ 0.05 in comparison to the 
respective reference (** p value ≤ 0.01; *** p value ≤ 0.005). 
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comparison to all other cells either stimulated or unstimulated (** p ≤ 0.01) (Figure 11C). To 
consider this observation an IFN-α ELISA using cell culture supernatants of stimulated and 
unstimulated cells was performed. Expression levels of IFN-α demonstrated that only the 
complex of CpG and S100B was able to induce high amounts of IFN-α secretion by pDCs 
(*** p ≤ 0.005) (Figure 11D). Moreover, HMGB1 was used to examine the activation potential 
of alarmin-CpG complexes. IFN-α transcripts (* p ≤ 0.05) (Figure 15E) as well as levels of 
secreted IFN-α (*** p ≤ 0.005) (Figure 11F) revealed that the CpG-HMGB1 complex activated 
pDCs in a significantly higher manner than single stimuli.  
These results showed that both RAGE ligands, S100B and HMGB1, in complex with CpG 
nucleotides are able to stimulate pDCs towards IFN-α secretion and raises the question if 
RAGE is involved in the investigated activation of pDCs. 
To address this, freshly isolated human pDCs were cultured for 16 h in chamber slides and 
were afterwards stimulated with the CpG-HMGB1 complex or left untreated. Cells were 
permeabilized and stained with an anti-RAGE antibody and DAPI. Immunofluorescence 
stainings demonstrated that less than one third of unstimulated cells expressed RAGE 
(Figure 12A, left panel). In contrast, almost all cells, stimulated with CpG-HMGB1, showed 
high expression levels of RAGE in the immunofluorescence analysis (Figure 12A, right 
panel). These observations were independent of the fact whether cells grew as single cell 
suspensions or in confluent cell layers.  
This immunofluorescence staining indicated a role for RAGE for the here-investigated 
mechanism of pDCs activation and consequent secretion of proinflammatory cytokines 
associated with chronic inflammations such as psoriasis. 
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To further investigate the participation of RAGE in pDC activation blocking experiments were 
performed. Therefore, prior stimulation with the respective alarmin-CpG-complex, pDCs were 
treated with a specific RAGE blocking antibody (αRAGE). The αRAGE antibody was applied 
three hours before the stimulation to the cells, and was maintained without interruption. To 
exclude side effects of the blocking antibody a third group of pDCs was treated with the 
corresponding IgG isotype control (IgG2B).  
Investigation of the secreted IFN-α amount via ELISA revealed that the unstimulated or CpG-
stimulated cells showed no effect upon administration of α-RAGE or IgG isotype control 
(Figure 12B, C). However, cells stimulated with HMGB1 alone showed a slide reduction upon 
treatment with αRAGE, whereas the IgG isotype control had no effect on the behavior of 
pDCs stimulated with HMGB1. Focusing now on the decisive part of the experiment, ELISA 
Figure 12 Alarmin-CpG-complexes activate pDCs via RAGE. 
Expression of RAGE in human primary unstimulated and HMGB1-CpG stimulated pDCs was 
detected by immunofluorescence staining using anti-RAGE antibody (ab37647, red staining; nuclei 
were stained with DAPI, blue signal) (A). pDCs were treated for 24 h with 5 µg/ml HMGB1, 5 µg/ml 
S100B, 37.5 nM CpG, HMGB1-CpG, or S100B-CpG (5 µg/ml, 37.5 nM CpG) and RAGE activation 
was blocked by the administration of an anti-RAGE antibody (MAB11451; αRAGE) 3 h prior 
treatment. The IgG2B isotype control (MAB004) was used for the exclusion of artefact distortions by 
the blocking antibody. At 24 h after the stimulation, cell culture supernatants were harvested to 
determine IFN-α protein levels by ELISA (B, C) Data are shown as mean ± SD of three independent 
experiments. P values were calculated by two-tailed, unpaired sample t-test. Asterisk indicates t-test 
p value of ≤ 0.05 in comparison to the respective reference (** p value ≤ 0.01). 
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analyses revealed that activated pDCs (CpG-HMGB1 stimulated cells) displayed a 
significantly reduced secretion of IFN-α upon blockade of RAGE signaling, whereas the IgG 
isotype control exhibited the same secretion capacity as the unblocked stimulated pDCs 
(** p ≤ 0.01) (Figure 12B). Similar results were obtained using S100B instead of HMGB1 
(** p ≤ 0.01) (Figure 12C). 
Taken together, these pDC experiments demonstrated that HMGB1 as well as S100B in 
complex with the dinucleotide CpG were able to activate the specialized DC population pDCs 
and furthermore that the activation of these cells is dependent on RAGE signaling.  
To confirm the role of RAGE on dendritic cells under chronic cutaneous conditions a second 
mouse model was applied to Rage-/- and wt mice. Intradermal injections of recombinant 
murine IL-23 (rIL-23) mimic constitutive DC activation resulting in the development of a 
psoriasiform inflammation in mice [53]. 
 
VIII.7. Normal inflammatory manifestation in Rage-/- mice upon rIL-23 
injection 
VIII.7.1. Clinical observations are unaltered in Rage-/- mice  
DC-secreted IL-23 is known to differentiate naïve T
 
cells into TH17 lineage, a cell type found 
to be elevated in psoriasis. IL-23 is described to induce a psoriasiform inflammation in mice 
[53]. Intradermal rIL-23 injections into the ear of mice over a period of 14 days induce a 
chronic inflammation, which phenotypically resembles human psoriasis. Every 48 h 500 ng 
rIL-23 were injected into the left ear of Rage-/- and wt mice (Figure 13A), whereas the right 
ear was left untreated and served as a control for ongoing inflammation (Figure 13B). During 
the treatment, the developing inflammatory response of Rage-/- and wt mice was graded 
using the adaptive PASI score and via measurement of ear swelling.  
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The ears treated with rIL-23 showed erythema as well as scales (data not shown). Analyzing 
the PASI score revealed two things: First, from day 1 to 8 under Rage-deficient conditions, 
and from day 1 to 10 in the wildtype situation the inflammation continuously increased. 
However, this slight delay was not significant. The inflammation became chronic at day 8 in 
Rage-/- mice and at day 10 in wt mice. Second, the statistical analysis of the PASI score 
revealed that the intensity of the inflammation caused by rIL-23 injections was not 
significantly altered in Rage-/- mice (Figure 13C). Another feature besides erythema and 
scale development, which displays the inflammatory progression, was the ear swelling. 
Figure 13D demonstrated that ear thickening started at the first day after initiation, and 
continuously increased until day 15. Again, no significant difference between Rage-/- and wt 
ear swelling was observed during the experiment (Figure 13D). This provided first evidence 
for rIL-23 injections to bypass the action of Rage in chronic inflammation. In order to further 
address this topic, microscopic investigations of the inflamed tissue were performed, as 
described in the next section. 
 
Figure 13 Rage-/- and wt mice show similar inflammatory responses to rIL-23 treatment. 
Confirmation of Rage deletion; genomic DNA was prepared from the tail of Rage-/- and wt mice. 
Equal amounts of DNA (50 ng) were used for PCR analysis with Rage- and eGFP-specific primers 
(A). Experimental design of the intradermal rIL-23 ear injections (B). Plaque formation was measured 
by applying the adaptive PASI score onto wt (n=9) and Rage-/- (n=9) mice (C) and by analysis of the 
ear swelling (D). P values were calculated by two-tailed, unpaired sample t-test. 
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VIII.7.2. Rage-/- mice exhibit no histological changes upon rIL-23 treatment 
Here, the ear skin of rIL-23-treated mice was histologically analyzed. Representative H&E 
images of the psoriasiform phenotype of wt (left panel) and Rage-/- (right panel) skin sample 
are illustrated in Figure 14A. H&E staining revealed a mild psoriatic phenotype represented 
by moderate acanthosis, parakeratosis, and dermal infiltrating cells. Furthermore similar 
development of hyperkeratosis was observed in wt and Rage-/-. An analysis of the cellular 
infiltration showed no significant alterations in the amount of infiltrating cells into the dermis 
between both genotypes investigated (Figure 14B). Moreover, the mild epidermal thickening 
due to hyperproliferation of keratinocytes was formed equally in wt and Rage-/- mice upon rIL-
23 injections (Figure 14C). Noteworthy, despite the low level of acanthosis keratinocytes 
exhibited a proliferative phenotype. Figure 14D displays representative pictures of 
immunofluorescence staining using an anti-Ki-67 antibody, showing epidermal cells in a 
proliferative state and furthermore the presence of proliferative cells in the dermal 
compartment. Statistical analysis revealed unaltered amount of Ki-67+ keratinocytes in wt 
and Rage-/- mice (Figure 14E).  
 
Figure 14 Psoriasiform features occur in wt as well as in Rage-/- mice upon rIL-23 injections. 
Brightfield microscopic pictures of hematoxylin-eosin stained (H&E staining) sections of Rage-/- (n=9) 
and wt (n=9) back skins, sacrificed 24 h after the last rIL-23 treatment (A). Cellular infiltration was 
measured by counting the dermal infiltrating cells (B) and acanthosis by counting epidermal layers 
(C). Proliferative cells in the epidermis of treated skins are detected by immunofluorescence staining 
using anti-Ki67 (red staining; nuclei were stained with DAPI, blue signal) (D) and statistically 
analyzed by expressing the number of Ki-67+ cells as percentage of DAPI+ cells in the epidermal 
compartment of treated skins. The dotted lines represent the dermal-epidermal junction (E). P values 
were calculated by two-tailed, unpaired sample t-test. 
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VIII.7.3. Composition of the inflammatory infiltrate is unchanged in Rage-/- mice upon 
rIL-23 treatment 
The investigation of infiltrating immune cells into the dermal compartment of rIL-23-induced 
inflamed ear skin revealed similar numbers for wt and Rage-/- mice as demonstrated by H&E 
staining (Figure 14A, B). Further analyses were performed to characterize the composition of 
dermal infiltrating cells in both genotypes. Therefore, immunofluorescence stainings using 
anti-Ly-6B.2 antibody for neutrophils, anti-F4/80 antibody for macrophages, and anti-Cd11c 
antibody for DCs were performed on wt and Rage-/- skin sections. Representative images of 
detected neutrophils (left panel), macrophages (middle panel), and DCs (right panel) within 
the dermis of inflamed tissue are illustrated in Figure 15A. Moreover, statistical analyses 
demonstrated that each population accounts for approximately 3 to 5 % of the infiltrating cells 
and that the individual cell types showed no significant difference between wt and Rage-/- 
mice (Figure 15B).  
DCs are known to be key players in the interface between the innate and adaptive immune 
system and thereby in immune mechanisms contributing to psoriasis [3], [395]. For this 
reason, next to dermal DC amounts the number of DCs in cervical lymph nodes, located in 
the nearest destination to the site of inflammation, was analyzed via flow cytometric analysis 
(Figure 15C). Isolated cells from lymph nodes of wt and Rage-/- mice were stained with anti-
Cd11c antibody conjugated with the fluorescent dye allophycocyanin (APC) (Figure 15C) or 
with the respective APC-conjugated IgG isotype control (data not shown). Differences in 
eGFP levels of wt and Rage-/- mice arise from characteristics of Rage-deletion construct. 
Rage deletion was confirmed by the expression of eGFP resulting in detectable green 
fluorescent signals [392]. The analysis verified the results of the immunofluorescence 
stainings by showing unaltered numbers of resting Cd11c+ DCs in inflamed lymph nodes wt 
and Rage-/- mice (Figure 15D).  
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Figure 15 Psoriasis-associated immune cell infiltration occurs in Rage-/- mice upon rIL-23 
injections. 
Infiltrating immune cells in the dermis of rIL-23 treated skins (n=9 per genotype) were detected by 
immunofluorescence stainings using anti-Ly-6B.2 for neutrophils, anti-F4/80 for macrophages, and 
anti-Cd11c for dendritic cells (red stainings; nuclei were stained with DAPI, blue staining). The dotted 
lines represent the dermal-epidermal junction (A). Statistical analyses of immunofluorescence 
pictures were accomplished by expressing the number of staining-positive cells as percentage of 
DAPI+ cells (B). Wt and Rage-/- cells from lymph nodes were isolated and stained with an anti-Cd11c-
APC antibody. Illustrations of a flow cytometric analysis of eGFP+/- Cd11c+ subpopulation of wt and 
Rage-/- cells (C). Comparison of the revealed percentages of Cd11c+ dendritic cells (D).  
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As described in VIII.2.2, S100A8 and S100A9 expression during a chronic inflammation is 
important for the development of a sustained activation of RAGE signaling. 
Immunofluorescence images exhibited an accumulation of S100a8- as well as S100a9-
positive cells in the dermal compartment, principally in the upper part of the dermis of rIL-23 
treated ear skins. Of note, also keratinocytes in the epidermis express S100 proteins as 
illustrated in Figure 16A. Moreover, the amount of S100 protein-expressing cells did not differ 
between wt and Rage-/- mice (Figure 16B).  
Next, wt and Rage-/- ear skins were analyzed in regard to their expression profile of psoriasis-
associated proinflammatory cytokines. Members of the interleukin cytokine family were 
described to play important roles in the initiation and maintenance of psoriasis. For instance, 
IL-23 predominantly secreted by DCs is a key cytokine in the survival and proliferation of 
TH17 cells. T helper cell migration into the psoriatic lesion has been characterized as the 
beginning of disease maintenance [55]. In turn, IL-17 and IL-22 released by these T cells 
lead to increased keratinocyte production of antimicrobial peptides (AMPs), characterized as 
another important event in psoriasis [55]. Therefore, further immunofluorescence-based 
analyses focused on the distribution of these interleukins. Representative images of the 
immunofluorescence using anti-IL-17, anti-IL-22, as well as anti-IL-23 antibodies exhibited a 
uniform distribution of all investigated interleukins within the dermis of rIL-23 treated mice. 
However, differences between the diverse interleukins were observed regarding the 
respective amounts of cells producing these cytokines, especially when comparing IL-17+ 
and IL-23+ cell numbers (Figure 16C, D). However, no significant alterations neither 
regarding quantity nor distribution of investigated interleukin-positive cells between wt and 
Rage-/- mice were found (Figure 16 D).  
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Figure 16 Similar S100 protein expression and interleukin levels upon rIL-23 in Rage-/- and wt 
mice. 
S100a8- and S100a9-positive cells of rIL-23-treated ears of wt (n=9) and Rage-/- (n=9) mice were 
detected using immunofluorescence with (red staining; nuclei are stained with DAPI, blue staining). 
The dotted line represents the dermal-epidermal junction (A). Immunofluorescence stainings for the 
detection of interleukin-positive cells in the dermal compartment of psoriasifrom ears were performed 
using anti-IL-17, anti-IL-22, and anti-IL-23 antibodies (red staining; nuclei were stained with DAPI, 
blue staining) (C). Statistical analysis of immunofluorescence pictures was performed by expressing 
the number of staining-positive cells as percentage of DAPI+ cells in the dermal compartment (B, D). 
Interleukin (IL-17, IL-22) protein levels in mice sera and leach out samples of tissue biopsies were 
measured by immunoassay (E). 
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Moreover, concentrations of secreted interleukins were measured in the sera of rIL-23-
treated mice via multiplex immunoassay. Wt and Rage-/- mice did not differ in the 
concentration of IL-17. In contrast, IL-22 serum concentration was markedly higher and 
furthermore exhibited an upregulation in Rage-/- mice in comparison to the wt controls (Figure 
16E).  
Taken together, the results from the in vivo rIL-23 model demonstrated that the injections of 
recombinant IL-23 lead to a psoriasiform inflammation of the skin. However, the quality and 
quantity of the inflammatory response is unaltered in Rage-/- mice compared to wildtypes, 
suggesting that rIL-23 induces psoriasiform inflammation independently of RAGE. 
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IX. Discussion 
 
Psoriasis is a common cutaneous chronic inflammation and difficult to treat. Importantly, 
despite tremendous progress in the past years underlying molecular mechanisms of 
psoriasis remain still unknown. In this thesis it was hypothesized that RAGE might play a 
central role in the initiation and maintenance of chronic inflammations such as psoriasis. In 
vivo data presented in this thesis revealed that Rage is involved in psoriasis pathogenesis 
and, furthermore, pointed out a role for Rage on innate immune cells. Finally, data are 
provided indicating that RAGE signaling on dendritic cells contributes to the development of 
cutaneous inflammatory diseases including psoriasis.   
 
IX.1. RAGE signaling initiates and maintains chronic inflammation 
The receptor for advanced glycation end-products (RAGE) has been implicated in the 
development of many different inflammatory diseases such as atherosclerosis, rheumatoid 
arthritis, inflammatory bowel disease, and cancer [224], [356], [401], [402]. The expression of 
RAGE by immune and cutaneous cells, the high stability of RAGE-ligand complexes, as well 
as the existence of a positive feed-forward loop of RAGE signaling suggested a potential role 
of RAGE in the initiation and maintenance of a cutaneous chronic inflammation inter alia 
psoriasis.  
Indeed, in this thesis RAGE was found to be highly expressed in the epidermal as well as in 
dermal compartments of human psoriatic plaques in comparison to matched non-lesional 
specimens (Figure 3A). Moreover, the overexpression of RAGE during inflammation was also 
observed in the murine system. Mouse models of psoriasis revealed increased Rage mRNA 
as well as protein levels (Figure 3B, C). In line with this investigation, an upregulation of 
RAGE has been reported for many other inflammatory diseases, as elevated RAGE levels in 
different tissues outside the lung are frequently associated with pathological manifestations 
[232], [252], [253]. For instance, atherosclerotic plaques in humans and mice were shown to 
highly overexpress RAGE [403], [404], and vice versa, Rage deficiency in a murine 
atherosclerosis model was associated with reduced MAP kinase and NF-κB activation 
leading to delayed plaque progression [238], [404], [405]. The same study showed that the 
expression of Rage correlated with the amounts of Rage ligands and, additionally, with the 
severity of the disease. This illustrates the high importance of the RAGE axis for the 
maintenance of some inflammations.  
Inflammatory responses can be classified as either acute or chronic, while the acute 
inflammation also displays the initial phase of the chronic process. In contrast to an acute 
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inflammation, which is terminated by a resolution phase, a chronic inflammation is constantly 
active. In the here-presented in vivo study, loss of Rage delayed and dampened the initiation 
of the IMQ-induced inflammation (Figure 4D). Moreover, in the absence of Rage the chronic 
state of the psoriasiform disease, which was defined as the phase when the inflammatory 
response plateaued, reached a significantly lower level, indicating a reduced chronic 
inflammatory response (Figure 4E). In terms of numbers, wt mice developed chronic 
inflammatory conditions designated with an adaptive PASI of almost 60, while IMQ-induced 
inflammation in Rage-/- mice plateaued at an approximately 3-fold lower value. Previous in 
vitro studies demonstrated that the initial phase of a developing cutaneous inflammation is 
dependent on the activation and recruitment of immune cells into the inflamed tissue [55]. 
The here-performed study showed for the first time that the loss of Rage during chronic 
inflammation in vivo leads to a reduction of infiltrating cells (Figure 5C) and thereby to a 
dampened development of psoriasis (Figure 4D).  
A role for Rage in acute inflammatory responses of the skin was already described by 
Gebhardt and coworkers. They revealed that Rage-deficient mice failed to develop an acute 
inflammation upon single treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) and a 
prolonged inflammation upon triple TPA treatment every 48 h [263]. However, as the 
inflammation induced by this model resolved within three to four days, the settings did not 
allow the investigation of the role of Rage in more chronic inflammatory conditions as seen in 
human pathology. This was underscored by the fact that no T cells were detectable within 
the dermis, indicating that the adaptive immune system was not activated, thereby limiting 
inflammatory responses to innate immune cells [384]. In contrast, the IMQ model comprises 
the activation of innate and adaptive immune cells, as shown by infiltrating T cells, thus 
allowing the investigation of Rage in fully implemented chronic inflammatory conditions [54]. 
Acute inflammation, as the initial process occurring in chronic inflammation, is mainly 
characterized by increased blood flow, increased vascular permeability for plasma proteins, 
and the emigration of leukocytes, predominantly neutrophils [18]. In the applied IMQ model, 
inflamed tissue of wt mice exhibiting a psoriasiform phenotype showed significantly higher 
neutrophil infiltrations compared to those of IMQ-treated Rage-/- mice (Figure 6A, D). In 
contrast to acute inflammations, in which predominantly neutrophils emigrate to sides of 
inflammation, macrophages take over their functions in chronic inflammation [24]. Indeed, 
data revealed that macrophage recruitment into inflamed tissue is dependent on the 
expression of Rage, thereby providing evidence that Rage plays a role in acute as well as in 
chronic inflammatory conditions (Figure 6A, C). Previous studies described dendritic cells 
(DCs) as key players in the development of a chronic inflammation [171]. These cells are the 
connecting link between the innate and adaptive immune system by being responsible for 
antigen presentation to T cells and thus for their differentiation into diverse TH cells [3]. For 
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instance, DC-secreted IL-23 has been reported to be involved in determining the fate of 
naïve CD4+ T cells into the TH17 cell lineage [8]–[10]. In fact, the applied IMQ model 
demonstrated that Rage loss was accompanied with significantly reduced amounts of 
infiltrating DCs into the psoriasiform skin (Figure 6A, B). Maturation of these DCs and their 
migration into draining lymph nodes, where antigen presentation takes place, is facilitated by 
RAGE signaling as shown by others [261]. This is of high importance for their functionality 
and will be discussed later in more detail. Data provided in the present study exhibited a 
significant difference in the quantity and quality of the response to IMQ in the chronic phase 
of the inflammation (Figure 4D).  
Psoriatic plaques are characterized by diverse histopathological changes of the skin, 
including acanthosis, papillomatosis, parakeratosis, as well as immune cell infiltration and 
keratinocyte hyperproliferation [55]. Analysis of IMQ-treated mice revealed the existence of 
all these psoriatic symptoms in wt mice (Figure 4D, 5). In contrast, Rage-/- mice showed 
diminished acanthosis as well as a reduced number of proliferating epidermal cells (Figure 
5B, E). These findings indicate that RAGE contributes to the development of the 
histopathological hallmarks of psoriasis.  
The positive feed-forward loop of RAGE is known to promote an inflammation by 
transactivating the expression of its own and of RAGE ligands [263]. On top, upregulated 
expression of the receptor and its ligands leads to sustained activation and thereby to the 
maintenance of an inflammatory response. The S100 family members S100a8 and S100a9 
mRNA levels were highly increased in IMQ-treated wt mice (data not shown), while the loss 
of Rage under psoriasiform conditions limited the expression of these two proteins 
significantly (Figure 6E, F). Besides S100a8/a9, many of the S100 protein family members 
including S100A7 are described as RAGE ligands [302].  Madsen and colleagues were able 
to demonstrate that S100A7 is upregulated in psoriatic plaques and released during 
inflammatory responses [386]. Secreted S100A7 proteins may potentiate the inflammatory 
response via its RAGE-mediated leukocyte-chemotactic function [302]. Using genetically 
modified mice that express elevated amounts of the human ortholog S100A7/A15, 
mS100a7a15, they concluded that the S100A7-RAGE interaction activates the MAP kinase 
pathway leading to an enhanced secretion of proinflammatory cytokines and to the 
upregulation of RAGE [303]. Activation of MAP kinases lead to subsequent NF-κB activation, 
a transcription factor known to regulate genes associated with stress response including 
inflammation [406]. In fact, Chen and colleagues were able to show that a constitutive 
activation of NF-κB due to deficiency in IκB-α, establishes severe psoriasiform dermatitis in 
adult mice [407]. In line with this data, the milder phenotype of Rage-deficient mice was 
accompanied with downregulation of NF-κB mRNA and upregulation of the inhibitor gene 
Discussion 
82 
Nfκbia under inflammatory conditions (IMQ treatment) in this thesis (Figure 7A), indicating 
that elevated levels of RAGE and its ligands S100A8/A9 activate the NF-κB signaling 
pathway in psoriasis. Moreover, key cytokines for establishing a proinflammatory milieu like 
Il-6, Il-1β and Tnf-α were downregulated in psoriasiform Rage-/- mice (Figure 7A). These 
cytokines are known to activate the canonical NF-κB pathway by binding their respective 
receptors and have been implicated in chronic inflammatory diseases such as rheumatoid 
arthritis, inflammatory bowel disease and asthma [408]–[410]. The exact signaling cascade 
downstream of RAGE for gene transactivation remains largely unclear and needs further 
investigations. However, the present data indicate that RAGE regulates the NF-κB pathway 
and subsequent gene induction in psoriasis.  
In addition to NF-κB induction, the presented data revealed a Rage-dependent activation of 
Stat-3 transcription (Figure 7A). STAT-3 has been reported to be involved in the 
pathogenesis of psoriasis, as epidermal keratinocytes in psoriatic plaques are characterized 
by elevated cytokine levels that promote STAT-3 activation [52], [411]. For instance, IL-22 a 
cytokine released by activated TH17 and TH22 cells, phosphorylates STAT-3 in keratinocytes, 
thereby contributing to the crosstalk between keratinocytes and immune cells in psoriasis 
[52], [412], [413]. IMQ-treated Rage-/- mice displayed significant reduced numbers of IL-22 
positive cells in the dermal compartment as well as less Il-22 transcripts in total skin (Figure 
7C, D). This indicates that besides transcriptional regulation of STAT-3, RAGE is also 
involved in posttranscriptional mechanisms controlling STAT-3 and maybe also NF-κB 
activation. Among the target genes of these transcription factors several cell cycle control 
and proliferation genes are listed [414]. Furthermore, Chen and colleagues reported a 
keratinocyte hyperplasia under constitutive NF-κB activation, indicating that RAGE-mediated 
activation of these transcriptional regulators results in enhanced proliferation capacity. 
Indeed, the proliferative activity of epidermal keratinocytes is enhanced by Rage signaling in 
the IMQ model (Figure 5D, E). Deregulated keratinocytes contribute to the development of 
typical skin aberrations of psoriatic patients [71]. In fact, the number of proliferative 
keratinocytes is highly upregulated in psoriatic plaques and is known to correlate with the 
clinical severity of psoriasis [394]. Such psoriatic hallmarks have been described for the 
convenient IMQ model, which induces a psoriasiform chronic inflammatory response via the 
IL-23/TH17 axis and which allows the elucidation of pathogenic mechanisms occurring 
between cutaneous and immune cells of the innate and adaptive immune components [54]. 
A number of alternative psoriasis mouse models exists, however, these models are often 
associated with genetic manipulations [43]. Therefore, the IMQ model has the advantage to 
induce psoriasiform inflammation without genetic alterations. IMQ initiates the inflammatory 
responses upon binding to TLR-7/8 on monocytes, macrophages, plasmacytoid dendritic 
cells, B cells as well as on differentiated keratinocytes. Repetitive topical treatment leads to 
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the development of chronic inflammation including the whole orchestra of cells involved in 
psoriasis. The examination of Tlr7 and Tlr8 transcript levels of in wt and Rage-/- mice 
revealed with Tlr-7 being slightly down- and Tlr-8 slightly upregulated only negligible 
differences (Figure 4C). This clarifies that the IMQ application can equally initiate an 
inflammatory response in both mice strains.  
Activation of the IL-23/TH17 pathway, characterized by IL-23 secreting DCs and 
accumulation of TH17 cells, plays a major role in the pathogenesis of IMQ-induced psoriasis-
like skin inflammation [54]. It has been shown that IL-23- or IL-17R-deficient mice fail to 
develop a chronic inflammation. In fact, the IMQ-treated skin of Rage-/- mice showed reduced 
TH17-related cytokine transcript levels including Il-17 and Il-22 (Figure 7C), along with the 
suppression of histopathological hallmarks (Figure 5) and inflammation-related genes (Figure 
7A, B). Additionally, IL-23 expressing cells were highly decreased (Figure 7D). These 
observations suggest that Rage activation leads to induction of IL-23/TH17 pathway resulting 
in psoriasiform skin inflammation in this model.  
Taken together, Rage promotes the initiation and maintenance of a chronic inflammation by 
activating the recruitment of innate immune cells into the inflamed tissue. Moreover, 
induction of RAGE by its ligands resulted in the activation of psoriasis-related transcription 
factors, thereby leading to the secretion of proinflammatory cytokines known to be involved in 
the establishment of chronic inflammations. However, Rage-deficient mice could not fully 
abolish the inflammatory response. This is in line with the observations from Ueyama and 
coworkers, who demonstrated that the loss of Tlr-7 diminished but not abrogated the 
development of a chronic inflammation upon IMQ application [415]. In summary, these data 
give a first hint for redundant functions of the PRR family members in promoting and 
maintaining inflammatory conditions. 
 
IX.2. The RAGE axis - a novel pattern recognition receptor signaling in 
chronic inflammation 
As discussed before, RAGE initiates and maintains chronic responses in the context of 
psoriasis. The consideration of all examined parameters showed that the inflammatory 
response is indeed significantly reduced in Rage-/- compared to wt mice (Figure 5, 6). 
However, the absence of RAGE cannot entirely suppress the development of a chronic 
inflammation. Indeed, Rage-independent upregulations of various inflammatory markers, e.g. 
interleukin amounts, were observed upon induction with inflammatory stimuli (Figure 7C-E). 
This leads to the conclusion that RAGE plays an important role in chronic disorders but 
raises the question what other receptors contribute to the development and maintenance of a 
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chronic inflammation. Besides RAGE, also TLRs belong to the pattern recognition receptor 
(PRR) family and their signaling result in the activation of immune and inflammatory 
responses [416]–[419]. RAGE and TLRs share several common ligands such as HMGB1 as 
well as S100A8/A9 and various more [278], [296], [353], [372], [381], [420]–[422]. For 
instance, under inflammatory conditions HMGB1 builds complexes with DNA and signals via 
binding to membrane-bound RAGE and/or TLR-9 on endosomes [257], [285]. Moreover, 
HMGB1–nucleosome complexes activate APCs via TLR-2, thereby contributing to the 
pathogenesis of systemic lupus erythematosus (SLE) [319]. Additionally, the functional 
association of HMGB1, RAGE and TLRs is known to enhance inflammatory responses in 
diabetes [423]. Ligand binding is known to enhance the heterodimerization, e.g. S100B 
stimulus leads to the stabilization of RAGE-TLR-2 heterodimers [235]. The existence of 
common ligands and heterodimer formation as well as the secretion of similar 
proinflammatory cytokines also point towards redundant functions between these two PRR 
family members. This is further indicated by the observed upregulation of different Tlrs such 
as Tlr-2 and Tlr-4 in IMQ-treated Rage-/- mice during chronic inflammation (Figure 4C). 
Similarities between RAGE and TLRs do not only exist with regard to pathway induction but 
also concerning downstream signaling. Stimulation of TLR signaling pathways requires in 
most cases the adaptor protein MyD88, and in case of TLR-2/TLR-4 also the presence of the 
adaptor molecule TIRAP and leads to the recruitment and induction of IRAK-4, IRAK-1, as 
well as TRAF-6 and subsequent to the formation and activation of the TGF-β activates 
kinase-1 (TAK-1) complex [181]. Activated TAK-1 phosphorylates the IKK complex and MAP 
kinases, such as c-Jun N-terminal kinase (JNK), thereby inducing the activation of NF-κB and 
AP-1, and the secretion of proinflammatory cytokines, respectively [181]. Although the 
complete signaling pathway of RAGE is still not fully understood and several different 
adaptor proteins of RAGE are described, it has been shown that TIRAP and MyD88 bind to 
the phosphorylated cytoplasmic domain of RAGE [424]. The interaction of RAGE with these 
adaptor proteins further induces the recruitment of IRAK-4, which subsequently activates 
downstream effector kinases such as MAP kinases and IKK complexes, leading to induction 
of proinflammatory cytokines via the activation of transcription factors including NF-κB and 
AP-1 (Figure 2). The presence of shared ligands as well as the similarities found by 
comparing downstream signaling provided first evidence that RAGE and some members of 
the TLR family functionally interact in order to regulate inflammatory responses. Functional 
support has been provided by Ueyama and coworkers, who showed that Tlr-7-/- mice 
demonstrated reduced levels of acanthosis and infiltrating inflammatory cells as well as 
amounts of TH17-related cytokines compared to wt mice. This indicates diminished 
inflammatory responses to IMQ, leading to the conclusion that Tlr-7 deficiency was not able 
to abolish the inflammation completely [415]. Interestingly, the upon IMQ treatment exhibited 
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phenotype of Rage-/- mice used in this thesis was comparable to that described for Tlr-7-/- 
mice (Figure 5A-C, 7C-E). These data along with the similarities of the two receptor families 
regarding their signaling pathways suggest that RAGE and TLRs possess a joint role in the 
pathogenesis of psoriasis. In order to verify the assumed redundant functions of RAGE and 
TLR-7 in psoriasiform inflammation and whether the receptors can compensate each other, it 
would be of high interest to generate Rage-Tlr-7 double knockout mice and apply the IMQ-
induced inflammation model.  
Furthermore, also other PRR such as RIG-I-like (RLRs), NOD-like (NLRs), and C-type lectin 
receptors are involved in the transcriptional regulation of inflammatory mediators [4]. This is 
consistent with the study from Rabeony and coworkers from 2015 showing that IMQ-induced 
skin inflammation was abolished in the absence of MyD88, the adaptor protein shared by 
RAGE, IL-1R and TLR signaling [425]. Major inflammatory cytokines released by activated 
DCs as a direct consequence of PRR signaling include IL-1, TNF-α, IFNs, IL-4, IL-5, IL-6, IL-
13, and IL-17 [426]. Gene expression data revealed that all of these cytokines are 
downregulated in Rage-/- mice (Figure 7A), suggesting an important contribution of RAGE in 
the PRR signaling on DCs.   
All these PRR share several downstream targets with RAGE and lead to the secretion of 
different subsets of proinflammatory cytokines, dependent on pathophysiological conditions, 
cell type, and ligand concentrations. The variety of influences hampered the investigation of 
a distinct receptor under pathophysiological conditions. Nevertheless, the data provided in 
this thesis proved that RAGE contributes and extends the inflammatory response of PRR in 
the context of psoriasis.  
 
IX.3. RAGE impacts immune response in psoriasis 
Despite a plethora of studies, the pathogenesis of psoriasis is still not completely understood. 
This is attributed, to some extent, to the complexity of the disorder. Psoriasis is driven by 
various cells, regulatory molecules of the innate and adaptive immune system as well as by 
skin epithelium and connective tissue [131]. The combination of environmental and potential 
genetic predisposition contributes to the development of psoriasis by promoting secretion of 
proinflammatory cytokines and antimicrobial peptides as well as the release of DNA/RNA 
molecules by keratinocytes [133]. These factors have chemoattractant and activating effects 
on different subsets of dendritic cells [55]. Plasmacytoid dendritic cells, when activated, 
secrete high amounts of IFN-α, which in turn leads to the maturation and activation of dermal 
dendritic into inflammatory dendritic cells [137], [138], [427]. Activated myeloid dendritic cells 
recognize and capture antigens, migrate to local draining lymph nodes and present antigens 
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to T cells, thereby inducing T cell differentiation [139]. Differentiation of T cells is dependent 
on the cytokine composition released by DCs; for instance IL-23 secreted by some DC 
subsets is responsible for the generation of TH17 cells and subsequent for the production of 
proinflammatory cytokines like IL-17 and IL-22. The IL-23/TH17 axis has been claimed to 
have an important role in the induction of psoriasis [167]. In addition, IL-12-triggered 
differentiation to TH1 cells contributes to the establishment of an inflammatory milieu via the 
secretion of proinflammatory cytokines including IFN-γ and TNF-α [97]. In turn, all these 
proinflammatory cytokines function on keratinocytes leading to a sustained activation of 
these cells, consequently to the secretion of other proinflammatory cytokines. These feed-
forward loops involving keratinocytes, innate and adaptive immune cells are responsible for 
the maintenance psoriasis [55].  
As mentioned before, IMQ is known to induce a psoriasiform phenotype in mice including 
histopathological changes and recruitment of CD4+ T cells, CD11+ DCs and plasmacytoid 
dendritic cells; cell types known to be important for the IL-23/TH17 axis of psoriasis [54]. An in 
vitro study from Li and colleagues showed that IMQ forces proinflammatory cytokine 
production by differentiated keratinocytes [166], indicating that IMQ induces early events of 
psoriasis pathogenesis. This thesis extends these findings by demonstrating that the IMQ-
induced activation of keratinocytes is independent of RAGE signaling (Figure 9G, H). 
Therefore, Rage-dependent induction of a psoriasiform inflammation in mice upon IMQ 
treatment must involve other cell types. Recently, Ueyama and colleagues were able to 
demonstrate that the low proinflammatory cytokine production by  bone marrow-derived DCs 
upon stimulation with IMQ could be enhanced when DCs were co-stimulated with IFN-α. 
Taken these data and the results of this thesis into account, one can suggest two things: 
First, keratinocytes contribute in a RAGE-independent manner to IMQ-induced psoriasiform 
conditions. Second, that other cell types, including dendritic cells, must be responsible for the 
RAGE-dependent effects of IMQ-treatment in the mouse model.  
IX.3.1. RAGE expressed by innate immune cells predominantly drives chronic 
inflammation 
By using the IMQ model, we could show that the absence of Rage decreased the number of 
infiltrating DC in dermal compartments of mice (Figure 6A, B), and that Rage was indeed 
expressed by human and murine DCs under inflammatory conditions (Figure 10A). 
Comparing human psoriatic plaques with high PASI to lesions with low PASI indicated a 
correlation of number of RAGE-expressing dendritic cells as well as RAGE expression itself 
and clinical severity of the disease (Figure 10B). This is in line with an observation gained by 
the generation of bone marrow chimeras, showing that Rage expression on immune cells, 
but not keratinocytes, was required for innate immune cell recruitment, a critical step in the 
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pathogenesis of psoriasis [55], [263]. Moreover, not only the expression of RAGE is 
upregulated on DCs, also the expression of genes associated with maturation and activation 
of DCs including Cd80, Cd86, and Cd40 depends on Rage (Figure 7A). CD80 and CD86 as 
well as CD40 are expressed on mature DCs, whereas immature DCs express only low levels 
of these co-stimulatory molecules, which are needed for the activation of T cells [3], [428], 
[429]. Manfredi showed that the RAGE-HMGB1 axis is involved in the homing of DCs to 
lymph nodes, where antigen presentation takes place [261]. Together with the data provided 
in this thesis, this indicates that Rage disrupts the interaction of DC and T cells, thereby 
inhibiting the differentiation of naïve T cells into T helper subsets. These data alone could not 
serve as an evidence for the role of RAGE on DCs, as the functions of co-stimulatory 
molecules are complex and depend, for instance, on the receptors they engage. More 
specifically, binding of CD80/CD86 to respective receptors can have contrarian effects: While 
engagement of CD28 activates T cells, the interaction with cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) induces the inhibition of T cell differentiation [430]. However, 
taking a closer look onto the gene expression data revealed an enormous downregulation of 
the TH cell subset marker Cd4 in mice lacking Rage (Figure 7A), thereby confirming the data 
from Manfredi and coworkers. These results indicate a role of RAGE on DCs in the 
pathogenesis of psoriasis; which was confirmed by the results from the rIL-23 mouse model. 
This in vivo model rescued the impaired inflammatory phenotype upon Rage loss by 
sustained addition of rIL-23, a cytokine secreted by activated DCs (Figure 14A). Taken 
together, this provides evidence that Rage expression by cells ‘upstream’ of T cells, but as 
discussed in the previous section, ‘downstream’ of keratinocytes is of enormous importance 
for the development of a chronic inflammation such as psoriasis.  
A small subpopulation of DCs, namely plasmacytoid dendritic cells (pDCs), is described to 
infiltrate the mouse back skin after IMQ administration [431], [432]. Additionally, in patients 
exacerbation of psoriasis is accompanied by an induction of IFN-α secretion and infiltration of 
pDCs in lesional skin, whereas pDCs are not detectable in healthy skin [433]. As RAGE 
expression was shown to be upregulated on DCs during psoriasis in humans or psoriasiform 
inflammation in mice (Figure 10), and as pDCs infiltrate psoriatic plaques, an investigation of 
RAGE on pDCs was indispensable. Furthermore, TLR-9, which is known to be involved in 
the activation of pDCs and which is exclusively expressed on B cells, keratinocytes and 
pDCs, was found to be downregulated in IMQ-treated Rage-/- mice compared to the controls 
(Figure 4C). This indicates that the PRR-mediated pDC activation plays a critical role in the 
pathogenesis of psoriasis. TLR-9 shows endosomal localization and provides protective 
immune functions by binding to viral or bacterial DNA [434]. However, extracellular 
mammalian self-DNA captured in immune complexes has been shown to contribute to 
autoimmune diseases via inducing the production of IFN-α [435]. This led to the hypothesis 
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that a surface-expressed receptor has to be involved in the recognition of self-DNA immune 
complexes. In vitro analysis of Rage-/- and wt pDCs revealed that Rage plays a crucial role in 
the activation of pDCs via HMGB1-CpG complexes in the context of SLE [257]. Furthermore, 
recent studies provided evidence that cell-free DNA can even be directly linked to psoriasis 
severity. Indeed, anti-psoriasis therapies were effective by just decreasing cell-free-DNA 
amounts [397]. The here-presented thesis provided evidence that two RAGE ligands, 
HMGB1 and S100B, in complex with self-DNA activate pDCs to secrete high amounts of IFN-
α, and that RAGE itself is involved in the initiation of this process.  
More specifically, high IFN-α concentrations were detected in the supernatants of alarmin-
self-DNA complexes-stimulated pDCs; but both, HMGB1 and S100B alone, could not trigger 
IFN-α secretion by pDCs (Figure 11C-F). CpG dinucleotides are known to have stimulatory 
effects on psoriasis-related pDCs without being complexed with other proteins in vitro  [436]–
[438]. As CpG concentrations used in these experiments showed no alterations, the 
observed increased in IFN-α secretion by pDCs is not mediated by a single administration of 
CpG; instead, it is induced by CpG-complex formation (Figure 11B). In addition, RAGE 
expression on pDCs was upregulated due to the presence of alarmin-CpG complexes 
(Figure 12A). Despite the fact, that the RAGE ligands, HMGB1 and S100B, are additionally 
described as ligands of the TLR family [235], [353], [421], we identified RAGE as a major 
receptor for the alarmin-CpG complexes by using a RAGE blocking antibody (Figure 12B). 
Consistent with our data, Tian and colleagues revealed that upon binding to DNA molecules 
the affinity of HMGB1 to RAGE is increased, and no binding to TLR-2 or TLR-4 on pDCs was 
observable [257]. Surprisingly, results from the same study showing that S100B in complex 
with self-DNA failed to activate pDCs could not be verified in this thesis [257]. Instead, 
S100B-CpG complexes were found to have similar stimulatory effects on pDCs as HMGB1-
CpG (Figure 11 D, F). An interplay of RAGE and TLR-9 upon HMGB1-CpG engagement is 
described for murine pDCs, and leads to the recruitment of the adaptor protein MyD88 [257]. 
This is in line with the observation that additionally to Tlr-9, transcript levels of Myd88 are 
downregulated in IMQ-treated Rage-/- mice in comparison to the inflamed wt mice (Figure 4C, 
7A). This suggests that the absence of Rage could lead to a blockade of pDC activation in 
vivo. The missing existence of a Rage-Tlr-9 axis might suppress the recruitment of Myd88, 
thereby preventing an upregulation of Tlr-9 on endosomes as well as the secretion of 
proinflammatory cytokines such as Ifn-α and Tnf-α. This could be confirmed by the study 
from Lande and colleagues, showing that another psoriasis-associated alarmin, LL-37, in 
complex with self-DNA led to the activation of psoriatic pDCs [136]. LL-37 protects self-DNA 
from proteolytic degradation und converts it in a potent pDCs activator. A comparable 
mechanism might be assumed for HMGB1 and S100B. Furthermore, an in vivo approach 
using CpG injections to induce inflammatory conditions in murine airways revealed an 
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impaired inflammatory response to DNA in Rage-deficient mice [400]. All these data indicate 
that the ongoing process in psoriatic inflammation is dependent on the alarmin-self-DNA-
RAGE axis of pDCs. 
As several hallmarks of psoriasis, e.g. acanthosis, are dependent on a deregulation of 
keratinocyte proliferation and differentiation, and since these psoriasiform symptoms were 
decreased in IMQ-treated Rage-/- mice (Figure 5A), one might claim a role of RAGE on 
keratinocytes in psoriasis. Indeed, under normal conditions RAGE is expressed on 
keratinocytes in vitro (Figure 8B). Moreover, inflammation induced in the absence of Rage 
was accompanied with a significant reduction of hyperproliferating epidermal cells, mainly 
keratinocytes (Figure 5 B, E). Interestingly, an impact of RAGE on keratinocyte proliferation 
and migration in wound healing has already been proposed [439]. Moreover, a study 
revealed a role of RAGE in keratinocytes during acute inflammation of the skin. RAGE was 
described to support the maintenance of epidermal keratinocyte activation thereby inhibiting 
the resolution phase of an acute inflammation in vivo [384]. Besides RAGE, also the 
expression of several other PRRs including members of the TLRs family and NLR family, 
sensitized keratinocytes to PAMPs and DAMPs [440]. Previous studies identified TLR-9 to be 
expressed on psoriatic keratinocytes. In contrast, normal keratinocytes express this TLR 
family member exclusively at basal levels. Modulation of TLR expression in chronic plaque 
psoriasis led to an enhanced response to bacterial DNA [441]–[443]. Inflammatory 
keratinocytes are the main source of IL-1β, a cytokine promoting T cell-dependent 
inflammation in the skin [444]. Investigations of transcripts and protein levels of IL-1β 
revealed a missing activation potential for alarmin-self-DNA complexes on keratinocytes 
(Figure 8C-E). These observations are in sharp contrast to the studies from Dombrowski and 
colleagues showing that self-DNA alone is a potent trigger of AIM2 activation in keratinocytes 
resulting in IL-1β secretion. Furthermore, they exhibited that LL-37, known to build 
complexes with self-DNA, thereby activating pDCs, has antiinflammatory effects on 
keratinocytes. In keratinocytes, binding of LL-37 to self-DNA neutralizes DNA-mediated 
inflammation [445]. Interestingly, the loss of Rage in keratinocytes in vivo had no effect on 
proinflammatory cytokine secretion, including IL-1β secretion, except TNF-α secretion [384]. 
This could explain the lack of upregulated IL-1β secretion upon CpG and/or alarmin stimulus 
(Figure 8C-E).  
Despite the conflicting data for self-DNA keratinocyte activation potential, there is no doubt 
about these cells being activated during chronic inflammation and contributing via the 
secretion of proinflammatory cytokines to the development of chronic inflammation. As Li and 
colleagues showed keratinocytes could be activated via TLR-7. This receptor is expressed 
only at basal levels by non-differentiated keratinocytes. Ongoing keratinocyte differentiation, 
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which takes place in psoriasis, is accompanied with a consequent increase in TLR-7 
expression and, respectively, with enhanced sensitivity of cells towards stimulation with the 
TLR-7/8 agonist IMQ. Furthermore, this study showed that IMQ-treated differentiated 
keratinocytes are able to secrete proinflammatory cytokines, including TNF-α and IL-8, 
indicating their involvement in IMQ-induced psoriasiform inflammation. Data provided in this 
thesis revealed that differentiated keratinocytes (Figure 9C) stimulated with IMQ are capable 
of secreting alarmins such as HMGB1 and S100B (Figure 9D-F). It has been already 
demonstrated that terminal differentiated keratinocytes release RNA and DNA to the 
extracellular matrix, molecules that are normally degraded immediately [135]. The additional 
secretion of alarmins might than lead to a complex formation of self-DNA and alarmins, as it 
is already described for HMGB1 [257]. As described before, these alarmins in combination 
with self-DNA are important activators of pDCs (Figure 10). This defines the activation of 
keratinocytes upon IMQ application as a trigger of pDCs activation by releasing pDC 
stimulants. 
Interestingly, the absence of RAGE on IMQ-treated differentiated keratinocytes did not 
influence the quantity of keratinocyte alarmin secretion (Figure 9G, H), revealing that the 
IMQ-induced secretion of HMGB1 and S100B by keratinocytes is independent of RAGE. 
Furthermore, these data indicate that the loss of Rage did not interfere with early events in 
the induction of a psoriasiform inflammation in mice.  
 
The in vivo IMQ model in line with the in vitro data revealed that RAGE is involved in the 
initiation and maintenance of cutaneous chronic inflammation. The relevance of RAGE in the 
initial phase of a chronic inflammation is shown by the dependence of pDCs on RAGE for 
their proper activation, which represents an important event in the establishment of psoriasis. 
In contrast to the study of Leibold and colleagues, an absence of a resolution phase was 
observed in the in vivo IMQ model [384], which is a hint for the importance of RAGE on these 
cells during maintenance of psoriasis.   
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Nevertheless, RAGE does not solely affect the activation of innate immune cells, but also 
their infiltration into inflamed tissue. Provided data indicate that Rage deficiency decreased 
the number of infiltrating macrophages, neutrophils, and dendritic cells into inflamed tissue 
(Figure 6 A-D). Similar observations have been exhibited by Gebhardt and coworkers in their 
model of TPA-induced skin inflammation [263]. Moreover, a decrease in the accumulation of 
innate immune cells, here neutrophils and macrophages, was also found in acute peritonitis-
like inflammation in Rage-/- mice [446]. These data strongly recommend a role of RAGE in 
mediating innate immune cell recruitment into inflamed tissues in vivo.  
Figure 17 Possible role of RAGE and its ligands in the pathogenesis of psoriasis. 
IMQ, a selective TLR-7/8 agonist, leads to the activation of differentiated keratinocytes. These 
activated keratinocytes secrete proinflammatory cytokines, AMPs, and alarmins inter alia HMGB1 
and S100B, as well as DNA and RNA molecules. These alarmins build complexes with self-DNA 
thereby activating pDCs via RAGE. Activated pDCs secrete high amounts of IFN-alpha, which leads 
to the activation and maturation of DCs. In turn, maturated DCs circulate to the lymph nodes and 
secrete cytokines such as IL-23 and IL-12. IL-23, a potential downstream target of RAGE, is a 
cytokine known to force the differentiation of naïve T cells into TH17 cells. Differentiated TH cells 
migrate into dermal compartments, where an interaction with innate immune cells and keratinocytes 
via the secretion of cytokines such as TNF-α, IFN-γ, IL-17, IL-22 takes place.  
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As aforementioned, the provided data consistently suggest that RAGE functions as a 
regulatory molecule on innate immune cells, especially on DCs. These cells are known to 
represent antigens to naïve T and B cells, which results in their activation. This highlights the 
importance of DCs as key players in the interface between the innate and adaptive immunity 
[3] and raises questions about potential consequences arising from a loss of RAGE on DCs 
for adaptive immune responses, especially for psoriasis-associated T cell functions.  
IX.3.2. RAGE signaling regulates adaptive immune responses by modulating innate 
immunity 
Apart from cells of the innate immune system, activated CD4+ and CD8+ T cells may also 
express RAGE [255]. A tremendous downregulation of Cd4 in the absence of Rage upon 
IMQ application indicates a reduced number of T helper cells in inflamed tissue (Figure 7A). 
This subset consists of IL-17 and IL-22-producing TH17 and/or TH22 cells as well as of IFN-γ 
and TNF-α- producing TH1 cells [97], whereas the role of Treg cells during psoriasis remains 
controversial. Interestingly, some genes associated with the differentiation of CD4+ T cells 
into TH1 or TH17 cells were found to be deregulated (Figure 7A). It has been shown that the 
frequency of IL-17+ and IL-22+CD4+ cells in the blood of psoriasis patients is increased [447], 
revealing that these cells have an important impact on the maintenance of psoriasis. These 
data support the idea that the loss of RAGE inhibits the recruitment of T helper cells into 
inflamed tissue. Whether RAGE expression on TH cells itself plays a role or if the missing 
maturation and activation of dendritic cells reduces the T cell infiltration requires further 
investigation. Nevertheless, both subsets, TH17 and TH22 cells, are influenced by the 
cytokine IL-23, which is required for their expansion and maintenance. IL-23 is highly 
expressed by DCs in the context of psoriasis [167]. Importantly, in the IMQ model Rage-
deficiency was accompanied by impaired Il-23 transcript levels (Figure 7C). As discussed 
before, this can be explained by the dependency of pDCs activation on RAGE in respect to 
the secretion of proinflammatory cytokines (Figure 12B, C). Intradermal rIL-23 injections into 
mice ears lead to the development of a psoriasiform phenotype in mice by mimicking 
constitutive DC activation resulting in the induction of the IL-23/TH-17 axis and, consequently, 
in the differentiation of T cells into TH17 cells [53]. Histopathological hallmarks of psoriasis 
were unaltered in Rage-/- mice upon rIL-23 injections when compared to the wildtype situation 
(Figure 14A). Moreover, the progression of the inflammatory reaction was not affected by the 
absence of Rage (Figure 13) and Rage deficiency had no impact on the amounts of 
infiltrating cells (Figure 14B, 15A, B). Furthermore, no alterations regarding the number of 
lymph node-infiltrating DCs in Rage-/- mice after rIL-23 injections was observed (Figure 15D) 
and rIL-23 injections also rescued the impaired infiltration of IL-17+, IL-22+, and IL-23+ cells 
into inflamed tissue in Rage-deficient mice (Figure 16D, E). This indicates that the presence 
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of IL-23 rescues the ineffectiveness of Rage-/- DCs in modulating the differentiation of naïve T 
cells into TH17 and/or TH22 cells. In other words, these data point towards a role of IL-23 as a 
downstream target of Rage and suggest that a functional RAGE axis in innate immune cells 
ensuring a proper differentiation and activation of T cells but not RAGE on T cells itself to be 
important for the development and maintenance of psoriasis. However, in order to fully prove 
this hypothesis, an investigation of T cell- or DC-specific Rage-deficient mice would be 
necessary. 
 
IX.4. RAGE axis as a possible therapeutic target for the treatment of 
chronic inflammatory diseases 
Any psoriasis therapy aims for the amelioration or even full resolution of clinco-pathological 
symptoms. However, although a range of diverse therapies is available for the treatment of 
psoriasis, this goal is difficult to reach and still cannot be achieved in several patients. The 
existing long-term systemic therapies are burdened with the risk of adverse events. 
Therefore, clinical research mainly focused on the development of new therapeutics, which 
target molecules involved in the pathogenic mechanisms of psoriasis. 
For instance, the IL-23/TH17 axis was assigned to play an important role in the induction of 
psoriasis. More specifically, DC-secreted IL-23 seems to be responsible for the production of 
TH17-related proinflammatory cytokines such as IL-17 and IL-22, which drives the disease 
[167]. Specific intervention of the IL-23/TH17 axis might inhibit the hyperactive immune 
responses. Therefore, numerous studies including monoclonal antibodies directed against 
these cytokines were performed.  
Consequently, antibodies directly blocking IL-12/IL-23, such as Ustekinumab and 
Briakinumab, were developed. These antibodies were shown to significantly reduce 
pathohistological hallmarks of psoriasis and ameliorate the disease burden [448]–[451]. 
Furthermore, anti-IL-17/IL-17R antibodies including Secukinumab, Ixekizumab, and 
Brodulumab were developed and represent therapeutics targeting downstream effects of IL-
23 [452]–[454]. These interleukin blockers support the idea of TH17 cells being key players in 
psoriasis and could perhaps replace the TNF-α pathway as a major therapeutic target in 
chronic inflammation [455]. Identifying and blocking pathways responsible for the secretion of 
IL-23 release would represent a great chance to prevent or resolve psoriatic lesions.    
Besides highlighting the important influence of RAGE in the pathogenesis of psoriasis the 
here-presented data identified IL-23 as a downstream target of RAGE. Blocking the RAGE 
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axis might diminish IL-23 production and therefore decrease the induction of adaptive 
immune responses leading to disease progression.  
In an Alzheimer´s disease (AD) mouse model Deane and coworkers identified a RAGE-
specific inhibitor (FPS-ZM1) that exclusively binds to RAGE with a high affinity, inhibiting 
amyloid β-induced cellular stress, thereby suppressing neuroinflammatory responses [456]. 
Furthermore the inhibitor was able to block the engagement of RAGE by other RAGE 
ligands, which have been suggested to contribute to RAGE-mediated tissue damage in 
models of diabetes, inflammatory disorders and AD [457]. In April 2015 a phase III trial with 
the small molecule RAGE antagonist TTP488 started in the US [458]. Before, TTP488 was 
demonstrated to be effective by reducing amyloid plaques in an AD transgenic mouse model 
and by revealing beneficial effects in a phase II trial comprising 400 patients with mild to 
moderate AD [459].  
These studies along with the results of this thesis point towards a potential use of RAGE as a 
selective therapeutic target arresting disease progression by blocking basic pathological 
mechanism of psoriasis. 
 
Taken together, this thesis proposes RAGE as a regulatory molecule in cutaneous chronic 
inflammations such as psoriasis. For the first time, its role in the manifestation of a chronic 
inflammation of the skin, including the development of characteristic hallmarks such as 
acanthosis, parakeratosis, and dermal infiltration of innate immune cells was uncovered. 
Although RAGE was found to be expressed by keratinocytes and CD11+ dendritic cells, 
these cell types demonstrated distinct degrees of dependence. The inflammation-associated 
activation of keratinocytes resulting in the release of two alarmins, HMGB1 and S100B, was 
found to occur in a RAGE-independent manner. In contrast, RAGE is essential for the 
alarmin-CpG-induced activation of plasmacytoid dendritic cells, illustrating an existing RAGE-
mediated epidermal-innate immune crosstalk in psoriasis. 
The rescue of the defective inflammatory phenotype by intradermal injections of rIL-23 
pointed towards two things: on IL-23 as a potential target of RAGE as well as on a role of 
RAGE on dendritic cells driving chronic inflammatory diseases. The hypothesis that RAGE 
signaling is important for the activation of the IL-23/TH17 axis was further supported by the 
observed downregulation of genes involved in the differentiation of T helper cells in the 
absence of RAGE. The indicated central role of RAGE in the IL-23/TH17 axis of psoriasis 
illustrates RAGE as a potential target of new therapeutic strategies intervening ‘upstream’ of 
IL-23. 
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XI. Abbreviations 
 
°C Degree Celsius 
µ Micro 
% Percent 
7-AAD 7-aminoactinomycin 
A Alanine 
A Adenine 
aa Amino acid 
ABIN A20-binding inhibitor of NF-κB 
ACT Actin 
AD Alzheimer´s Disease 
AGE Advanced glycation end-products 
AGER Gene coding for RAGE 
AMP Antimicrobial peptide 
AP Activator protein 
APC Antigen-presenting cell 
Apcs Gene coding for amyloid P component serum 
ATP Adenosine triphosphate 
B.C. Before Christ 
BCR B cell receptor 
BDCA Blood DC antigen 
BSA Bovine serum albumin 
bp Base pair 
C Cysteine 
C Cytosine 
C3/C5a Complement component 3/5a 
Ca2+ Calcium 
CCHCR coiled-coil, α-helical rod 
CCL Chemokine (C-C-motif) ligand 
CCR Chemokine (C-C-motif) receptor 
CD Cluster of differentiation 
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cDNA complementary DNA 
CDSN corneodesmosin 
CHCl3 Chloroform 
CO2 carbon dioxide 
CpG Cytosine-phosphate-guanine dinucleotide (unmethylated) 
Crp Gene coding for C-reactive protein 
CTLA Cytotoxic T lymphocyte-associated protein 
CTTP Cytoplasmic transductional-transcritional processor 
C-type/unit Constant type/unit 
CXCL Chemokine (C-X-C-motif) ligand 
CXCR Chemokine (C-X-C-motif) receptor 
Cy Cyanine 
DAMPs Danger-associated molecule pattern 
DAPI 4’,6-diamidino-2-phenylindole 
DC Dendritic cell 
ddH2O Double-distilled water 
DIA Diaphanous 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide 
EDC epidermal differentiation complex  
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced green fluorescent protein 
ELISA Enzyme-linked immunosorbent assay 
ERK Extracellular signal-regulated protein kinase 
EtOH Ethanol 
FACS Fluorescence-activated cell sorting 
FCS Fetal bovine serum  
FDA Food and Drug Administration 
fl Full-length 
Foxp3 Gene coding for forkhead box p3 
FPS-ZM1 N-Benzyl-4-chloro-N-cyclohexylbenzamide 
Abbreviations 
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FRET Fluorescence resonance energy transfer 
g Gramm 
G Guanine 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GWAS Genome-wide association studies 
h Hours 
H&E Hematoxylin and eosin 
H2O Water 
H2SO4 Sulfuric acid 
HCl Hydrochloric acid 
HKGS Human keratinocyte growth supplement 
HLA Human leukocyte antigen 
HMGB1 High-mobility group box 1 
HRP Horse-radish peroxidase 
Hs Homo sapiens 
HSPG Heparin sulfate proteoglycan 
ICAM Intracellular adhesion molecule 
IF Immunofluorescence 
IFN Interferon 
IgG Immunoglobin G 
IκB nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor 
IKK IκB kinase complex 
IL Interleukin 
IMQ Imiquimod 
iNOS Inducible nitric oxide synthase 
IRAK IL-receptor associated kinase 
IRF IFN regulatory factor 
JNK c-Jun N-terminal kinase 
k Kilo 
kb Kilo base pairs 
KCl Potassium chloride 
kDa Kilodalton 
Abbreviations 
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KIR Killer immunoglobulin-like receptor 
l Liter 
LPS Lipopolysaccharide  
µ Micro 
M Molar 
m Milli 
MAC-1 Macrophage-1 antigen 
MAP Mitogen-activated protein 
MED Minimal erythermogenic dose 
MeOH Methanol 
MHC Major histocompatibility complex 
min Minutes 
Mm Mouse musculus 
MMP metallopeptidase 
miRNA Micro RNA 
mRNA Messenger RNA 
MTX Methotrexate 
MyD88 Myeloid differentiation factor 88 
n Nano 
NaCl Sodium chloride 
NAD+ nicotinamide adenine dinucleotide 
nbUVB Narrow ultraviolet-B 
NF-κB Nuclear factor κ B 
NFKBIA Gene coding for IκB 
NHEK Normal human epidermal keratinocyte 
NK cell Natural killer cell 
NLR Nucleotide-binding oligomerization domain receptor (NOD-like 
receptor) 
PAMPs Pathogen-associated molecule pattern 
PASI Psoriasis area and severity index 
PBMC Peripheral Blood Mononuclear Cell 
PBS Phosphate-buffered saline 
Abbreviations 
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PD-L Programmed death ligand 
pDC Plasmacytoid dendritic cell 
PFA Paraformaldehyde 
PI3K Phosphoinositide 3-kinase 
PKA Protein kinase A 
PRR Pattern recognition receptors 
PSORS Psoriasis susceptibility (loci) 
PUVA Psoralen combined with ultraviolet-A 
Q Glutamine 
qPCR Quantitative real-time polymerase chain reaction 
R Arginine 
RAGE Receptor for advanced glycation end products 
Rage-/- Rage-deficient [mouse] 
rcf Relative centrifugal force 
rIL-23 Recombinant interleukin 23 
RLR Retinoic acid-inducible gene-1 like receptors (RIG-I-like receptors) 
RNA Ribonucleic acid 
rpm Rounds per minute 
RT Room temperature 
SD Standard Deviation 
SDS Sodium dodecyl sulfate 
sec Seconds 
Slan-DC 6-sulfo LacNAc dendritic cell 
SLE Systemic lupus erythematosus 
SNP Single nucleotide polymorphism 
SP Specificity protein  
sRAGE Soluble RAGE 
SSC Squamous cell carcinoma 
STAT Signal transducer and activator of transcription 
T Threonine 
T Thymine 
TAK TGF-β activated kinase 
Abbreviations 
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TBS Tris-buffered saline 
TC Cytotoxic T lymphocyte 
TGF-β Transforming growth factor-β 
TH Helper T lymphocyte 
Tip-DC TNF-α/iNOS-producing dendritic cell 
TIRAP Toll-interleukin 1 receptor domain containing adaptor protein 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TNFAIP Tumor necrosis factor α-induced protein 
TNFR TNF receptor 
TNIP TNFAIP3 interacting protein 
TPA 12-O-tetradecanoylphorbol-13-acetate 
TRAF TNFR-associated factor 
TRAF3IP TRAF-3 interacting protein 
Treg Regulatory T lymphocyte 
UTR Untranslated region 
UV Ultraviolet 
V Volt 
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor 
V-type/unit Variable type/unit 
v/v Volume/volume 
wt Wildtype [mouse] 
w/v Mass/volume 
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